WO2014033192A1 - Stabilised proteins for immunising against staphylococcus aureus - Google Patents

Stabilised proteins for immunising against staphylococcus aureus Download PDF

Info

Publication number
WO2014033192A1
WO2014033192A1 PCT/EP2013/067855 EP2013067855W WO2014033192A1 WO 2014033192 A1 WO2014033192 A1 WO 2014033192A1 EP 2013067855 W EP2013067855 W EP 2013067855W WO 2014033192 A1 WO2014033192 A1 WO 2014033192A1
Authority
WO
WIPO (PCT)
Prior art keywords
seq
polypeptide
amino acid
antigen
composition
Prior art date
Application number
PCT/EP2013/067855
Other languages
French (fr)
Inventor
Fabio Bagnoli
Simone BUFALI
Simona Cianetti
Anna Coslovi
Guido Grandi
Mikkel Nissum
Michele Pallaoro
Silvana Savino
Michele SOTGIU
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Priority to US14/420,229 priority Critical patent/US20150202277A1/en
Priority to EP13758801.8A priority patent/EP2890387A1/en
Priority to JP2015529013A priority patent/JP2015528457A/en
Priority to CN201380042842.7A priority patent/CN104736165A/en
Publication of WO2014033192A1 publication Critical patent/WO2014033192A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • C07K14/3156—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci from Streptococcus pneumoniae (Pneumococcus)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine

Definitions

  • This invention relates to immunogenic compositions comprising antigens derived from Staphylococcus aureus and to their use in immunisation.
  • S. aureus is a Gram-positive spherical bacterium and is the leading cause of infection of the bloodstream, lower respiratory tract, and skin and other soft tissues. It causes a range of illnesses from minor skin infections to life-threatening diseases including pneumonia and septicaemia, and the mortality associated with S. aureus per annum in the US exceeds that of any other infectious disease, including HIV/AIDS.
  • Reference 5 discloses various S.aureus antigens and their combinations, including "Combo- 1" (a mixture of EsxA, EsxB, a mutant Hla, Sta006, and StaOl l) and "Combo-2" (a mixture of EsxA, EsxB, IsdA, Sta006, and StaOl 1) as vaccine strategics.
  • Reference 6 discloses that S.aureus polypeptide antigens can be unstable in a simple buffer solution, and that antigens can be stabilised by the presence of a stabilizing additive, e.g. EDTA.
  • Instability of the antigens is undesirable because (1) it does not allow vaccines to be stored for a long period of time before administration, and (2) inconsistency of vaccines from batch to batch can affect quality and regulatory approval requirements. Furthermore, manufacture of vaccines containing these unstable antigens can be complicated and involve multiple purification steps. Therefore it is an object of the invention to identify further strategies to stabilize S.aureus polypeptide antigens in immunogenic compositions.
  • compositions containing these covalent dimers can be unstable, and may form aggregates or influence the stability of the other antigens in the composition, if present. Covalent dimer formation can be prevented by replacing, modifying or deleting the cysteine residues such that disulphide bond formation is eliminated. Interestingly, preventing these antigens to form covalent dimers improves antigen stability and keeps a high total selectivity of the composition (i.e.
  • cysteine- deficient antigens remain effective in eliciting an immune response against the wild-type cysteine-containing antigens. Therefore, cysteine- deficient antigens can be included in vaccine compositions to improve antigen stability.
  • the Sta006 and StaOl l antigens naturally have N-terminus cysteines in their mature forms.
  • the EsxB protein naturally contains an internal cysteine residue.
  • the inventors found that a combination of the wild-type cysteine-containing Sta006, StaOl l, Hla and EsxAB does not have good long-term stability in aqueous conditions.
  • the wild-type cysteine-containing EsxAB, Sta006 and StaOl l can perform redox reactions in buffer solutions and form homo- or heterodimers (e.g. Sta006/Sta011, etc.) which are unstable. These dimers may be produced as a result of disulphide bond formation between cysteine residues.
  • an immunogenic composition comprising variants of EsxAB, Sta006 and StaOl 1 that do not contain any free thiol group under reducing conditions (and hence do not form homo- or heterodimers) is more stable compared to an immunogenic composition containing the wild-type antigens that contain cysteine residues (i.e. containing free thiol groups under reducing conditions).
  • the inventors observed that the immunogenic composition containing antigen variants with no thiol groups are stable for at least four weeks in liquid formulation. This immunogenic composition also demonstrates higher selectivity, reproducibility, stability, purity and improved process characteristics. Hence, the immunogenic compositions of the invention can be produced with fewer purification steps. The manufacturing process is thus simpler and more efficient.
  • the invention provides an immunogenic composition that comprises: (i) a EsxB antigen, e.g. a polypeptide having an amino acid sequence that has at least 90% (e.g. >91%, >92%, >93%, >94%, >95%, >96%, >97%, >98%) identity to SEQ ID NO: 16; (ii) a Sta006 antigen, e.g. a polypeptide having an amino acid sequence that has having at least 90% (e.g.
  • a StaOl l antigen e.g. a polypeptide having an amino acid sequence that has having at least 90%> (e.g. >91%>, >92%>, >93%>, >94%, >95%, >96%, >97%, >98%, >99%, >99.5%) identity to SEQ ID NO: 24; and/or (iii) a StaOl l antigen, e.g. a polypeptide having an amino acid sequence that has having at least 90%> (e.g. >91%>, >92%>, >93%>, >94%, >95%, >96%, >97%, >98%, >99%, >99.5%) identity to SEQ ID NO: 28, provided that none of the antigens contains any free thiol group, and each of the polypeptides (i) to (iii) can elicit antibodies (e.g.
  • (i) when administered to a human) which recognise the respective wild-type cysteine-containing antigen.
  • (i) can elicit antibodies which recognise SEQ ID NO: 2 (EsxB)
  • (ii) can elicit antibodies which recognise SEQ ID NO: 10 (Sta006)
  • (iii) can elicit antibodies which recognise SEQ ID NO: 11 (StaOl l).
  • the immunogenic composition may further comprise Hla (preferably in a non-toxic form e.g. Hla-H35L as discussed below).
  • Hla preferably in a non-toxic form e.g. Hla-H35L as discussed below.
  • the immunogenic composition preferably also comprises: (iv) a H35L mutant form of Hla e.g. comprising SEQ ID NO: 9, which can elicit antibodies which recognise SEQ ID NO: 67 (wild-type Hla).
  • the EsxB antigen can be combined as a hybrid polypeptide with EsxA, as discussed below, e.g. an EsxAB hybrid with an EsxB antigen downstream of EsxA antigen. These antigens are discussed in detail in Reference 5.
  • a useful composition of the invention includes: (i) a first polypeptide having amino acid sequence SEQ ID NO: 59 (EsxAB); (ii) a second polypeptide having amino acid sequence SEQ ID NO: 26 (Sta006); and/or (iii) a third polypeptide having amino acid sequence SEQ ID NO: 32 (StaOl l); and optionally further comprising (iv) a fourth polypeptide having amino acid sequence SEQ ID NO: 9 (Hla- H35L).
  • the composition may include one or more further polypeptides; in other embodiments the only polypeptides in the composition are those discussed above. If the composition does include one or more further polypeptides, it is preferred that these do not contain any free thiol groups.
  • the immunogenic composition comprises further antigens which can be polypeptides and/or saccharides.
  • they can also include one or more S. aureus capsular saccharide conjugate(s) e.g. against a serotype 5 and/or a serotype 8 strain.
  • the composition includes no additional staphylococcal polypeptide antigens.
  • the composition includes no additional staphylococcal antigens.
  • the composition includes no additional antigens.
  • polypeptides When more than one polypeptides are present, they may be present at substantially equal masses i.e. the mass of each of them is within +5% of the mean mass of all the polypeptides. Thus, when four polypeptides are present, they may be present at a mass ratio of a:b:c:d, where each of a-d is between 0.95 and 1.05.
  • the invention also provides a lyophilizate of the immunogenic composition of the invention.
  • This lyophilizate can be reconstituted with aqueous material to provide an aqueous immunogenic composition of the invention.
  • the lyophilizate is thus reconstituted with a suitable liquid diluent ⁇ e.g. a buffer, saline solution, water for injections (WFI)).
  • the liquid diluent can include an adjuvant e.g. an aluminium salt or an oil-in-water emulsion adjuvant.
  • composition of the invention can be in aqueous form, in which case it ideally has a pH of between 5 and 8.
  • the composition may also include an adjuvant e.g. an aluminium salt.
  • EsxA antigens that are useful can elicit antibodies ⁇ e.g. when administered to a human) that recognise a wild-type EsxA antigen ⁇ e.g. SEQ ID NO: 1).
  • the polypeptide may comprise an amino acid sequence: (a) having 80% or more identity ⁇ e.g. 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5% or more) to SEQ ID NO: 1 ; and/or (b) comprising a fragment of at least 'n' consecutive amino acids of SEQ ID NO: 1, wherein 'n' is 7 or more ⁇ e.g. 8, 10, 12, 14, 16, 18, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90 or more).
  • EsxA proteins include variants of SEQ ID NO: 1.
  • Preferred fragments of (b) comprise an epitope from SEQ ID NO: 1.
  • Other preferred fragments lack one or more amino acids ⁇ e.g. 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25 or more) from the C-terminus and/or one or more amino acids (e.g. 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25 or more) from the N-terminus of SEQ ID NO: 1 while retaining at least one epitope of SEQ ID NO: 1.
  • Other fragments omit one or more protein domains.
  • EsxA can be present as a hybrid polypeptide with EsxB as discussed below.
  • the 'EsxB' antigen is disclosed as a useful immunogen in Reference 5. It is SAOUHSC 00265 in the NCTC 8325 strain and has amino acid sequence SEQ ID NO: 2 (GI:88194070).
  • the invention uses a form of EsxB that cannot form covalent dimers via disulphide bonds.
  • the polypeptide does not contain any free thiol group (under reducing conditions). It can elicit antibodies (e.g. when administered to a human) which recognise a wild-type EsxB antigen (e.g. SEQ ID NO: 2).
  • the polypeptide may comprise an amino acid sequence having 80% or more identity (e.g.
  • SEQ ID NOs: 16, 19, 20, 21, 22, 23, 43, 44, or 45 may also include an upstream amino acid sequence having 80% or more identity (e.g. 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5% or more) to any of SEQ ID NOs: 15, 17, 18, 42, 46 or 47.
  • SEQ ID NO: 16 is the C-terminus of SEQ ID NO: 2, from amino acids 32-104.
  • Met-1 and Cys-31 are absent in SEQ ID NO: 23.
  • SEQ ID NO: 15 is amino acid residues 2-30 of SEQ ID NO: 2.
  • SEQ ID NO: 17 has an additional amino acid residue 'Jf at the C-terminus, wherein 'Jf is an amino acid that does not contain a free thiol group (e.g. Ala, to give SEQ ID NO: 18).
  • Useful EsxB polypeptides may comprise a N-terminus methionine (e.g. SEQ ID NOs: 42-47).
  • a useful EsxB may comprise at least one point mutation that replaces, modifies or deletes the cysteine residue present in the wild-type form of the antigen.
  • a EsxB polypeptide may comprise an amino acid sequence having SEQ ID NO: 2, wherein the cysteine residue at position 31 of SEQ ID NO: 2 is replaced, modified or deleted.
  • the replacement is with a serine residue or with an alanine residue (e.g. providing SEQ ID NO: 45).
  • the cysteine residue is deleted (e.g. providing SEQ ID NO: 43).
  • EsxB can be present as a hybrid polypeptide with EsxA as discussed below.
  • the 'Sta006' antigen is disclosed as a useful immunogen in Reference 5. It was originally annotated as 'ferrichrome-binding protein', and has also been referred to as 'FhuD2' in the literature [7].
  • Sta006 is SAOUHSC 02554 and has amino acid sequence SEQ ID NO: 3 (GL88196199).
  • nwmn_2185 GL151222397. Mutant forms of Sta006 are reported in Reference 8.
  • the known Sta006 antigen has a N-terminus cysteine in its mature form which may be lipidated.
  • Wild- type cysteine-containing Sta006 can exist as a monomer or an oligomer (e.g. covalent dimer).
  • the invention uses a variant form of Sta006 that cannot form covalent dimers via disulphide bonds.
  • the polypeptide does not contain any free thiol group (under reducing conditions). It can elicit antibodies (e.g. when administered to a human) which recognise a wild-type Sta006 antigen (e.g. SEQ ID NO: 10).
  • the polypeptide may comprise an amino acid sequence having 80% or more identity (e.g. 85%, 90%>, 91%>, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5% or more) to any of SEQ ID NOs: 24, 25, 26 and 27.
  • SEQ ID NO: 24 is amino acid residues 19-302 of SEQ ID NO: 3.
  • SEQ ID NO: 25 has an additional amino acid residue 'Jf at the N-terminus, wherein 'Jf is an amino acid that does not contain a free thiol group.
  • SEQ ID NO: 26 has a Met-Ala-Ser-sequence at the N-terminus.
  • SEQ ID NO: 27 has a Met-Ala-Ser-sequence at the N- terminus.
  • a Sta006 polypeptide comprising any of SEQ ID NOs: 24, 25, 26 and 27 can be used with the invention.
  • a useful variant form of Sta006 may comprise at least one point mutation that replaces, modifies or deletes the cysteine residue present in the wild-type form of the antigen.
  • a Sta006 polypeptide may comprise an amino acid sequence having SEQ ID NO: 12, wherein the cysteine residue at position 4 of SEQ ID NO: 12 is replaced, modified or deleted.
  • the replacement is with a serine or an alanine residue.
  • the cysteine residue is deleted (e.g. providing SEQ ID NO: 26).
  • the 'StaOl l' antigen is disclosed as a useful immunogen in Reference 5. It was originally annotated merely as 'lipoprotein'.
  • StaOl l is SAOUHSC 00052 and has amino acid sequence SEQ ID NO: 4 (GL88193872).
  • the known StaOl l antigen has a N-terminus cysteine in its mature form, which may be lipidated. Wild-type cysteine-containing StaOl 1 can exist as a monomer or an oligomer (e.g. covalent dimer), with Ca ++ ions favouring oligomerization.
  • the invention uses a variant form of StaOl 1 that cannot form covalent dimers via disulphide bonds.
  • the polypeptide does not contain any free thiol group (under reducing conditions). It can elicit antibodies (e.g. when administered to a human) which recognise a wild-type StaOl l antigen (e.g. SEQ ID NO: 11).
  • the polypeptide may comprise an amino acid sequence having 80%> or more identity (e.g. 85%>, 90%>, 91%>, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5% or more) to any of SEQ ID NOs: 28, 29, 30, 31, 32 and33.
  • SEQ ID NO: 28 is amino acid residues 26-256 of SEQ ID NO: 4.
  • SEQ ID NO: 30 has a Met-Gly- sequence at the N-terminus of SEQ ID NO: 28.
  • SEQ ID NO: 31 has a Met-Gly-sequence at the N- terminus of SEQ ID NO: 29.
  • SEQ ID NO: 32 has the sequence of SEQ ID NO: 31, wherein ' is serine.
  • a StaOl l polypeptide comprising any of SEQ ID NOs: 28, 29, 30, 31, 32 and 33 can be used with the invention.
  • Variant forms of SEQ ID NO: 4 which may be used for preparing a StaOl 1 polypeptide of the invention include, but are not limited to, SEQ ID NOs: 6, 7 and 8 with various Ile/Val/Leu substitutions.
  • SEQ ID NO: 6 has Leu-146 instead of Ile-146 and Ile-165 instead of Leu-165.
  • SEQ ID NO: 7 has Val-146 instead of He- 146 and Ilel65 instead of Leu- 165.
  • SEQ ID NO: 8 has Leu-146 instead of Ile-146 and Val-165 instead of Leu-165.
  • a StaOl 1 polypeptide of the invention can comprise residues 26-256 of any of SEQ ID NOs: 4, 6, 7 and 8, and it can elicit antibodies (e.g. when administered to a human) which recognise a mature StaOl l antigen (e.g. SEQ ID NO: 11, 86, 87 or 88).
  • a useful variant form of StaO 11 may comprise at least one point mutation that replaces, modifies or deletes the cysteine residue present in the wild-type form of the antigen.
  • a StaOl l polypeptide may comprise an amino acid sequence having SEQ ID NO: 13, wherein the cysteine residue at position 3 of SEQ ID NO: 13 is replaced, modified or deleted.
  • the replacement is with a serine residue (e.g. providing SEQ ID NO: 32) or an alanine residue.
  • the cysteine residue is deleted.
  • the 'Hla' antigen is the 'alpha-hemolysin precursor' also known as 'alpha toxin' or simply 'hemolysin'.
  • Hla is SAOUHSC 01121 and has amino acid sequence SEQ ID NO: 67 (GL88194865).
  • Hla is an important virulence determinant produced by most strains of S. aureus, having pore-forming and haemolytic activity.
  • Anti-Hla antibodies can neutralise the detrimental effects of the toxin in animal models, and Hla is particularly useful for protecting against pneumonia. Mutant forms of Hla are disclosed as a useful immunogens in Reference 5.
  • SEQ ID NO: 67 has no free thiol group (e.g. it does not contain any cysteine residue).
  • Hla used with the invention ideally also has no free thiol group.
  • Various forms of Hla antigens that are suitable for use in this invention are discussed in Reference 5.
  • Hla antigens used with the invention can elicit an antibody (e.g. when administered to a human) that recognises SEQ ID NO: 67 and/or may comprise an amino acid sequence: (a) having 80% or more identity (e.g.
  • SEQ ID NO: 67 SEQ ID NO: 67
  • b comprising a fragment of at least 'n' consecutive amino acids of SEQ ID NO: 67, wherein 'n' is 7 or more (e.g. 8, 10, 12, 14, 16, 18, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100, 150, 200, 250 or more).
  • Hla proteins include variants of SEQ ID NO: 67.
  • Preferred fragments of (b) comprise an epitope from SEQ ID NO: 67.
  • Other preferred fragments lack one or more amino acids (e.g.
  • Hla's toxicity can be avoided in compositions of the invention by chemical inactivation (e.g. using formaldehyde, glutaraldehyde or other cross-linking reagents). Instead, however, it is preferred to use mutant forms of Hla which remove its toxic activity while retaining its immunogenicity. Such detoxified mutants are already known in the art.
  • residue 61 may not be histidine, and may instead be e.g. He, Val or preferably Leu.
  • SEQ ID NO: 69 is the mature mutant Hla-H35L sequence (i.e. SEQ ID NO: 68 with a H35L mutation) and a useful Hla antigen comprises SEQ ID NO: 69.
  • Another useful mutation replaces a long loop with a short sequence e.g. to replace the 39mer at residues 136-174 of SEQ ID NO: 67 with a tetramer such as PSGS (SEQ ID NO: 70), as in SEQ ID NO: 71 (which also includes the H35L mutation) and SEQ ID NO: 72 (which does not include the H35L mutation).
  • Another useful mutation replaces residue Y101 e.g.
  • SEQ ID NOs: 77, 78 & 79 are three useful fragments of SEQ ID NO: 67 ('H ve', 'H so' and 'Hla 27 - 79 ', respectively).
  • SEQ ID NOs: 80, 81 and 82 are the corresponding fragments from SEQ ID NO: 69.
  • Hla sequence is SEQ ID NO: 9, which was used in the examples. It has a N-terminal Met, then an Ala-Ser dipeptide from the expression vector, then SEQ ID NO: 69 (from NCTC8325 strain). It has no cysteine residues and is encoded by SEQ ID NO: 83.
  • Antigens used in the invention may be present in the composition as individual separate polypeptides. Where more than one antigen is used, however, they do not have to be present as separate polypeptides. Instead, at least two (e.g. 2, 3, 4, 5, or more) antigens can be expressed as a single polypeptide chain (a 'hybrid' polypeptide).
  • the hybrid polypeptide used with the invention ideally has no free thiol group.
  • Hybrids consisting of amino acid sequences from two, three, four, or more antigens are useful.
  • hybrids consisting of amino acid sequences from two, three, four, or five antigens are preferred, such as two antigens.
  • hybrid polypeptides may be mixed together in a single formulation.
  • the hybrid polypeptides can also be combined with conjugates or non-S. aureus antigens as described elsewhere herein.
  • One hybrid polypeptide of the invention may include a EsxA antigen and a variant form of EsxB that does not contain any free thiol group.
  • a single polypeptide can elicit antibodies (e.g. when administered to a human) that recognise both wild-type EsxA and wild-type cysteine-containing EsxB antigen (i.e. both SEQ ID NO: 1 and SEQ ID NO: 2).
  • the single polypeptide can include: (i) a first polypeptide sequence having 80% or more identity (e.g.
  • the first and second polypeptide sequences can be in either order, N- to C- terminus.
  • the hybrid polypeptide can also comprise third polypeptide sequence that has at least 90%> (e.g. >91%>, >92%, >93%, >94%, >95%, >96%, >97%, >98%) identity to SEQ ID NO: 15, and any such third sequence is ideally located upstream of the second polypeptide sequence (but if it is the first polypeptide sequence is upstream of the second polypeptide sequence then the third sequence should be downstream of the first).
  • third polypeptide sequence that has at least 90%> (e.g. >91%>, >92%, >93%, >94%, >95%, >96%, >97%, >98%) identity to SEQ ID NO: 15, and any such third sequence is ideally located upstream of the second polypeptide sequence (but if it is the first polypeptide sequence is upstream of the second polypeptide sequence then the third sequence should be downstream of the first).
  • SEQ ID NOs: 34-41 and 48-63 are 'EsxAB' hybrids, with EsxA upstream of EsxB; in contrast, SEQ ID NOs: 64 and 65 are 'EsxBA' hybrids, with EsxB to the N-terminus of EsxA. All of SEQ ID NOs: 34-65 include hexapeptide linker ASGGGS (SEQ ID NO: 66) and no cysteine residues. SEQ ID NOs: 52-65 include N-terminus methionine residues, whereas the 'EsxAB' hybrids of SEQ ID NOs: 34-41 and 48-51 do not.
  • a useful polypeptide comprises an amino acid sequence having 80% or more identity (e.g. 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5% or more) to any of SEQ ID NOs: 34-41 and 48-63, wherein the polypeptide does not contain any free thiol group.
  • These polypeptides e.g. SEQ ID NO: 295) can elicit antibodies (e.g. when administered to a human) which recognise both the wild-type staphylococcal protein comprising SEQ ID NO: 1 and the wild-type staphylococcal protein comprising SEQ ID NO: 2.
  • the immune response will recognise both EsxA and EsxB staphylococcal antigens.
  • Another hybrid polypeptide of the invention may include: (i) Hla and Sta006 antigens, (ii) Hla, EsxA and EsxB antigens or (iii) Sta006, EsxA and EsxB antigens, wherein variants of EsxB, Sta006 and StaOl 1 are used instead of the wild-type antigen, and the variants do not contain any free thiol groups.
  • these hybrid polypeptides can elicit antibodies (e.g. when administered to a human) that recognise each of the wild-type staphylococcal proteins (e.g. as shown in the sequence listing) represented in the hybrid e.g. which recognise both wild-type EsxA and wild-type EsxB, or which recognise both wild-type Hla and wild-type Sta006, or which recognise wild-type Hla, wild-type EsxA and wild-type EsxB, or which recognise wild-type Sta006, wild-type EsxA and wild-type EsxB.
  • the wild-type staphylococcal proteins e.g. as shown in the sequence listing
  • the invention also provides a polypeptide comprising amino acid sequence Zi-Z 2 -Z 3 wherein: Zi is an amino acid sequence having at least 90% (e.g. >91%, >92%, >93%, >94%, >95%, >96%, >97%, >98%) identity to SEQ ID NO: 15; Z 2 is either absent or is an amino acid sequence having up to 5 amino acids; Z 3 is an amino acid sequence having at least 90% (e.g.
  • polypeptide includes no cysteine residues; and the polypeptide can elicit antibodies which recognise a wild-type EsxB antigen (e.g. SEQ ID NO: 2).
  • a polypeptide comprises amino acid sequence Zi-Z 2 -Z 3
  • the amino acid sequence Zi is sequence Z ia - Z ib - Z ic wherein: Z ia comprises an amino acid sequence (a) having 80% or more identity (e.g. 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5% or more) to SEQ ID NO: 1 ; and/or (b) comprising a fragment of at least 'n' consecutive amino acids of SEQ ID NO: 1, wherein 'n' is 7 or more (e.g.
  • Z lb is either absent or is a linker sequence (as defined below); and Z ic comprises an amino acid sequence (a) having 80% or more identity (e.g. 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5% or more) to SEQ ID NO: 15; and/or (b) comprising a fragment of at least 'n' consecutive amino acids of SEQ ID NO: 15, wherein 'n' is 7 or more (e.g. 8, 10, 12, 14, 16, 18, 20, 25 or more).
  • a useful linker is GSGGGG (SEQ ID NO: 84), with the Gly-Ser dipeptide being formed from a BamHI restriction site thus aiding cloning and manipulation, and the (Gly)4 tetrapeptide (SEQ ID NO: 85) being a typical poly- glycine linker.
  • Other suitable linkers are ASGGGS (SEQ ID NO: 66) or a Leu-Glu dipeptide.
  • the invention uses variant forms of S. aureus antigens that do not form disulphide bonds.
  • S. aureus antigens that contain free thiol groups e.g. cysteine amino acids
  • the covalent dimers are usually produced by oxidation of the thiol groups of cysteine residues resulting in a disulphide bond (i.e. the formation of a cystine).
  • the polypeptides of the invention do not contain any free thiol groups (under reducing conditions) that can react to form disulphide bonds.
  • a free thiol group also known as an unprotected thiol group, or a free or unprotected -SH, has a reactive sulphur atom.
  • a cysteine amino acid residue has a free thiol group under reducing conditions, and thus the polypeptides of the invention do not contain any cysteine amino acid residue.
  • a cysteine residue can be derivatised such that the thiol group is protected and cannot react to form disulphide bonds, e.g. by adding a thiol protecting group.
  • Thiol protecting groups are known in the art, e.g. thioether, thioester or derivatives thereof [12].
  • the polypeptides of the invention may contain derivatised cysteine amino acid residues, provided that the derivatised cysteine amino acid residues do not have free thiol groups (under reducing conditions) that can form disulphide bonds.
  • a polypeptide can include a thiol group, but this thiol group is not part of the side chain in a cysteine residue. Ideally, however, a polypeptide includes no thiol groups at all.
  • polypeptide contains neither cysteine nor cystine.
  • the polypeptide may contain amino acid 'Jf .
  • 'Jf can be any amino acid, provided that it does not contain a free thiol group.
  • the amino acid can be a natural or a non-natural amino acid.
  • Natural amino acids are known in the art, e.g. alanine, arginine, asparagine, aspartic acid, glutamine, glutamic acid, glycine, histidine, isoleucine, leucine lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine or valine.
  • Cysteine has a free thiol group, and so 'Jf cannot be a cysteine residue.
  • a non-natural amino acid can be a derivatised or modified amino acid.
  • 'Jf can be a derivatised amino acid that does not contain a free thiol group, e.g. methyl-c
  • Polypeptides used with the invention can take various forms (e.g. native, fusions, glycosylated, non-glycosylated, lipidated, non-lipidated, phosphorylated, non-phosphorylated, myristoylated, non-myristoylated, monomeric, multimeric, particulate, denatured, etc.).
  • Polypeptides used with the invention can be prepared by various means (e.g. recombinant expression, purification from cell culture, chemical synthesis, etc.). Recombinantly-expressed proteins are preferred, particularly for hybrid polypeptides.
  • Antigens in composition of the invention are separated from the organism in which they were expressed before being combined. Polypeptides are thus provided in purified or substantially purified for before being used i.e. substantially free from other staphylococcal or host cell polypeptides.
  • a polypeptide is generally at least about 80% pure (by weight) before being combined with other polypeptides in compositions of the invention, and usually at least about 90% pure i.e. less than about 20%, and preferably less than about 10% ⁇ e.g. ⁇ 5%) of a polypeptide composition is made up of other polypeptides before being added to a mixture.
  • Preferred polypeptides used with the invention have a N-terminus methionine, but in some embodiments a methionine which was present at the N-terminus of a nascent polypeptide may be absent from the polypeptide in a composition of the invention.
  • Polypeptides used with the invention are preferably staphylococcal polypeptides.
  • polypeptide refers to amino acid polymers of any length.
  • the polymer may be linear or branched, it may comprise modified amino acids, and it may be interrupted by non-amino acids.
  • the terms also encompass an amino acid polymer that has been modified naturally or by intervention; for example, disulphide bond formation, glycosylation, lipidation, acetylation, phosphorylation, or any other manipulation or modification, such as conjugation with a labelling component.
  • polypeptides containing one or more analogs of an amino acid including, for example, unnatural amino acids, etc.
  • Polypeptides can occur as single chains or associated chains.
  • the invention provides polypeptides comprising a sequence -P-Q- or -Q-P-, wherein: -P- is an amino acid sequence as defined above and -Q- is not a sequence as defined above i.e. the invention provides fusion proteins, provided that the polypeptides do not contain any free thiol group.
  • -P- is an amino acid sequence as defined above
  • the N-terminus codon of -P- is not ATG, but this codon is not present at the N-terminus of a polypeptide, it will be translated as the standard amino acid for that codon rather than as a Met. Where this codon is at the N-terminus of a polypeptide, however, it will be translated as Met.
  • heterologous host for expression (recombinant expression).
  • the heterologous host may be prokaryotic ⁇ e.g. a bacterium) or eukaryotic. It may be E.coli, but other suitable hosts include Bacillus subtilis, Vibrio cholerae, Salmonella typhi, Salmonella typhimurium, Neisseria lactamica, Neisseria cinerea, Mycobacteria ⁇ e.g. M.tuberculosis), yeasts, etc.
  • the invention provides nucleic acid encoding polypeptides and hybrid polypeptides of the invention. It also provides nucleic acid comprising a nucleotide sequence that encodes one or more polypeptides or hybrid polypeptides of the invention.
  • the invention provides a process for producing nucleic acid of the invention, wherein the nucleic acid is synthesised in part or in whole using chemical means.
  • the invention provides vectors comprising nucleotide sequences of the invention (e.g. cloning or expression vectors) and host cells transformed with such vectors.
  • a nucleic acid sequence may be modified by replacing the codon for cysteine with a codon for another amino acid.
  • the cysteine may be replaced with any other amino acid, including serine, alanine, glycine, valine, leucine, or isoleucine, or modified forms of an amino acid that does not have free thiol groups (i.e. cannot readily form disulphide bonds).
  • the cysteine residue may simply be deleted from the sequence. Thus, a deletion must remove the codon for the cysteine from the nucleic acid sequence without introducing a frameshift.
  • Techniques for making substitution and deletion mutations at predetermined sites in a nucleic acid having a known sequence are well known and include, but are not limited to, primer mutagenesis and other forms of site-directed mutagenesis.
  • the invention also provides nucleic acid comprising nucleotide sequences having sequence identity to such nucleotide sequences. Identity between sequences is preferably determined by the Smith Waterman homology search algorithm as described above. Such nucleic acids include those using alternative codons to encode the same amino acid.
  • Nucleic acid according to the invention can take various forms (e.g. single stranded, double stranded, vectors, primers, probes, labelled etc.). Nucleic acids of the invention may be circular or branched, but will generally be linear. Unless otherwise specified or required, any embodiment of the invention that utilizes a nucleic acid may utilize both the double-stranded form and each of two complementary single- stranded forms which make up the double stranded form. Nucleic acids of the invention are preferably provided in purified or substantially purified form i.e. substantially free from other nucleic acids (e.g.
  • nucleic acids of the invention are preferably staphylococcal nucleic acids.
  • Nucleic acids of the invention may be prepared in many ways e.g. by chemical synthesis (e.g. phosphoramidite synthesis of DNA) in whole or in part, by digesting longer nucleic acids using nucleases (e.g. restriction enzymes), by joining shorter nucleic acids or nucleotides (e.g. using ligases or polymerases), from genomic or cDNA libraries, etc.
  • nucleases e.g. restriction enzymes
  • ligases or polymerases e.g. using ligases or polymerases
  • nucleic acid includes in general means a polymeric form of nucleotides of any length, which contain deoxyribonucleotides, ribonucleotides, and/or their analogs. It includes DNA, RNA, DNA/RNA hybrids. It also includes DNA or RNA analogs, such as those containing modified backbones (e.g. peptide nucleic acids (PNAs) or phosphorothioates) or modified bases.
  • PNAs peptide nucleic acids
  • the invention includes mRNA, tRNA, rRNA, ribozymes, DNA, cDNA, recombinant nucleic acids, branched nucleic acids, plasmids, vectors, probes, primers, etc. Where nucleic acid of the invention takes the form of RNA, it may or may not have a 5' cap.
  • Nucleic acids of the invention may be part of a vector i.e. part of a nucleic acid construct designed for transduction/transfection of one or more cell types.
  • Vectors may be, for example, "cloning vectors” which are designed for isolation, propagation and replication of inserted nucleotides, "expression vectors” which are designed for expression of a nucleotide sequence in a host cell, "viral vectors” which is designed to result in the production of a recombinant virus or virus-like particle, or “shuttle vectors", which comprise the attributes of more than one type of vector.
  • Preferred vectors are plasmids.
  • a "host cell” includes an individual cell or cell culture which can be or has been a recipient of exogenous nucleic acid.
  • Host cells include progeny of a single host cell, and the progeny may not necessarily be completely identical (in morphology or in total DNA complement) to the original parent cell due to natural, accidental, or deliberate mutation and/or change.
  • Host cells include cells transfected or infected in vivo or in vitro with nucleic acid of the invention.
  • nucleic acid is DNA
  • U in a RNA sequence
  • T in the DNA
  • RNA RNA
  • T in a DNA sequence
  • complement or “complementary” when used in relation to nucleic acids refers to Watson- Crick base pairing.
  • the complement of C is G
  • the complement of G is C
  • the complement of A is T (or U)
  • the complement of T is A.
  • bases such as I (the purine inosine) e.g. to complement pyrimidines (C or T).
  • An exemplary amino acid and nucleotide sequence for the antigens described herein can easily be found in public sequence databases from the NCTC 8325 and/or Newman S. aureus strain using their GI numbers, for example, but the invention is not limited to sequences from the NCTC 8325 and Newman strains. Genome sequences of several other strains of S. aureus are available, including those of MRSA strains N315 and Mu50 [13], MW2, N315, COL, MRSA252, MSSA476, RF122, USA300 (very virulent), JH1 and JH9. Standard search and alignment techniques can be used to identify in any of these (or other) further genome sequences the homolog of any particular sequence from the Newman or NCTC 8325 strain.
  • the available sequences from the Newman and NCTC 8325 strains can be used to design primers for amplification of homologous sequences from other strains.
  • the invention is not limited to these two strains, but rather encompasses such variants and homologs from other strains of S. aureus, as well as non-natural variants.
  • suitable variants of a particular SEQ ID NO include its allelic variants, its polymorphic forms, its homologs, its orthologs, its paralogs, its mutants, etc., provided they do not contain any free thiol group.
  • polypeptides used with the invention may, compared to the SEQ ID NO herein, include one or more ⁇ e.g. 1, 2, 3, 4, 5, 6, 7, 8, 9, etc.) amino acid substitutions, such as conservative substitutions ⁇ i.e. substitutions of one amino acid with another which has a related side chain), provided that the new amino acid residue does not contain a free thiol group.
  • the polypeptides of the invention do not contain any cysteine residue.
  • Genetically-encoded amino acids are generally divided into four families: (1) acidic i.e. aspartate, glutamate; (2) basic i.e. lysine, arginine, histidine; (3) non-polar i.e.
  • polypeptide of the invention cannot be substituted with a cysteine.
  • the polypeptides may also include one or more (e.g.
  • the polypeptides may also include one or more (e.g. 1 , 2, 3, 4, 5, 6, 7, 8, 9, etc.) insertions (e.g. each of 1 , 2, 3, 4 or 5 amino acids) relative to the SEQ ID NO sequences, provided that the inserted amino acid residue does not contain any free thiol group (e.g. the inserted amino acid is not a cysteine).
  • polypeptide used with the invention may comprise an amino acid sequence that:
  • ⁇ is identical (i.e. 100% identical) to a sequence disclosed in the sequence listing;
  • sequence identity e.g. 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5% or more
  • ⁇ has 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 (or more) single amino acid alterations (deletions, insertions, substitutions), which may be at separate locations or may be contiguous, as compared to the sequences of (a) or (b); and
  • each moving window of x amino acids from N-terminus to C-terminus (such that for an alignment that extends to p amino acids, where p>x, there are p-x+1 such windows) has at least xy identical aligned amino acids, where: x is selected from 20, 25, 30, 35, 40, 45, 50, 60, 70,
  • polypeptide does not contain any free thiol group.
  • deletions or substitutions may be at the N-terminus and/or C-terminus, or may be between the two termini.
  • Truncations may involve deletion of up to 40 (or more) amino acids at the N-terminus and/or C-terminus.
  • N-terminus truncation can remove leader peptides e.g. to facilitate recombinant expression in a heterologous host.
  • C-terminus truncation can remove anchor sequences e.g. to facilitate recombinant expression in a heterologous host.
  • an antigen comprises a sequence that is not identical to a complete S. aureus sequence from the sequence listing (e.g. when it comprises a sequence listing with ⁇ 100%> sequence identity thereto, or when it comprises a fragment thereof) it is preferred in each individual instance that the antigen can elicit an antibody which recognises the respective complete S. aureus sequence.
  • the immunogenic compositions of the invention may further comprise saccharide antigens (e.g. known saccharide antigens include the exopolysaccharide of S. aureus, which is a poly-N-acetylglucosamine (PNAG), and the capsular saccharides of S.aureus, which can be e.g. from type 5, type 8 or type 336).
  • saccharide antigens include the exopolysaccharide of S. aureus, which is a poly-N-acetylglucosamine (PNAG), and the capsular saccharides of S.aureus, which can be e.g. from type 5, type 8 or type 336).
  • PNAG poly-N-acetylglucosamine
  • capsular saccharides of S.aureus which can be e.g. from type 5, type 8 or type 336.
  • a composition does not include a S.aureus saccharide antigen.
  • the immunogenic compositions of the invention may further comprise non-staphylococcal antigens, and in particular with antigens from bacteria associated with nosocomial infections.
  • the immunogenic composition may further comprise one or more antigen(s) selected from the group consisting of: Clostridium difficile; Pseudomonas aeruginosa; Candida albicans; and extraintestinal pathogenic Escherichia coli.
  • antigen(s) selected from the group consisting of: Clostridium difficile; Pseudomonas aeruginosa; Candida albicans; and extraintestinal pathogenic Escherichia coli.
  • Further suitable antigens for use in combination with staphylococcal antigens of the invention are listed on pages 33-46 of Reference 16.
  • a preferred composition of the invention comprises any two or more (e.g. 2, 3 or all 4) of the antigens selected from: (i) a EsxB polypeptide of the invention, e.g. having at least 90% (e.g. >91%, >92%, >93%, >94%, >95%, >96%, >97%, >98%) identity to SEQ ID NO: 16, wherein the EsxB antigen has no free thiol group, and can elicit antibodies (e.g. when administered to a human) which recognise a wild-type EsxB antigen (e.g. SEQ ID NO: 2); (ii) a Sta006 polypeptide of the invention, e.g. having at least 90% (e.g.
  • Sta006 antigen has no free thiol group, and can elicit antibodies (e.g. when administered to a human) which recognise a wild-type Sta006 antigen (e.g. SEQ ID NO: 10); (iii) a StaOl 1 polypeptide of the invention, e.g. having at least 90% (e.g.
  • StaOl 1 antigen has no free thiol group, and can elicit antibodies (e.g. when administered to a human) which recognise a wild-type StaOl l antigen (e.g. SEQ ID NO: 11); and (iv) a H35L mutant form of Hla e.g. comprising SEQ ID NO: 9, wherein H35L polypeptide can elicit antibodies which recognise a wild-type Hla (e.g. SEQ ID NO: 67).
  • the composition comprises: (a) the EsxB polypeptide of (i) and the Sta006 polypeptide of (ii); (b) the EsxB polypeptide of (i) and the StaOl l polypeptide of (iii); (c) the Sta006 polypeptide of (ii) and the StaOl 1 polypeptide of (iii); (d) the EsxB polypeptide of (i) and the Hla-H35L polypeptide of (iv); (e) the Sta006 polypeptide of (ii) and the Hla-H35L polypeptide of (iv); or (f) the StaOl 1 polypeptide of (iii) and the Hla-H35L polypeptide of (iv).
  • the composition comprises: (a) the EsxB polypeptide of (i), the Sta006 polypeptide of (ii) and the StaOl 1 polypeptide of (iii); (b) the EsxB polypeptide of (i), the Sta006 polypeptide of (ii) and the Hla- H35L polypeptide of (iv); (c) the Sta006 polypeptide of (ii) and the StaOl l polypeptide of (iii) and the Hla-H35L polypeptide of (iv); or (d) the EsxB polypeptide of (i) and the StaOl l polypeptide of (iii) and the Hla-H35L polypeptide of (iv).
  • Another preferred composition of the invention includes all four of the EsxB polypeptide of (i), the Sta006 polypeptide of (ii), the StaOl 1 polypeptide of (iii), and the Hla-H35L polypeptide of (iv).
  • the EsxB polypeptide of (i) can also comprise (a) an upstream amino acid sequence having at least 90%> (e.g. >91%, >92%, >93%, >94%, >95%, >96%, >97%, >98%) identity to SEQ ID NO: 15 and (b) a further upstream amino acid sequence having at least 90% (e.g. >91%, >92%, >93%, >94%, >95%, >96%, >97%, >98%) identity to SEQ ID NO: 1.
  • the polypeptide can be an EsxAB polypeptide as disclosed above, and it can elicit antibodies which recognise both SEQ ID NO: 1 and SEQ ID NO: 2.
  • the EsxAB hybrid polypeptide can comprise an amino acid sequence having 80% or more identity to SEQ ID NO: 59, wherein the EsxAB hybrid polypeptide can elicit antibodies which recognise SEQ ID NOs: 1 and 2.
  • a composition of the invention may comprise: (i) a single polypeptide including both an EsxA antigen and an EsxB antigen e.g. comprising SEQ ID NO: 14; (ii) a Sta006 antigen e.g. comprising SEQ ID NO: 12; and /or (iii) a StaOl 1 antigen e.g. comprising SEQ ID NO: 13; wherein at least one (e.g. 1, 2 or all 3) of (i), (ii) or (iii) comprises at least one point mutation that replaces, modifies or deletes the cysteine residue present in the wild-type form of the antigen (e.g. present in each of SEQ ID NOs: 12, 13 & 14).
  • the cysteine residues at position 133 of SEQ ID NO: 14, at position 4 of SEQ ID NO: 12 and at position 3 of SEQ ID NO: 13 may independently be replaced, modified or deleted.
  • the replacement is with a serine or an alanine residue.
  • the cysteine residue is deleted.
  • none of the polypeptides contains any cysteine residues.
  • Each of the polypeptides (i) to (iii) can elicit antibodies (e.g. when administered to a human) which recognise the respective wild-type cysteine-containing antigen.
  • (i) can elicit antibodies which recognise SEQ ID NO: 2 (EsxB)
  • (ii) can elicit antibodies which recognise SEQ ID NO: 10 (Sta006)
  • (iii) can elicit antibodies which recognise SEQ ID NO: 11 (StaOl 1).
  • composition may further comprise (iv) a H35L mutant form of Hla e.g. comprising SEQ ID NO: 9, which can elicit antibodies which recognise a wild-type Hla (e.g. SEQ ID NO: 67).
  • a H35L mutant form of Hla e.g. comprising SEQ ID NO: 9, which can elicit antibodies which recognise a wild-type Hla (e.g. SEQ ID NO: 67).
  • a useful composition of the invention comprises: (i) a Sta006 polypeptide having amino acid sequence SEQ ID NO: 26; (ii) a StaOl 1 polypeptide having amino acid sequence SEQ ID NO: 32; and/or (iii) a EsxAB hybrid polypeptide having amino acid sequence SEQ ID NO: 59.
  • the composition can further comprise a Hla polypeptide having amino acid sequence SEQ ID NO: 9.
  • the polypeptides When two or more of the polypeptides are present in the composition, the polypeptides may be present at substantially equal masses i.e. the mass of each of them is within +5% of the mean mass of all the polypeptides. Thus when four polypeptides are present, they may be present at a mass ratio of a:b:c:d, where each of a-d is between 0.95 and 1.05.
  • the composition may include one or more further polypeptides; in other embodiments the only polypeptides in the composition are the polypeptides discussed above. If the composition does include one or more further polypeptides, it is preferred that these do not contain any free thiol groups (under reducing conditions).
  • the further polypeptides are staphylococcal polypeptides, e.g. the S. aureus polypeptides disclosed in Reference 5.
  • composition of the invention is particularly useful when using TLR7 agonists of formula (K). These agonists are discussed in detail in Reference 17:
  • R 1 is H, Ci-Cgalkyl, -C(R 5 ) 2 OH, -L ⁇ 5 , -L l R 6 , -L 2 R 5 , -L 2 R 6 , -OL 2 R 5 , or -OL 2 R 6 ;
  • L 1 is -C(O)- or -0-;
  • L 2 is Ci-C 6 alkylene, C 2 -C 6 alkenylene, arylene, heteroarylene or -((CR 4 R 4 ) p O) q (CH 2 ) p -, wherein the CpCealkylene and C2-C 6 alkenylene of L 2 are optionally substituted with 1 to 4 fluoro groups; each L 3 is independently selected from d-Cealkylene and -((CR 4 R 4 ) p O) q (CH 2 ) p -, wherein the Cp Cealkylene of L 3 is optionally substituted with 1 to 4 fluoro groups;
  • L 4 is arylene or heteroarylene
  • R 2 is H or Ci-Cgalkyl
  • R 3 is selected from C r C 4 alkyl, -L 3 R 5 , -L ⁇ 5 , -L 3 R 7 , -L 3 L 4 L 3 R 7 , -L 3 L 4 R 5 , -L 3 L 4 L 3 R 5 , -OL 3 R 5 , -OL 3 R 7 , -OL 3 L 4 R 7 , -OL 3 L 4 L 3 R 7 , -OR 8 , -OL 3 L 4 R 5 , -OL 3 L 4 L 3 R 5 and -C(R 5 ) 2 OH ;
  • each R 4 is independently selected from H and fluoro
  • R 5 is -P(0)(OR 9 ) 2 ,
  • R 6 is -CF 2 P(0)(OR 9 ) 2 or -C(0)OR 10 ;
  • R 7 is -CF 2 P(0)(OR 9 ) 2 or -C(0)OR 10 ;
  • R 8 is H or C r C 4 alkyl
  • each R 9 is independently selected from H and Ci-Cealkyl
  • R 10 is H or C r C 4 alkyl
  • each p is independently selected from 1, 2, 3, 4, 5 and 6, and
  • q 1, 2, 3 or 4.
  • the compound of formula (K is preferably of formula ( ⁇ '):
  • P 1 is selected from H, Ci-C 6 alkyl optionally substituted with COOH and -Y-L-X- P(0)(OR x )(OR Y );
  • P 2 is selected from H, C r C 6 alkyl, C r C 6 alkoxy and -Y-L-X-P(0)(OR x )(OR Y );
  • R B is selected from H and Ci-C 6 alkyl
  • R x and R Y are independently selected from H and CpCealkyl
  • X is selected from a covalent bond, O and NH;
  • Y is selected from a covalent bond, O, C(O), S and NH;
  • L is selected from, a covalent bond Ci-C 6 alkylene, Ci-C 6 alkenylene, arylene, heteroarylene, C r Cealkyleneoxy and -((CH 2 ) p O) q (CH 2 ) p - each optionally substituted with 1 to 4 substituents independently selected from halo, OH, C r C 4 alkyl, -OP(0)(OH) 2 and -P(0)(OH) 2 ;
  • each p is independently selected from 1, 2, 3, 4, 5 and 6;
  • q is selected from 1, 2, 3 and 4.
  • P 1 is selected from CpCealkyl optionally substituted with COOH and -Y-L-X-P(0)(OR x )(OR Y );
  • P 2 is selected from C r C 6 alkoxy and -Y-L-X-P(0)(OR x )(OR Y );
  • R B is C r Cealkyl;
  • X is a covalent bond;
  • L is selected from CpCealkylene and -((CH 2 ) p O) q (CH 2 ) p - each optionally substituted with 1 to 4 substituents independently selected from halo, OH, Ci-C 4 alkyl, -OP(0)(OH) 2 and -P(0)(OH) 2 ; each p is independently selected from 1, 2 and 3; q is selected from 1 and 2.
  • a preferred compound of formula (K) for use with the invention is 3-(5-amino-2-(2-methyl-4-(2-(2-(2-(2-(2-phosphonoethoxy) ethoxy)ethoxy)phenethyl)benzo[fj [1 ,7] naphthyridin-8-yl)propanoic acid, or compound ' ⁇ :
  • This compound can be used as free base or in the form of a pharmaceutically acceptable salt e.g. an arginine salt.
  • Compounds of formula (K) can be mixed with an insoluble metal salt (preferably an aluminium salt, such as an aluminium hydroxide), and the compound is typically adsorbed to the metal salt.
  • the antigen of the invention (and, optionally, further antigen(s) in a composition) can also be adsorbed to the metal salt.
  • a preferred composition comprises (i) an antigen as defined herein (e.g. Sta006, StaOl 1 or EsxB) (ii) a TLR7 agonist of formula (K), such as formula (Kl), and (iii) an insoluble metal salt, such as an aluminium hydroxide.
  • the TLR7 agonist and the antigen are preferably adsorbed to the metal salt.
  • an immunogenic composition includes a stabilizing additive.
  • additives include, but are not limited to, chelators of divalent metal cations (e.g. EDTA, ethylenediaminetetraacetic acid), sugars (e.g. disaccharides such as sucrose or trehalose), sugar alcohols (e.g. mannitol), free amino acids (e.g. arginine), buffer salts (e.g. phosphate, citrate), polyols (e.g. glycerol, mannitol), or protease inhibitors.
  • chelators of divalent metal cations e.g. EDTA, ethylenediaminetetraacetic acid
  • sugars e.g. disaccharides such as sucrose or trehalose
  • sugar alcohols e.g. mannitol
  • free amino acids e.g. arginine
  • buffer salts e.g. phosphate, citrate
  • polyols e
  • EDTA is a preferred additive.
  • the final concentration of EDTA in the immunogenic composition of the invention can be about 1-50 mM, about 1-10 mM or about 1-5 mM, preferably about 2.5 mM.
  • a buffer is another useful additive, in order to control pH of a composition. This can be particularly important after reconstitution of lyophilized material.
  • Compositions of the invention may include one or more buffer(s). Typical buffers include: a phosphate buffer; a Tris buffer; a borate buffer; a succinate buffer; a histidine buffer; or a citrate buffer. A phosphate buffer is preferable. Buffers will typically be included in the 5-20 mM range.
  • Aqueous compositions of the invention preferably have a pH of between 5 and 8 e.g. between 5.5-6.5, or 5.9-6.1, or a pH of 6.
  • a saccharide or sugar alcohol (or mixture thereof e.g. a mannitol/sucrose mixture) is also useful, particularly when using lyophilization.
  • Suitable materials include, but are not limited to, mannitol, lactose, sucrose, trehalose, dextrose, etc.
  • sucrose is particularly preferred.
  • Such materials can be present at a concentration of about 1% by weight per volume, or about 3% to about 6% by weight per volume, or up to about 10% or about 12.5% by weight per volume, preferably about 5 % by weight per volume.
  • One way of storing immunogenic compositions of the invention is in lyophilized form. This procedure can be used with or without the addition of a metal chelator (e.g. EDTA).
  • EDTA metal chelator
  • the inventors have also shown that EDTA does not have a significant impact on the thermal characteristic of the vaccine and does not introduce any undesired plasticizing effect, thus meaning that EDTA-containing compositions can be lyophilized to further enhance storage stability.
  • the invention also provides a lyophilizate which comprises a divalent metal cation chelator (e.g. EDTA) and at least one antigen (e.g. at least one polypeptide antigen).
  • a divalent metal cation chelator e.g. EDTA
  • at least one antigen e.g. at least one polypeptide antigen
  • the invention also provides a lyophilizate of an aqueous immunogenic composition of the invention.
  • This is prepared by lyophilising an aqueous composition of the invention. It can then be reconstituted with aqueous material to provide an aqueous immunogenic composition of the invention.
  • Materials present in the material which is lyophilized will remain in the lyophilizate and will thus also be present after reconstitution e.g. buffer salts, lyoprotectants (e.g. sucrose and/or mannitol), chelators, etc. If the material is reconstituted with a smaller volume of material than before lyophilization then these materials will be present in more concentrated form.
  • the reconstituted lyophilizate preferably contains lyoprotectants (e.g.
  • sucrose and/or mannitol at a concentration of up to about 2.5% by weight per volume, preferably about 1%) to about 2% by weight per volume.
  • the amount of EDTA which is present in a composition prior to lyophilization is ideally at least 0.75 mM, and preferably at least 2.5 mM. A maximum of 50 mM is envisaged.
  • Liquid materials useful for reconstituting lyophilizates include, but are not limited to: salt solutions, such as physiological saline; buffers, such as PBS; water, such as wfi. They usefully have a pH between 4.5 and 7.5 e.g. between 6.8 and 7.2.
  • the reconstituted lyophilizate preferably has a pH of between 5-6.5 e.g.
  • a liquid material for reconstitution can include an adjuvant e.g. an aluminium salt adjuvant.
  • adjuvants e.g. an aluminium salt adjuvant.
  • Aqueous suspensions of adjuvants are useful for simultaneously reconstituting and adsorbing lyophilized polypeptides.
  • the liquid material is adjuvant-free.
  • the lyophilizate does not include an insoluble metal salt adjuvant.
  • the invention also provides a lyophilizate which comprises EDTA and at least one antigen.
  • Immunogenic compositions of the invention may be useful as vaccines.
  • Vaccines according to the invention may either be prophylactic (i.e. to prevent infection) or therapeutic (i.e. to treat infection), but will typically be prophylactic.
  • compositions may thus be pharmaceutically acceptable. They will usually include components in addition to the antigens e.g. they typically include one or more pharmaceutical carrier(s) and/or excipient(s). A thorough discussion of such components is available in Reference 43.
  • compositions will generally be administered to a mammal in aqueous form. Prior to administration, however, the composition may have been in a non-aqueous form. For instance, although some immunogenic compositions are manufactured in aqueous form, then filled and distributed and administered also in aqueous form, other immunogenic compositions are lyophilized during manufacture and are reconstituted into an aqueous form at the time of use. Thus a composition of the invention may be dried, such as a lyophilized formulation.
  • composition of the invention includes more than one polypeptide
  • the mass of each different polypeptide can be the same or different. Ideally they are present at substantially equal masses i.e. the mass of each of them is within +5% of the mean mass of all the polypeptides. In embodiments where two antigens are present as a hybrid polypeptide, the hybrid is considered as a single polypeptide for this purpose.
  • the factors that can influence the amount of the polypeptide to be included in a multivalent formulation include the amount of polypeptide sufficient to elicit an immune response and the amount that would cause aggregation (with itself or with other polypeptide) or influence the stability of the other polypeptide. Typical masses of a polypeptide in an immunogenic composition are between l-100 ⁇ g.
  • the composition may include preservatives such as thiomersal or 2-phenoxyethanol. It is preferred, however, that the immunogenic compositions should be substantially free from (i.e. less than 5 ⁇ g/ml) mercurial material e.g. thiomersal-free. Compositions containing no mercury are more preferred. Preservative-free compositions are particularly preferred.
  • a composition may include a temperature protective agent. Further details of such agents are provided below.
  • a physiological salt such as a sodium salt.
  • Sodium chloride (NaCl) is preferred, which may be present at between 1 and 20 mg/ml e.g. about 10+2 mg/ml NaCl.
  • Other salts that may be present include potassium chloride, potassium dihydrogen phosphate, disodium phosphate dehydrate, magnesium chloride, calcium chloride, etc.
  • Compositions will generally have an osmolality of between 200 mOsm/kg and 400 mOsm/kg, preferably between 240-360 mOsm/kg, and will more preferably fall within the range of 290-310 mOsm/kg.
  • Compositions may include one or more buffers.
  • Typical buffers include: a phosphate buffer; a Tris buffer; a borate buffer; a succinate buffer; a histidine buffer (particularly with an aluminium hydroxide adjuvant); or a citrate buffer.
  • Buffers will typically be included in the 5-20 mM range.
  • the buffer is preferably 10 mM potassium phosphate.
  • the pH of the compositions are preferably between about 5 and about 8, and more preferably between about 5.5 and about 6.5, and most preferably at about 6.
  • the composition is preferably sterile.
  • the composition is preferably non-pyrogenic e.g. containing ⁇ 1 EU (endotoxin unit, a standard measure) per dose, and preferably ⁇ 0.1 EU per dose.
  • the composition is preferably gluten free.
  • the composition may include material for a single immunisation, or may include material for multiple immunisations (i.e. a 'multidose' kit).
  • a preservative is preferred in multidose arrangements.
  • the compositions may be contained in a container having an aseptic adaptor for removal of material.
  • Human vaccines are typically administered in a dosage volume of about 0.5ml, although a half dose (i.e. about 0.25ml) may be administered to children.
  • Immunogenic compositions of the invention may also comprise one or more immunoregulatory agents.
  • one or more of the immunoregulatory agents include one or more adjuvants.
  • the adjuvants may include a TH1 adjuvant and/or a TH2 adjuvant, further discussed below.
  • the immunogenic compositions may further comprise an adjuvant, such as an aluminium salt adjuvant (for example, one or more antigens may be adsorbed to aluminium salt).
  • adjuvants which may be used in compositions of the invention include, but are not limited to, those already listed in Reference 5. These include mineral-containing adjuvants and oil-in-water emulsions.
  • Mineral containing adjuvants include mineral salts such as aluminium salts and calcium salts (or mixtures thereof).
  • the composition contains an aluminium salt adjuvant.
  • Aluminium salts include hydroxides, phosphates, etc., with the salts taking any suitable form (e.g. gel, crystalline, amorphous, etc.).
  • Calcium salts include calcium phosphate (e.g. the "CAP" particles disclosed in Ref. 18). Adsorption to these salts is preferred (e.g. all antigens may be adsorbed).
  • the mineral containing compositions may also be formulated as a particle of metal salt [19].
  • the adjuvants known as aluminium hydroxide and aluminium phosphate may be used. These names are conventional, but are used for convenience only, as neither is a precise description of the actual chemical compound which is present (e.g. see chapter 9 of Reference 20)).
  • the invention can use any of the "hydroxide” or "phosphate” adjuvants that are in general use as adjuvants.
  • the adjuvants known as "aluminium hydroxide” are typically aluminium oxyhydroxide salts, which are usually at least partially crystalline.
  • the adjuvants known as "aluminium phosphate” are typically aluminium hydroxyphosphates, often also containing a small amount of sulphate (i.e. aluminium hydroxyphosphate sulphate). They may be obtained by precipitation, and the reaction conditions and concentrations during precipitation influence the degree of substitution of phosphate for hydroxyl in the salt.
  • a fibrous morphology (e.g. as seen in transmission electron micrographs) is typical for aluminium hydroxide adjuvants.
  • the pi of aluminium hydroxide adjuvants is typically about 11 i.e. the adjuvant itself has a positive surface charge at physiological pH.
  • Adsorptive capacities of between 1.8-2.6 mg protein per mg Al +++ at pH 7.4 have been reported for aluminium hydroxide adjuvants.
  • Aluminium phosphate adjuvants generally have a PO 4 /AI molar ratio between 0.3 and 1.2, preferably between 0.8 and 1.2, and more preferably 0.95+0.1.
  • the aluminium phosphate will generally be amorphous, particularly for hydroxyphosphate salts.
  • a typical adjuvant is amorphous aluminium hydroxyphosphate with PO 4 /AI molar ratio between 0.84 and 0.92, included at 0.6mg Al 3+ /ml.
  • the aluminium phosphate will generally be particulate (e.g. plate-like morphology as seen in transmission electron micrographs). Typical diameters of the particles are in the range 0.1-10 ⁇ (e.g. about 0.1-5 ⁇ ) after any antigen adsorption.
  • Adsorptive capacities of between 0.7-1.5 mg protein per mg Al +++ at pH 7.4 have been reported for aluminium phosphate adjuvants.
  • Suspensions of aluminium salts used to prepare compositions of the invention may contain a buffer (e.g. a phosphate or a histidine or a Tris buffer), but this is not always necessary.
  • the suspensions are preferably sterile and pyrogen-free.
  • a suspension may include free aqueous phosphate ions e.g. present at a concentration between 1.0 and 20 mM, preferably between 5 and 15 mM, and more preferably about 10 mM.
  • the suspensions may also comprise sodium chloride.
  • the preferred aluminium salt adjuvant is an aluminium hydroxide adjuvant.
  • the invention can use a mixture of both an aluminium hydroxide and an aluminium phosphate.
  • there may be more aluminium phosphate than hydroxide e.g. a weight ratio of at least 2: 1 e.g. >5: 1, >6: l, >7: l, >8: l, >9:l, eic.
  • the concentration of Al +++ in a composition for administration to a patient is preferably less than lOmg/ml e.g. ⁇ 5 mg/ml, ⁇ 4 mg/ml, ⁇ 3 mg/ml, ⁇ 2 mg/ml, ⁇ 1 mg/ml, etc.
  • a preferred range is between 0.3 and lmg/ml.
  • a maximum of 0.85mg/dose is preferred.
  • a mineral salt can usefully have a TLR agonist, such as a TLR7 agonist, adsorbed to it (e.g. see Ref. 21).
  • the adsorbed TLR7 agonist is usefully a compound of formula (K) as described above.
  • Oil emulsion compositions suitable for use as adjuvants in the invention include oil-in-water emulsions such as MF59 (Chapter 10 of Ref. 20; see also Ref. 22) and AS03. Complete Freund's adjuvant (CFA) and incomplete Freund's adjuvant (IF A) may also be used.
  • CFA Complete Freund's adjuvant
  • IF A incomplete Freund's adjuvant
  • oil-in-water emulsion adjuvants typically include at least one oil and at least one surfactant, with the oil(s) and surfactant(s) being biodegradable (metabolisable) and biocompatible.
  • the oil droplets in the emulsion are generally less than 5 ⁇ in diameter, and ideally have a sub-micron diameter, with these small sizes being achieved with a microfluidiser to provide stable emulsions. Droplets with a size less than 220nm are preferred as they can be subjected to filter sterilization.
  • the emulsion can comprise oils such as those from an animal (such as fish) or vegetable source.
  • Sources for vegetable oils include nuts, seeds and grains. Peanut oil, soybean oil, coconut oil, and olive oil, the most commonly available, exemplify the nut oils.
  • Jojoba oil can be used e.g. obtained from the jojoba bean. Seed oils include safflower oil, cottonseed oil, sunflower seed oil, sesame seed oil and the like. In the grain group, corn oil is the most readily available, but the oil of other cereal grains such as wheat, oats, rye, rice, teff, triticale and the like may also be used.
  • 6-10 carbon fatty acid esters of glycerol and 1 ,2-propanediol may be prepared by hydrolysis, separation and esterification of the appropriate materials starting from the nut and seed oils.
  • Fats and oils from mammalian milk are metabolizable and may therefore be used in the practice of this invention.
  • the procedures for separation, purification, saponification and other means necessary for obtaining pure oils from animal sources are well known in the art.
  • Most fish contain metabolizable oils which may be readily recovered. For example, cod liver oil, shark liver oils, and whale oil such as spermaceti exemplify several of the fish oils which may be used herein.
  • a number of branched chain oils are synthesized biochemically in 5-carbon isoprene units and are generally referred to as terpenoids.
  • Shark liver oil contains a branched, unsaturated terpenoids known as squalene, 2,6,10,15, 19,23-hexamethyl-2,6,10, 14,18,22- tetracosahexaene, which is particularly preferred herein.
  • Squalane the saturated analog to squalene
  • Fish oils, including squalene and squalane are readily available from commercial sources or may be obtained by methods known in the art. Other preferred oils are the tocopherols (see below). Mixtures of oils can be used.
  • Surfactants can be classified by their 'HLB' (hydrophile/lipophile balance). Preferred surfactants of the invention have a HLB of at least 10, preferably at least 15, and more preferably at least 16.
  • the invention can be used with surfactants including, but not limited to: the polyoxyethylene sorbitan esters surfactants (commonly referred to as the Tweens), especially polysorbate 20 and polysorbate 80; copolymers of ethylene oxide (EO), propylene oxide (PO), and/or butylene oxide (BO), sold under the DOWFAXTM tradename, such as linear EO/PO block copolymers; octoxynols, which can vary in the number of repeating ethoxy (oxy-l,2-ethanediyl) groups, with octoxynol-9 (Triton X-100, or t-octylphenoxypolyethoxyethanol) being of particular interest; (octylphenoxy)polyeth
  • Non-ionic surfactants are preferred.
  • Preferred surfactants for including in the emulsion are Tween 80 (polyoxyethylene sorbitan monooleate), Span 85 (sorbitan trioleate), lecithin and Triton X-100.
  • surfactants can be used e.g. Tween 80/Span 85 mixtures.
  • a combination of a polyoxyethylene sorbitan ester such as polyoxyethylene sorbitan monooleate (Tween 80) and an octoxynol such as t-octylphenoxypolyethoxyethanol (Triton X-100) is also suitable.
  • Another useful combination comprises laureth 9 plus a polyoxyethylene sorbitan ester and/or an octoxynol.
  • Preferred amounts of surfactants are: polyoxyethylene sorbitan esters (such as Tween 80) 0.01 to 1%, in particular about 0.1 %>; octyl- or nonylphenoxy polyoxyethanols (such as Triton X-100, or other detergents in the Triton series) 0.001 to 0.1 %>, in particular 0.005 to 0.02%; polyoxyethylene ethers (such as laureth 9) 0.1 to 20 %, preferably 0.1 to 10 % and in particular 0.1 to 1 % or about 0.5%.
  • Preferred emulsion adjuvants have an average droplets size of ⁇ 1 ⁇ e.g. ⁇ 750nm, ⁇ 500nm, ⁇ 400nm, ⁇ 300nm, ⁇ 250nm, ⁇ 220nm, ⁇ 200nm, or smaller. These droplet sizes can conveniently be achieved by techniques such as microfluidisation.
  • Specific oil- in- water emulsion adjuvants useful with the invention include, but are not limited to:
  • a submicron emulsion of squalene, polysorbate 80, and sorbitan trioleate can be present at a volume ratio of 10: 1 : 1 or a weight ratio of 39:47:47.
  • the composition of the emulsion by volume can be about 5%> squalene, about 0.5%> polysorbate 80 and about 0.5%> sorbitan trioleate. In weight terms, these ratios become 4.3%> squalene, 0.5%> polysorbate 80 and 0.48%) sorbitan trioleate.
  • This adjuvant is known as 'MF59' [23-25], as described in more detail in
  • the MF59 emulsion advantageously includes citrate ions e.g. 10 mM sodium citrate buffer.
  • An emulsion of squalene, a tocopherol, and polysorbate 80 may include phosphate buffered saline. It may also include Span 85 (e.g. at 1%>) and/or lecithin. These emulsions may have from 2 to 10%> squalene, from 2 to 10%> tocopherol and from 0.3 to 3%> polysorbate 80, and the weight ratio of squalene:tocopherol is preferably ⁇ 1 as this provides a more stable emulsion. Squalene and polysorbate 80 may be present volume ratio of about 5:2 or at a weight ratio of about 11 :5.
  • the three components may be present at a weight ratio of 1068:1186:485 or around 55:61 :25.
  • One such emulsion ('AS03') can be made by dissolving Tween 80 in PBS to give a 2%> solution, then mixing 90ml of this solution with a mixture of (5g of DL-a-tocopherol and 5ml squalene), then microfluidising the mixture.
  • the resulting emulsion may have submicron oil droplets e.g. with an average diameter of between 100 and 250nm, preferably about 180nm.
  • the emulsion may also include a 3-de-O-acylated monophosphoryl lipid A (3d-MPL).
  • 3d-MPL 3-de-O-acylated monophosphoryl lipid A
  • Another useful emulsion of this type may comprise, per human dose, 0.5-10 mg squalene, 0.5-11 mg tocopherol, and 0.1-4 mg polysorbate 80 [28] e.g. in the ratios discussed above.
  • An emulsion of squalene, a tocopherol, and a Triton detergent e.g. Triton X-100
  • the emulsion may also include a 3d-MPL (see below).
  • the emulsion may contain a phosphate buffer.
  • An emulsion comprising a polysorbate (e.g. polysorbate 80), a Triton detergent (e.g. Triton X-100) and a tocopherol (e.g. an a-tocopherol succinate).
  • the emulsion may include these three components at a mass ratio of about 75: 1 1 : 10 (e.g.
  • the emulsion may also include squalene.
  • the emulsion may also include a 3d-MPL (see below).
  • the aqueous phase may contain a phosphate buffer.
  • An emulsion of squalane, polysorbate 80 and poloxamer 401 (“PluronicTM L121").
  • the emulsion can be formulated in phosphate buffered saline, pH 7.4.
  • This emulsion is a useful delivery vehicle for muramyl dipeptides, and has been used with threonyl-MDP in the "SAF-1" adjuvant [29] (0.05- 1% Thr-MDP, 5% squalane, 2.5% Pluronic L121 and 0.2% polysorbate 80). It can also be used without the Thr-MDP, as in the "AF" adjuvant [30] (5% squalane, 1.25% Pluronic L121 and 0.2% polysorbate 80). Microfluidisation is preferred.
  • An emulsion comprising squalene, an aqueous solvent, a polyoxyethylene alkyl ether hydrophilic nonionic surfactant (e.g. polyoxyethylene (12) cetostearyl ether) and a hydrophobic nonionic surfactant (e.g. a sorbitan ester or mannide ester, such as sorbitan monoleate or 'Span 80').
  • the emulsion is preferably thermoreversible and/or has at least 90%> of the oil droplets (by volume) with a size less than 200 nm [31 ].
  • the emulsion may also include one or more of: alditol; a cryoprotective agent (e.g.
  • the emulsion may include a TLR4 agonist [32]. Such emulsions may be lyophilized.
  • preferred phospholipid components are phosphatidylcholine, phosphatidylethanolamine, phosphatidylserine, phosphatidylinositol, phosphatidylglycerol, phosphatidic acid, sphingomyelin and cardiolipin. Submicron droplet sizes are advantageous.
  • Additives may be included, such as QuilA saponin, cholesterol, a saponin- lipophile conjugate (such as GPI-0100, described in Reference 35, produced by addition of aliphatic amine to desacylsaponin via the carboxyl group of glucuronic acid), dimethyidioctadecylammonium bromide and/or N,N-dioctadecyl-N,N-bis (2- hydroxyethyl)propanediamine.
  • a non-metabolisable oil such as light mineral oil
  • surfactant such as lecithin, Tween 80 or Span 80.
  • Additives may be included, such as QuilA saponin, cholesterol, a saponin- lipophile conjugate (such as GPI
  • An emulsion in which a saponin (e.g. QuilA or QS21) and a sterol (e.g. a cholesterol) are associated as helical micelles [36].
  • An emulsion comprising a mineral oil, a non-ionic hydrophilic ethoxylated fatty alcohol, and a non-ionic lipophilic surfactant (e.g. an ethoxylated fatty alcohol and/or polyoxyethylene- polyoxypropylene block copolymer) [37].
  • an emulsion may be mixed with antigen extemporaneously, at the time of delivery, and thus the adjuvant and antigen may be kept separately in a packaged or distributed composition, ready for final formulation at the time of use.
  • an emulsion is mixed with antigen during manufacture, and thus the composition is packaged in a liquid adjuvanted form,.
  • the antigen will generally be in an aqueous form, such that the composition is finally prepared by mixing two liquids.
  • the volume ratio of the two liquids for mixing can vary (e.g. between 5: 1 and 1 :5) but is generally about 1 : 1. Where concentrations of components are given in the above descriptions of specific emulsions, these concentrations are typically for an undiluted composition, and the concentration after mixing with an antigen solution will thus decrease.
  • compositions include a tocopherol
  • any of the ⁇ , ⁇ , ⁇ , ⁇ , ⁇ or ⁇ tocopherols can be used, but a-tocopherols are preferred.
  • the tocopherol can take several forms e.g. different salts and/or isomers. Salts include organic salts, such as succinate, acetate, nicotinate, etc. D-a-tocopherol and DL-a-tocopherol can both be used.
  • Tocopherols are advantageously included in compositions for use in elderly patients (e.g. aged 60 years or older) because vitamin E has been reported to have a positive effect on the immune response in this patient group [38]. They also have antioxidant properties that may help to stabilize the emulsions [39].
  • a preferred a-tocopherol is DL-a-tocopherol, and the preferred salt of this tocopherol is the succinate.
  • aluminium hydroxide and/or aluminium phosphate adjuvant are particularly preferred, and antigens are generally adsorbed to these salts.
  • compositions of the invention may elicit both a cell mediated immune response as well as a humoral immune response.
  • This immune response will preferably induce long lasting (e.g. neutralising) antibodies and a cell mediated immunity that can quickly respond upon exposure to S. aureus.
  • the immune response may be one or both of a TH1 immune response and a TH2 response.
  • immune response provides for one or both of an enhanced TH1 response and an enhanced TH2 response.
  • the enhanced immune response may be one or both of a systemic and a mucosal immune response.
  • the immune response provides for one or both of an enhanced systemic and an enhanced mucosal immune response.
  • the mucosal immune response is a TH2 immune response.
  • the mucosal immune response includes an increase in the production of IgA.
  • compositions of the invention may be prepared in various forms.
  • the compositions may be prepared as injectables, either as liquid solutions or suspensions.
  • Solid forms suitable for solution in, or suspension in, liquid vehicles prior to injection can also be prepared (e.g. a lyophilized composition or a spray-freeze dried composition).
  • the composition may be prepared for topical administration e.g. as an ointment, cream or powder.
  • the composition may be prepared for oral administration e.g. as a tablet or capsule, as a spray, or as a syrup (optionally flavoured).
  • the composition may be prepared for pulmonary administration e.g. as an inhaler, using a fine powder or a spray.
  • the composition may be prepared as a suppository or pessary.
  • the composition may be prepared for nasal, aural or ocular administration e.g. as drops.
  • the composition may be in kit form, designed such that a combined composition is reconstituted just prior to administration to a patient.
  • kits may comprise one or more antigens in liquid form and one or more lyophilized antigens.
  • kits may comprise two vials, or it may comprise one ready- filled syringe and one vial, with the contents of the syringe being used to reactivate the contents of the vial prior to injection.
  • Immunogenic compositions used as vaccines comprise an immunologically effective amount of antigen(s), as well as any other components, as needed.
  • 'immunologically effective amount' it is meant that the administration of that amount to an individual, either in a single dose or as part of a series, is effective for treatment or prevention. This amount varies depending upon the health and physical condition of the individual to be treated, age, the taxonomic group of individual to be treated (e.g. non- human primate, primate, etc.), the capacity of the individual's immune system to synthesise antibodies, the degree of protection desired, the formulation of the vaccine, the treating doctor's assessment of the medical situation, and other relevant factors. It is expected that the amount will fall in a relatively broad range that can be determined through routine trials. Where more than one antigen is included in a composition then two antigens may be present at the same dose as each other or at different doses.
  • a composition may include a temperature protective agent, and this component may be particularly useful in adjuvanted compositions (particularly those containing a mineral adjuvant, such as an aluminium salt).
  • a liquid temperature protective agent may be added to an aqueous vaccine composition to lower its freezing point e.g. to reduce the freezing point to below 0°C.
  • the temperature protective agent also permits freezing of the composition while protecting mineral salt adjuvants against agglomeration or sedimentation after freezing and thawing, and may also protect the composition at elevated temperatures e.g. above 40°C.
  • a starting aqueous vaccine and the liquid temperature protective agent may be mixed such that the liquid temperature protective agent forms from 1 -80% by volume of the final mixture.
  • Suitable temperature protective agents should be safe for human administration, readily miscible/soluble in water, and should not damage other components (e.g. antigen and adjuvant) in the composition.
  • examples include glycerin, propylene glycol, and/or polyethylene glycol (PEG).
  • PEGs may have an average molecular weight ranging from 200- 20,000 Da.
  • the polyethylene glycol can have an average molecular weight of about 300 Da ('PEG-300').
  • the invention also provides a method for raising an immune response in a mammal comprising the step of administering a composition of the invention to the mammal.
  • the immune response is preferably protective and preferably involves antibodies and/or cell-mediated immunity.
  • the method may raise a booster response.
  • At least some of the antibodies raised in response to polypeptides which are administered in accordance with the invention should be protective.
  • the invention also provides the use of variant forms of: a EsxB antigen, a Sta006 antigen and/or a StaOl 1 antigen, as described above, provided that the variant does not contain any free thiol group, in the manufacture of a medicament for raising an immune response in a mammal.
  • the use may also involve a Hla antigen and a EsxA antigen. It may also involve the use of an adjuvant.
  • the mammal By raising an immune response in the mammal by these uses and methods, the mammal can be protected against S. aureus infection, including a nosocomial infection. More particularly, the mammal may be protected against a skin infection, pneumonia, meningitis, osteomyelitis endocarditis, toxic shock syndrome, and/or septicaemia.
  • the invention also provides a kit comprising a first component and a second component wherein neither the first component nor the second component is a composition of the invention as described above, but wherein the first component and the second component can be combined to provide a composition of the invention as described above.
  • the kit may further include a third component comprising one or more of the following: instructions, syringe or other delivery device, adjuvant, or pharmaceutically acceptable formulating solution.
  • the invention also provides a delivery device pre-filled with an immunogenic composition of the invention.
  • the mammal is preferably a human.
  • the human is preferably a child ⁇ e.g. a toddler or infant) or a teenager; where the vaccine is for therapeutic use, the human is preferably a teenager or an adult.
  • a vaccine intended for children may also be administered to adults e.g. to assess safety, dosage, immunogenicity, etc.
  • Other mammals which can usefully be immunised according to the invention are cows, dogs, horses, and pigs.
  • One way of checking efficacy of therapeutic treatment involves monitoring S. aureus infection after administration of the compositions of the invention.
  • One way of checking efficacy of prophylactic treatment involves monitoring immune responses, systemically (such as monitoring the level of IgGl and IgG2a production) and/or mucosally (such as monitoring the level of IgA production), against the antigens in the compositions of the invention after administration of the composition.
  • antigen-specific serum antibody responses are determined post-immunisation but pre-challenge whereas antigen- specific mucosal antibody responses are determined post-immunisation and post-challenge.
  • Another way of assessing the immunogenicity of the compositions of the present invention is to express the proteins recombinantly for screening patient sera or mucosal secretions by immunoblot and/or microarrays.
  • a positive reaction between the protein and the patient sample indicates that the patient has mounted an immune response to the protein in question.
  • This method may also be used to identify immunodominant antigens and/or epitopes within antigens.
  • the efficacy of immunogenic compositions can also be determined in vivo by challenging animal models of S. aureus infection, e.g., guinea pigs or mice, with the immunogenic compositions. In particular, there are three useful animal models for the study of S.
  • aureus infectious disease namely: (i) the murine abscess model [41], (ii) the murine lethal infection model [41] and (iii) the murine pneumonia model [42].
  • the abscess model looks at abscesses in mouse kidneys after intravenous challenge.
  • the lethal infection model looks at the number of mice which survive after being infected by a normally- lethal dose of S. aureus by the intravenous or intraperitoneal route.
  • the pneumonia model also looks at the survival rate, but uses intranasal infection.
  • a useful immunogenic composition may be effective in one or more of these models.
  • compositions of the invention will generally be administered directly to a patient.
  • Direct delivery may be accomplished by parenteral injection ⁇ e.g. subcutaneously, intraperitoneally, intravenously, intramuscularly, or to the interstitial space of a tissue), or mucosally, such as by rectal, oral ⁇ e.g. tablet, spray), vaginal, topical, transdermal or transcutaneous, intranasal, ocular, aural, pulmonary or other mucosal administration.
  • the invention may be used to elicit systemic and/or mucosal immunity, preferably to elicit an enhanced systemic and/or mucosal immunity.
  • the enhanced systemic and/or mucosal immunity is reflected in an enhanced TH1 and/or TH2 immune response.
  • the enhanced immune response includes an increase in the production of IgGl and/or IgG2a and/or IgA.
  • Dosage can be by a single dose schedule or a multiple dose schedule. Multiple doses may be used in a primary immunisation schedule and/or in a booster immunisation schedule. In a multiple dose schedule the various doses may be given by the same or different routes e.g. a parenteral prime and mucosal boost, a mucosal prime and parenteral boost, etc. Multiple doses will typically be administered at least 1 week apart ⁇ e.g. about 2 weeks, about 3 weeks, about 4 weeks, about 6 weeks, about 8 weeks, about 10 weeks, about 12 weeks, about 16 weeks, etc.).
  • Vaccines prepared according to the invention may be used to treat both children and adults.
  • a human patient may be less than 1 year old, 1-5 years old, 5-15 years old, 15-55 years old, or at least 55 years old.
  • Preferred patients for receiving the vaccines are the elderly ⁇ e.g. >50 years old, >60 years old, and preferably >65 years), the young ⁇ e.g. ⁇ 5 years old), hospitalised patients, healthcare workers, armed service and military personnel, pregnant women, the chronically ill, or immunodeficient patients.
  • the vaccines are not suitable solely for these groups, however, and may be used more generally in a population.
  • Vaccines produced by the invention may be administered to patients at substantially the same time as ⁇ e.g. during the same medical consultation or visit to a healthcare professional or vaccination centre) other vaccines e.g. at substantially the same time as an influenza vaccine, a measles vaccine, a mumps vaccine, a rubella vaccine, a MMR vaccine, a varicella vaccine, a MMRV vaccine, a diphtheria vaccine, a tetanus vaccine, a pertussis vaccine, a DTP vaccine, a conjugated H.influenzae type b vaccine, an inactivated poliovirus vaccine, a hepatitis B virus vaccine, a meningococcal conjugate vaccine (such as a tetravalent A-C-W135-Y vaccine), a respiratory syncytial virus vaccine, etc.
  • Further non-staphylococcal vaccines suitable for co-administration may include one or more antigens listed on pages 33-46 of Reference 16.
  • Gl numbering is used above.
  • a Gl number or “Genlnfo Identifier” is a series of digits assigned consecutively to each sequence record processed by NCBI when sequences are added to its databases. The Gl number bears no resemblance to the accession number of the sequence record.
  • a sequence is updated ⁇ e.g. for correction, or to add more annotation or information) then it receives a new Gl number.
  • the sequence associated with a given Gl number is never changed.
  • this epitope may be a B-cell epitope and/or a T-cell epitope.
  • Such epitopes can be identified empirically (e.g. using PEPSCAN [51,52] or similar methods), or they can be predicted (e.g. using the Jameson-Wolf antigenic index [53], matrix-based approaches [54], MAPITOPE [55], TEPITOPE [56,57], neural networks [58], OptiMer & EpiMer [59, 60], ADEPT [61], Tsites [62], hydrophilicity [63], antigenic index [64] or the methods disclosed in References 65-69, etc.).
  • Epitopes are the parts of an antigen that are recognised by and bind to the antigen binding sites of antibodies or T-cell receptors, and they may also be referred to as "antigenic determinants”.
  • an antigen "domain” is omitted, this may involve omission of a signal peptide, of a cytoplasmic domain, of a transmembrane domain, of an extracellular domain, etc.
  • composition comprising X may consist exclusively of X or may include something additional e.g. X + Y.
  • references to a percentage sequence identity between two amino acid sequences means that, when aligned, that percentage of amino acids are the same in comparing the two sequences.
  • This alignment and the percent homology or sequence identity can be determined using software programs known in the art, for example those described in section 7.7.18 of Ref. 70.
  • a preferred alignment is determined by the Smith- Waterman homology search algorithm using an affine gap search with a gap open penalty of 12 and a gap extension penalty of 2, BLOSUM matrix of 62.
  • the Smith- Waterman homology search algorithm is disclosed in Ref. 71.
  • the percentage sequence identity between two sequences of different lengths is preferably calculated over the length of the longer sequence.
  • Phosphorous-containing adjuvants used with the invention may exist in a number of protonated and deprotonated forms depending on the pH of the surrounding environment, for example the pH of the solvent in which they are dissolved. Therefore, although a particular form may be illustrated, it is intended that these illustrations are merely representative and not limiting to a specific protonated or deprotonated form.
  • Compounds can exist as pharmaceutically acceptable salts.
  • compounds e.g. adjuvants
  • Figure 1 shows the anti-EsxAB antibody titres in CD1 mice which have been immunized with various compositions.
  • "Combo Cys(+) Lyo form” mice immunized with tetravalent vaccine containing EsxAB- Cys(+), Sta006 Cys(+), StaOl l Cys(+), HlaH35L and aluminium hydroxide adjuvant.
  • "Combo Cys(-)” mice immunized with tetravalent vaccine containing EsxAB Cys(-), Sta006 Cys(-), StaOl l Cys(-), HlaH35L and aluminium hydroxide adjuvant.
  • "Alum 2mg/ml+NaCl” mice received equal amounts of PBS and aluminium hydroxide adjuvant.
  • FIG 2 shows the anti-Sta006 antibody titres in CD1 mice which have been immunized with various compositions. The mice groups are as explained in Figure 1 above.
  • FIG 3 shows the anti-StaOl l antibody titres in CD1 mice which have been immunized with various compositions. The mice groups are as explained in Figure 1 above.
  • FIG 4 shows the anti-HlaH35L antibody titres in CD1 mice which have been immunized with various compositions. The mice groups are as explained in Figure 1 above.
  • Figure 5 shows the normalised melting curves of the Sta006 Cys(+) and Cys(-) antigens.
  • Figure 6 shows the normalised melting curves of the StaOl 1 Cys(+) and Cys(-) antigens.
  • Figure 7 shows SDS-PAGE of vaccines with cysteine-containing antigens (A) and cysteine- deficient antigens (B).
  • EsxAB monomer (22.8 kDa), StaOl l monomer (27 kDa), Sta006 monomer (32 kDa), HlaH35L (33 kDa), EsxAB dimer (45.6 kDa), StaOl l dimer (54 kDa), Sta006 dimer (64 kDa), Sta006- EsxAB dimer (54.8 kDa), StaOl 1-EsxAB dimer (49.8 kDa) and Sta006-Sta011 dimer (49.8 kDa).
  • Figure 8 shows RP-HPLC profiles of vaccines with cysteine-containing antigens (A) and cysteine- deficient antigens (B).
  • mice are split into three groups: (1) "Combo Cys(+) Lyo form”: mice immunized with tetravalent vaccine containing EsxAB Cys(+), Sta006 Cys(+), StaOl l Cys(+), HlaH35L and aluminium hydroxide adjuvant; (2) "Combo Cys(-)”: mice immunized with tetravalent vaccine containing EsxAB Cys(-), Sta006 Cys(-), StaOl l Cys(-), HlaH35L and aluminium hyrdroxide adjuvant; and (3) "Alum 2mg/ml+NaCl”: control mice received equal amounts of PBS and aluminium hydroxide adjuvant.
  • the assay read-out is a measure of fluorescence intensity expressed as arbitrary Relative Luminex Units (RLU/mL).
  • the antigens were recombinant proteins purified from E.coli.
  • the SEQ ID NOs of the antigens in the Combo Cys(+) and Combo Cys(-) are listed in Table 1.
  • Table 1 SEQ ID NOs of the antigens used in the experiments.
  • Figures 1 -4 report antibody titres of mice following immunization.
  • the antibody titres for each antigen do not differ significantly between the Combo Cys(+)/Alum and Combo Cys (-)/Alum mice groups, as confirmed by the Mann- Whitney test.
  • RLU/mL Relative Luminex Units
  • DSF Differential Scanning Calorimetry
  • Table 2 Melting temperatures of Cys(+) and Cys(-) antigens.
  • the oxidative dimerization reaction step was no longer necessary as the antigen can be purified as a monomer.
  • the cHT chromatography step was also simplified because it was no longer necessary to separate the monomer from the dimer.
  • the CaptoQ chromatography step was simplified as the antigen can be purified as a monomer.
  • the cHT chromatography step was also simplified because it was no longer necessary to separate the monomer from the dimer.
  • a SPFF chromatography step is added between steps 3 and 4 above to improve the purity/introduction of a pH gradient elution for fractions collection.
  • Purity and yield of the antigens obtained from the process explained above were determined, and the results are shown in Table 3. Purity is determined using detector PDA 214nm. Yield is calculated by: total proteins (mBCA content (mg/ml)) x purity (RPC (%) 214nm).
  • Biomass of fermentation recovered was about 54% (theoretical yield without slurry from centrifugation loss was: 1.176 g/L ferm)
  • Biomass of fermentation recovered was about 79% (theoretical yield without slurry from centrifugation loss was: 0.110 g/L ferm)
  • Biomass of fermentation recovered was about 79%) (theoretical yield without slurry from centrifugation loss was: 0.110 g/L ferm) Cys(+) 80.8 0.216
  • the purified Cys(-) antigens had comparable purity and yield to the corresponding Cys(+) antigens.
  • the analytical panel conformed to in-house specification limits. Removal of cysteines allowed higher flexibility in the purification process.
  • the purification process can be further optimised in order to improve purity and yield.
  • the three antigens were stable in freezing/thawing cycles and had good stability at 2-8 °C storage temperature.
  • the tested vaccines contained EsxAB (Cys(+)), HlaH35L, Sta006 (Cys(+)) and StaOl 1 (Cys(+)) antigens.
  • the adjuvants tested were: Alum, Alum/TLR7 (i.e. formula Kl discussed above) and MF59. The following observations were made:
  • Alum/TLR7 Same behaviour as for the Alum vaccines. Alum/TLR7 stably adsorbed on Alum in the full liquid formulation of proteins at all doses tested (1 - 50 ⁇ g)
  • the tested adjuvants are suitable for use with the tetravalent vaccine containing EsxAB Cys(+), HlaH35L, Sta006 Cys(+) and StaOl l Cys(+) antigens.
  • the samples was also analysed using HPLC.
  • the HPLC profiles of the Cys(+) vaccine is shown in Figure 8A, and of the Cys(-) vaccine is shown in Figure 8B.
  • Cys(-) antigens provided a superior stability for the tetravalent combination with respect to the Cys(+) antigens.
  • the Cys(+) antigens provide a complex analysis due to the presence of homo/heterodimers species.
  • the Cys(-) proteins provide no additional peaks observed in Alum containing vaccines.
  • modifying the antigens from Cys(+) to Cys(-) allows a better analytical resolution or definition of each antigen in the vaccine.
  • the samples were analysed using RP-HPLC, and the pH and osmolality were also analysed (3 determinations on 3 different vials at each temperature and timepoint).
  • the following two conditions were used for desorption: (1) 300 mM KH2P04 pH 6.8 with overnight incubation at 25°C (to desorb StaOl l, Sta006 and EsxA-B); and (2) 300 mM KH2P04 pH 6.8 / Tween80 0.05% with o/n incubation at 25°C (to desorb HlaH35L).
  • the same conditions were applied for sample treatment at all time points (assumption: no influence of vaccine aging).
  • the vaccines also provided high purity, as shown in Table 4.
  • Table 4 Purity of the antigens in vaccines.
  • Vaccine Adjuvants Preparation Methods and Research Protocols (Volume 42 of Methods in Molecular Medicine series). ISBN: 1-59259-083-7. Ed. O'Hagan.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Elimination of disulphide bond formation ofcysteine-containing S.aureus antigens enhances antigen stability. The invention provides a composition comprising variant forms of cysteine-containing S.aureus antigen with a point mutation that replaces, deletes or modifies the cysteine residue.

Description

STABILISED PROTEINS FOR IMMUNISING AGAINST STAPHYLOCOCCUS AUREUS
This application claims the benefit of US provisional application 61/695,782 filed August 31st, 2012, the complete contents of all of which are hereby incorporated herein by reference for all purposes.
TECHNICAL FIELD
This invention relates to immunogenic compositions comprising antigens derived from Staphylococcus aureus and to their use in immunisation.
BACKGROUND ART
S. aureus is a Gram-positive spherical bacterium and is the leading cause of infection of the bloodstream, lower respiratory tract, and skin and other soft tissues. It causes a range of illnesses from minor skin infections to life-threatening diseases including pneumonia and septicaemia, and the mortality associated with S. aureus per annum in the US exceeds that of any other infectious disease, including HIV/AIDS.
There is currently no authorised vaccine against S.aureus. A vaccine based on a mixture of surface polysaccharides from bacterial types 5 and 8, StaphVAX™, failed to reduce infections when compared to the placebo group in a phase III clinical trial in 2005. Reference 1 reports data on the "V710" vaccine from Merck and Intercell which is based on a single antigen, IsdB, a conserved iron-sequestering cell- surface protein [2,3]. However, the clinical trials of V710 were terminated in 2011 based on the observation that V710 was unlikely to demonstrate a statistically significant clinical benefit, and a safety concern regarding overall mortality and multi- organ dysfunction that occurred with greater frequency in vaccine recipients compared with placebo recipients [4].
Reference 5 discloses various S.aureus antigens and their combinations, including "Combo- 1" (a mixture of EsxA, EsxB, a mutant Hla, Sta006, and StaOl l) and "Combo-2" (a mixture of EsxA, EsxB, IsdA, Sta006, and StaOl 1) as vaccine strategics. Reference 6 discloses that S.aureus polypeptide antigens can be unstable in a simple buffer solution, and that antigens can be stabilised by the presence of a stabilizing additive, e.g. EDTA. Instability of the antigens is undesirable because (1) it does not allow vaccines to be stored for a long period of time before administration, and (2) inconsistency of vaccines from batch to batch can affect quality and regulatory approval requirements. Furthermore, manufacture of vaccines containing these unstable antigens can be complicated and involve multiple purification steps. Therefore it is an object of the invention to identify further strategies to stabilize S.aureus polypeptide antigens in immunogenic compositions.
DISCLOSURE OF THE INVENTION
The inventors have found that preventing oligomerization of antigens is an effective strategy to enhance antigen stability. Various S.aureus antigens contain cysteine residues, and they can form oligomers in standard buffer solutions, including covalent dimers formed by disulphide bonds between cysteine residues. The inventors have found that compositions containing these covalent dimers can be unstable, and may form aggregates or influence the stability of the other antigens in the composition, if present. Covalent dimer formation can be prevented by replacing, modifying or deleting the cysteine residues such that disulphide bond formation is eliminated. Interestingly, preventing these antigens to form covalent dimers improves antigen stability and keeps a high total selectivity of the composition (i.e. a high proportion of single isoform relative to total antigen) and purity. Furthermore, the inventors found that these cysteine- deficient antigens remain effective in eliciting an immune response against the wild-type cysteine-containing antigens. Therefore, cysteine- deficient antigens can be included in vaccine compositions to improve antigen stability.
The Sta006 and StaOl l antigens naturally have N-terminus cysteines in their mature forms. The EsxB protein naturally contains an internal cysteine residue. The inventors found that a combination of the wild-type cysteine-containing Sta006, StaOl l, Hla and EsxAB does not have good long-term stability in aqueous conditions. The wild-type cysteine-containing EsxAB, Sta006 and StaOl l can perform redox reactions in buffer solutions and form homo- or heterodimers (e.g. Sta006/Sta011, etc.) which are unstable. These dimers may be produced as a result of disulphide bond formation between cysteine residues. The inventors found that elimination of disulphide bond formation (e.g. by replacing, modifying or deleting the cysteine residues) minimizes the antigens' interference with each other and other components. Hence, an immunogenic composition comprising variants of EsxAB, Sta006 and StaOl 1 that do not contain any free thiol group under reducing conditions (and hence do not form homo- or heterodimers) is more stable compared to an immunogenic composition containing the wild-type antigens that contain cysteine residues (i.e. containing free thiol groups under reducing conditions). The inventors observed that the immunogenic composition containing antigen variants with no thiol groups are stable for at least four weeks in liquid formulation. This immunogenic composition also demonstrates higher selectivity, reproducibility, stability, purity and improved process characteristics. Hence, the immunogenic compositions of the invention can be produced with fewer purification steps. The manufacturing process is thus simpler and more efficient.
Accordingly, the invention provides an immunogenic composition that comprises: (i) a EsxB antigen, e.g. a polypeptide having an amino acid sequence that has at least 90% (e.g. >91%, >92%, >93%, >94%, >95%, >96%, >97%, >98%) identity to SEQ ID NO: 16; (ii) a Sta006 antigen, e.g. a polypeptide having an amino acid sequence that has having at least 90% (e.g. >91%, >92%, >93%, >94%, >95%, >96%, >97%, >98%, >99%, >99.5%) identity to SEQ ID NO: 24; and/or (iii) a StaOl l antigen, e.g. a polypeptide having an amino acid sequence that has having at least 90%> (e.g. >91%>, >92%>, >93%>, >94%, >95%, >96%, >97%, >98%, >99%, >99.5%) identity to SEQ ID NO: 28, provided that none of the antigens contains any free thiol group, and each of the polypeptides (i) to (iii) can elicit antibodies (e.g. when administered to a human) which recognise the respective wild-type cysteine-containing antigen. For example, (i) can elicit antibodies which recognise SEQ ID NO: 2 (EsxB), (ii) can elicit antibodies which recognise SEQ ID NO: 10 (Sta006), and (iii) can elicit antibodies which recognise SEQ ID NO: 11 (StaOl l).
The immunogenic composition may further comprise Hla (preferably in a non-toxic form e.g. Hla-H35L as discussed below). Thus, the immunogenic composition preferably also comprises: (iv) a H35L mutant form of Hla e.g. comprising SEQ ID NO: 9, which can elicit antibodies which recognise SEQ ID NO: 67 (wild-type Hla).
The EsxB antigen can be combined as a hybrid polypeptide with EsxA, as discussed below, e.g. an EsxAB hybrid with an EsxB antigen downstream of EsxA antigen. These antigens are discussed in detail in Reference 5. Thus a useful composition of the invention includes: (i) a first polypeptide having amino acid sequence SEQ ID NO: 59 (EsxAB); (ii) a second polypeptide having amino acid sequence SEQ ID NO: 26 (Sta006); and/or (iii) a third polypeptide having amino acid sequence SEQ ID NO: 32 (StaOl l); and optionally further comprising (iv) a fourth polypeptide having amino acid sequence SEQ ID NO: 9 (Hla- H35L).
In some embodiments the composition may include one or more further polypeptides; in other embodiments the only polypeptides in the composition are those discussed above. If the composition does include one or more further polypeptides, it is preferred that these do not contain any free thiol groups.
In some embodiments of the invention, the immunogenic composition comprises further antigens which can be polypeptides and/or saccharides. For example, they can also include one or more S. aureus capsular saccharide conjugate(s) e.g. against a serotype 5 and/or a serotype 8 strain. In other embodiments, the composition includes no additional staphylococcal polypeptide antigens. In other embodiments, the composition includes no additional staphylococcal antigens. In yet another embodiment, the composition includes no additional antigens.
When more than one polypeptides are present, they may be present at substantially equal masses i.e. the mass of each of them is within +5% of the mean mass of all the polypeptides. Thus, when four polypeptides are present, they may be present at a mass ratio of a:b:c:d, where each of a-d is between 0.95 and 1.05.
The invention also provides a lyophilizate of the immunogenic composition of the invention. This lyophilizate can be reconstituted with aqueous material to provide an aqueous immunogenic composition of the invention. For administration, the lyophilizate is thus reconstituted with a suitable liquid diluent {e.g. a buffer, saline solution, water for injections (WFI)). The liquid diluent can include an adjuvant e.g. an aluminium salt or an oil-in-water emulsion adjuvant.
The composition of the invention can be in aqueous form, in which case it ideally has a pH of between 5 and 8. The composition may also include an adjuvant e.g. an aluminium salt.
S.aureus antigens
EsxA
The 'EsxA' antigen is disclosed as a useful immunogen in Reference 5. It was originally annotated merely as 'protein'. In the NCTC 8325 strain, EsxA is SAOUHSC 00257 and has amino acid sequence SEQ ID NO: 1 (GI:88194063). SEQ ID NO: 1 has no cysteine residues and contains no free thiol group. EsxA used with the invention should also have no free thiol group. Various forms of EsxA antigens that are suitable for use in this invention are discussed in Reference 5. EsxA antigens that are useful can elicit antibodies {e.g. when administered to a human) that recognise a wild-type EsxA antigen {e.g. SEQ ID NO: 1). The polypeptide may comprise an amino acid sequence: (a) having 80% or more identity {e.g. 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5% or more) to SEQ ID NO: 1 ; and/or (b) comprising a fragment of at least 'n' consecutive amino acids of SEQ ID NO: 1, wherein 'n' is 7 or more {e.g. 8, 10, 12, 14, 16, 18, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90 or more). These EsxA proteins include variants of SEQ ID NO: 1. Preferred fragments of (b) comprise an epitope from SEQ ID NO: 1. Other preferred fragments lack one or more amino acids {e.g. 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25 or more) from the C-terminus and/or one or more amino acids (e.g. 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25 or more) from the N-terminus of SEQ ID NO: 1 while retaining at least one epitope of SEQ ID NO: 1. Other fragments omit one or more protein domains.
EsxA can be present as a hybrid polypeptide with EsxB as discussed below.
EsxB
The 'EsxB' antigen is disclosed as a useful immunogen in Reference 5. It is SAOUHSC 00265 in the NCTC 8325 strain and has amino acid sequence SEQ ID NO: 2 (GI:88194070). The invention uses a form of EsxB that cannot form covalent dimers via disulphide bonds. The polypeptide does not contain any free thiol group (under reducing conditions). It can elicit antibodies (e.g. when administered to a human) which recognise a wild-type EsxB antigen (e.g. SEQ ID NO: 2). The polypeptide may comprise an amino acid sequence having 80% or more identity (e.g. 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5% or more) to any of SEQ ID NOs: 16, 19, 20, 21, 22, 23, 43, 44, or 45. It may also include an upstream amino acid sequence having 80% or more identity (e.g. 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5% or more) to any of SEQ ID NOs: 15, 17, 18, 42, 46 or 47.
SEQ ID NO: 16 is the C-terminus of SEQ ID NO: 2, from amino acids 32-104. Compared to SEQ ID NO: 16, SEQ ID NO: 19 has an additional amino acid residue 'Jf at the N-terminus, wherein 'Jf is an amino acid that does not contain a free thiol group (e.g. Ala = SEQ ID NO: 20). Compared to SEQ ID NO: 2, SEQ ID NO: 21 has no N-terminus methionine, and has amino acid residue 'Jf instead of Cys-31, wherein 'Jf is an amino acid that does not contain a free thiol group (e.g. Ala = SEQ ID NO: 22). Compared to SEQ ID NO: 2, Met-1 and Cys-31 are absent in SEQ ID NO: 23.
SEQ ID NO: 15 is amino acid residues 2-30 of SEQ ID NO: 2. Compared to SEQ ID NO: 15, SEQ ID NO: 17 has an additional amino acid residue 'Jf at the C-terminus, wherein 'Jf is an amino acid that does not contain a free thiol group (e.g. Ala, to give SEQ ID NO: 18).
Useful EsxB polypeptides may comprise a N-terminus methionine (e.g. SEQ ID NOs: 42-47).
A useful EsxB may comprise at least one point mutation that replaces, modifies or deletes the cysteine residue present in the wild-type form of the antigen. For example, a EsxB polypeptide may comprise an amino acid sequence having SEQ ID NO: 2, wherein the cysteine residue at position 31 of SEQ ID NO: 2 is replaced, modified or deleted. Preferably, the replacement is with a serine residue or with an alanine residue (e.g. providing SEQ ID NO: 45). Alternatively, the cysteine residue is deleted (e.g. providing SEQ ID NO: 43).
EsxB can be present as a hybrid polypeptide with EsxA as discussed below.
Sta006
The 'Sta006' antigen is disclosed as a useful immunogen in Reference 5. It was originally annotated as 'ferrichrome-binding protein', and has also been referred to as 'FhuD2' in the literature [7]. In the NCTC 8325 strain, Sta006 is SAOUHSC 02554 and has amino acid sequence SEQ ID NO: 3 (GL88196199). In the Newman strain it is nwmn_2185 (GL151222397). Mutant forms of Sta006 are reported in Reference 8. The known Sta006 antigen has a N-terminus cysteine in its mature form which may be lipidated. Wild- type cysteine-containing Sta006 can exist as a monomer or an oligomer (e.g. covalent dimer). The invention uses a variant form of Sta006 that cannot form covalent dimers via disulphide bonds. The polypeptide does not contain any free thiol group (under reducing conditions). It can elicit antibodies (e.g. when administered to a human) which recognise a wild-type Sta006 antigen (e.g. SEQ ID NO: 10). The polypeptide may comprise an amino acid sequence having 80% or more identity (e.g. 85%, 90%>, 91%>, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5% or more) to any of SEQ ID NOs: 24, 25, 26 and 27.
SEQ ID NO: 24 is amino acid residues 19-302 of SEQ ID NO: 3. Compared to SEQ ID NO: 24, SEQ ID NO: 25 has an additional amino acid residue 'Jf at the N-terminus, wherein 'Jf is an amino acid that does not contain a free thiol group. Compared to SEQ ID NO: 24, SEQ ID NO: 26 has a Met-Ala-Ser-sequence at the N-terminus. Compared to SEQ ID NO: 25, SEQ ID NO: 27 has a Met-Ala-Ser-sequence at the N- terminus. A Sta006 polypeptide comprising any of SEQ ID NOs: 24, 25, 26 and 27 can be used with the invention.
A useful variant form of Sta006 may comprise at least one point mutation that replaces, modifies or deletes the cysteine residue present in the wild-type form of the antigen. For example, a Sta006 polypeptide may comprise an amino acid sequence having SEQ ID NO: 12, wherein the cysteine residue at position 4 of SEQ ID NO: 12 is replaced, modified or deleted. Preferably, the replacement is with a serine or an alanine residue. Alternatively, the cysteine residue is deleted (e.g. providing SEQ ID NO: 26).
StaOll
The 'StaOl l' antigen is disclosed as a useful immunogen in Reference 5. It was originally annotated merely as 'lipoprotein'. In the NCTC 8325 strain StaOl l is SAOUHSC 00052 and has amino acid sequence SEQ ID NO: 4 (GL88193872). The known StaOl l antigen has a N-terminus cysteine in its mature form, which may be lipidated. Wild-type cysteine-containing StaOl 1 can exist as a monomer or an oligomer (e.g. covalent dimer), with Ca++ ions favouring oligomerization.
The invention uses a variant form of StaOl 1 that cannot form covalent dimers via disulphide bonds. The polypeptide does not contain any free thiol group (under reducing conditions). It can elicit antibodies (e.g. when administered to a human) which recognise a wild-type StaOl l antigen (e.g. SEQ ID NO: 11). The polypeptide may comprise an amino acid sequence having 80%> or more identity (e.g. 85%>, 90%>, 91%>, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5% or more) to any of SEQ ID NOs: 28, 29, 30, 31, 32 and33.
SEQ ID NO: 28 is amino acid residues 26-256 of SEQ ID NO: 4. Compared to SEQ ID NO: 28, SEQ ID NO: 29 has and an additional amino acid residue 'Jf at the N-terminus, wherein 'Jf is an amino acid that does not contain a free thiol group (e.g. is Ser = SEQ ID NO: 33). SEQ ID NO: 30 has a Met-Gly- sequence at the N-terminus of SEQ ID NO: 28. SEQ ID NO: 31 has a Met-Gly-sequence at the N- terminus of SEQ ID NO: 29. SEQ ID NO: 32 has the sequence of SEQ ID NO: 31, wherein ' is serine. A StaOl l polypeptide comprising any of SEQ ID NOs: 28, 29, 30, 31, 32 and 33 can be used with the invention.
Variant forms of SEQ ID NO: 4 which may be used for preparing a StaOl 1 polypeptide of the invention include, but are not limited to, SEQ ID NOs: 6, 7 and 8 with various Ile/Val/Leu substitutions. Compared to SEQ ID NO: 4, SEQ ID NO: 6 has Leu-146 instead of Ile-146 and Ile-165 instead of Leu-165. Compared to SEQ ID NO: 4, SEQ ID NO: 7 has Val-146 instead of He- 146 and Ilel65 instead of Leu- 165. Compared to SEQ ID NO: 4, SEQ ID NO: 8 has Leu-146 instead of Ile-146 and Val-165 instead of Leu-165. The first 23 N-terminal amino acids of SEQ ID NOs: 4, 6, 7 and 8 (i.e. the signal peptide) can be usefully omitted to provide SEQ ID NOs: 1 1, 86, 87 and 88, respectively. Thus, a StaOl 1 polypeptide of the invention can comprise residues 26-256 of any of SEQ ID NOs: 4, 6, 7 and 8, and it can elicit antibodies (e.g. when administered to a human) which recognise a mature StaOl l antigen (e.g. SEQ ID NO: 11, 86, 87 or 88).
A useful variant form of StaO 11 may comprise at least one point mutation that replaces, modifies or deletes the cysteine residue present in the wild-type form of the antigen. For example, a StaOl l polypeptide may comprise an amino acid sequence having SEQ ID NO: 13, wherein the cysteine residue at position 3 of SEQ ID NO: 13 is replaced, modified or deleted. Preferably, the replacement is with a serine residue (e.g. providing SEQ ID NO: 32) or an alanine residue. Alternatively, the cysteine residue is deleted.
Hla
The 'Hla' antigen is the 'alpha-hemolysin precursor' also known as 'alpha toxin' or simply 'hemolysin'. In the NCTC 8325 strain Hla is SAOUHSC 01121 and has amino acid sequence SEQ ID NO: 67 (GL88194865). Hla is an important virulence determinant produced by most strains of S. aureus, having pore-forming and haemolytic activity. Anti-Hla antibodies can neutralise the detrimental effects of the toxin in animal models, and Hla is particularly useful for protecting against pneumonia. Mutant forms of Hla are disclosed as a useful immunogens in Reference 5.
SEQ ID NO: 67 has no free thiol group (e.g. it does not contain any cysteine residue). Hla used with the invention ideally also has no free thiol group. Various forms of Hla antigens that are suitable for use in this invention are discussed in Reference 5. Hla antigens used with the invention can elicit an antibody (e.g. when administered to a human) that recognises SEQ ID NO: 67 and/or may comprise an amino acid sequence: (a) having 80% or more identity (e.g. 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5% or more) to SEQ ID NO: 67; and/or (b) comprising a fragment of at least 'n' consecutive amino acids of SEQ ID NO: 67, wherein 'n' is 7 or more (e.g. 8, 10, 12, 14, 16, 18, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100, 150, 200, 250 or more). These Hla proteins include variants of SEQ ID NO: 67. Preferred fragments of (b) comprise an epitope from SEQ ID NO: 67. Other preferred fragments lack one or more amino acids (e.g. 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25 or more) from the C-terminus and/or one or more amino acids (e.g. 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25 or more) from the N-terminus of SEQ ID NO: 67 while retaining at least one epitope of SEQ ID NO: 67. The first 26 N-terminal amino acids of SEQ ID NO: 67 can usefully be omitted (e.g. to give SEQ ID NO: 68). Truncation at the C-terminus can also be used e.g. leaving only 50 amino acids (residues 27-76 of SEQ ID NO: 67) [9]. Other fragments omit one or more protein domains.
Hla's toxicity can be avoided in compositions of the invention by chemical inactivation (e.g. using formaldehyde, glutaraldehyde or other cross-linking reagents). Instead, however, it is preferred to use mutant forms of Hla which remove its toxic activity while retaining its immunogenicity. Such detoxified mutants are already known in the art. One useful Hla antigen has a mutation at residue 61 of SEQ ID NO: 67, which is residue 35 of the mature antigen (i.e. after omitting the first 26 N-terminal amino acids = residue 35 of SEQ ID NO: 68). Thus residue 61 may not be histidine, and may instead be e.g. He, Val or preferably Leu. A His-Arg mutation at this position can also be used. For example, SEQ ID NO: 69 is the mature mutant Hla-H35L sequence (i.e. SEQ ID NO: 68 with a H35L mutation) and a useful Hla antigen comprises SEQ ID NO: 69. Another useful mutation replaces a long loop with a short sequence e.g. to replace the 39mer at residues 136-174 of SEQ ID NO: 67 with a tetramer such as PSGS (SEQ ID NO: 70), as in SEQ ID NO: 71 (which also includes the H35L mutation) and SEQ ID NO: 72 (which does not include the H35L mutation). Another useful mutation replaces residue Y101 e.g. with a leucine (SEQ ID NO: 73). Another useful mutation replaces residue D152 e.g. with a leucine (SEQ ID NO: 74). Another useful mutant replaces residues H35 and Y101 e.g. with a leucine (SEQ ID NO: 75). Another useful mutant replaces residues H35 and D152 e.g. with a leucine (SEQ ID NO: 76). Further useful Hla antigens are disclosed in References 10 and 1 1.
SEQ ID NOs: 77, 78 & 79 are three useful fragments of SEQ ID NO: 67 ('H ve', 'H so' and 'Hla27- 79', respectively). SEQ ID NOs: 80, 81 and 82 are the corresponding fragments from SEQ ID NO: 69.
One useful Hla sequence is SEQ ID NO: 9, which was used in the examples. It has a N-terminal Met, then an Ala-Ser dipeptide from the expression vector, then SEQ ID NO: 69 (from NCTC8325 strain). It has no cysteine residues and is encoded by SEQ ID NO: 83.
Hybrid polypeptides
Antigens used in the invention may be present in the composition as individual separate polypeptides. Where more than one antigen is used, however, they do not have to be present as separate polypeptides. Instead, at least two (e.g. 2, 3, 4, 5, or more) antigens can be expressed as a single polypeptide chain (a 'hybrid' polypeptide). The hybrid polypeptide used with the invention ideally has no free thiol group.
Hybrids consisting of amino acid sequences from two, three, four, or more antigens are useful. In particular, hybrids consisting of amino acid sequences from two, three, four, or five antigens are preferred, such as two antigens.
Different hybrid polypeptides may be mixed together in a single formulation. The hybrid polypeptides can also be combined with conjugates or non-S. aureus antigens as described elsewhere herein.
One hybrid polypeptide of the invention may include a EsxA antigen and a variant form of EsxB that does not contain any free thiol group. Thus a single polypeptide can elicit antibodies (e.g. when administered to a human) that recognise both wild-type EsxA and wild-type cysteine-containing EsxB antigen (i.e. both SEQ ID NO: 1 and SEQ ID NO: 2). The single polypeptide can include: (i) a first polypeptide sequence having 80% or more identity (e.g. 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5% or more) to SEQ ID NO: 1 ; and (ii) a second polypeptide sequence having 80% or more identity (e.g. 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5% or more) to SEQ ID NO: 16, provided that it has no free thiol group. The first and second polypeptide sequences can be in either order, N- to C- terminus.
The hybrid polypeptide can also comprise third polypeptide sequence that has at least 90%> (e.g. >91%>, >92%, >93%, >94%, >95%, >96%, >97%, >98%) identity to SEQ ID NO: 15, and any such third sequence is ideally located upstream of the second polypeptide sequence (but if it is the first polypeptide sequence is upstream of the second polypeptide sequence then the third sequence should be downstream of the first).
SEQ ID NOs: 34-41 and 48-63 are 'EsxAB' hybrids, with EsxA upstream of EsxB; in contrast, SEQ ID NOs: 64 and 65 are 'EsxBA' hybrids, with EsxB to the N-terminus of EsxA. All of SEQ ID NOs: 34-65 include hexapeptide linker ASGGGS (SEQ ID NO: 66) and no cysteine residues. SEQ ID NOs: 52-65 include N-terminus methionine residues, whereas the 'EsxAB' hybrids of SEQ ID NOs: 34-41 and 48-51 do not.
Thus a useful polypeptide comprises an amino acid sequence having 80% or more identity (e.g. 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5% or more) to any of SEQ ID NOs: 34-41 and 48-63, wherein the polypeptide does not contain any free thiol group. These polypeptides (e.g. SEQ ID NO: 295) can elicit antibodies (e.g. when administered to a human) which recognise both the wild-type staphylococcal protein comprising SEQ ID NO: 1 and the wild-type staphylococcal protein comprising SEQ ID NO: 2. Thus the immune response will recognise both EsxA and EsxB staphylococcal antigens.
Another hybrid polypeptide of the invention may include: (i) Hla and Sta006 antigens, (ii) Hla, EsxA and EsxB antigens or (iii) Sta006, EsxA and EsxB antigens, wherein variants of EsxB, Sta006 and StaOl 1 are used instead of the wild-type antigen, and the variants do not contain any free thiol groups.
Usefully, these hybrid polypeptides can elicit antibodies (e.g. when administered to a human) that recognise each of the wild-type staphylococcal proteins (e.g. as shown in the sequence listing) represented in the hybrid e.g. which recognise both wild-type EsxA and wild-type EsxB, or which recognise both wild-type Hla and wild-type Sta006, or which recognise wild-type Hla, wild-type EsxA and wild-type EsxB, or which recognise wild-type Sta006, wild-type EsxA and wild-type EsxB.
The invention also provides a polypeptide comprising amino acid sequence Zi-Z2-Z3 wherein: Zi is an amino acid sequence having at least 90% (e.g. >91%, >92%, >93%, >94%, >95%, >96%, >97%, >98%) identity to SEQ ID NO: 15; Z2 is either absent or is an amino acid sequence having up to 5 amino acids; Z3 is an amino acid sequence having at least 90% (e.g. >91%, >92%, >93%, >94%, >95%, >96%, >97%, >98%) identity to SEQ ID NO: 16; the polypeptide includes no cysteine residues; and the polypeptide can elicit antibodies which recognise a wild-type EsxB antigen (e.g. SEQ ID NO: 2).
Where a polypeptide comprises amino acid sequence Zi-Z2-Z3, in some embodiments the amino acid sequence Zi is sequence Zia- Zib- Zic wherein: Zia comprises an amino acid sequence (a) having 80% or more identity (e.g. 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5% or more) to SEQ ID NO: 1 ; and/or (b) comprising a fragment of at least 'n' consecutive amino acids of SEQ ID NO: 1, wherein 'n' is 7 or more (e.g. 8, 10, 12, 14, 16, 18, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90 or more); Zlb is either absent or is a linker sequence (as defined below); and Zic comprises an amino acid sequence (a) having 80% or more identity (e.g. 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5% or more) to SEQ ID NO: 15; and/or (b) comprising a fragment of at least 'n' consecutive amino acids of SEQ ID NO: 15, wherein 'n' is 7 or more (e.g. 8, 10, 12, 14, 16, 18, 20, 25 or more).
In some embodiments antigens in a single hybrid polypeptide are joined together by a linker amino acid sequence. Linker amino acid sequences will typically be short (e.g. 20 or fewer amino acids i.e. 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, 1). Examples comprise short peptide sequences which facilitate cloning, or poly-glycine linkers (i.e. comprising Gly where n = 2, 3, 4, 5, 6 or more). Other suitable linker amino acid sequences will be apparent to those skilled in the art. A useful linker is GSGGGG (SEQ ID NO: 84), with the Gly-Ser dipeptide being formed from a BamHI restriction site thus aiding cloning and manipulation, and the (Gly)4 tetrapeptide (SEQ ID NO: 85) being a typical poly- glycine linker. Other suitable linkers are ASGGGS (SEQ ID NO: 66) or a Leu-Glu dipeptide.
Polypeptides used with the invention
The invention uses variant forms of S. aureus antigens that do not form disulphide bonds. S. aureus antigens that contain free thiol groups (e.g. cysteine amino acids) can form oligomers, including covalent homo- or hetero-dimers in standard buffers. The covalent dimers are usually produced by oxidation of the thiol groups of cysteine residues resulting in a disulphide bond (i.e. the formation of a cystine). To eliminate covalent dimer formation, the polypeptides of the invention do not contain any free thiol groups (under reducing conditions) that can react to form disulphide bonds. A free thiol group, also known as an unprotected thiol group, or a free or unprotected -SH, has a reactive sulphur atom. A cysteine amino acid residue has a free thiol group under reducing conditions, and thus the polypeptides of the invention do not contain any cysteine amino acid residue. A cysteine residue can be derivatised such that the thiol group is protected and cannot react to form disulphide bonds, e.g. by adding a thiol protecting group. Thiol protecting groups are known in the art, e.g. thioether, thioester or derivatives thereof [12]. Thus, the polypeptides of the invention may contain derivatised cysteine amino acid residues, provided that the derivatised cysteine amino acid residues do not have free thiol groups (under reducing conditions) that can form disulphide bonds.
In some exceptional embodiments, a polypeptide can include a thiol group, but this thiol group is not part of the side chain in a cysteine residue. Ideally, however, a polypeptide includes no thiol groups at all.
Preferably the polypeptide contains neither cysteine nor cystine.
In some embodiments, the polypeptide may contain amino acid 'Jf . 'Jf can be any amino acid, provided that it does not contain a free thiol group. The amino acid can be a natural or a non-natural amino acid. Natural amino acids are known in the art, e.g. alanine, arginine, asparagine, aspartic acid, glutamine, glutamic acid, glycine, histidine, isoleucine, leucine lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine or valine. Cysteine has a free thiol group, and so 'Jf cannot be a cysteine residue. A non-natural amino acid can be a derivatised or modified amino acid. 'Jf can be a derivatised amino acid that does not contain a free thiol group, e.g. methyl-cysteine.
Polypeptides used with the invention can take various forms (e.g. native, fusions, glycosylated, non-glycosylated, lipidated, non-lipidated, phosphorylated, non-phosphorylated, myristoylated, non-myristoylated, monomeric, multimeric, particulate, denatured, etc.).
Polypeptides used with the invention can be prepared by various means (e.g. recombinant expression, purification from cell culture, chemical synthesis, etc.). Recombinantly-expressed proteins are preferred, particularly for hybrid polypeptides.
Antigens in composition of the invention are separated from the organism in which they were expressed before being combined. Polypeptides are thus provided in purified or substantially purified for before being used i.e. substantially free from other staphylococcal or host cell polypeptides. A polypeptide is generally at least about 80% pure (by weight) before being combined with other polypeptides in compositions of the invention, and usually at least about 90% pure i.e. less than about 20%, and preferably less than about 10% {e.g. <5%) of a polypeptide composition is made up of other polypeptides before being added to a mixture.
Preferred polypeptides used with the invention have a N-terminus methionine, but in some embodiments a methionine which was present at the N-terminus of a nascent polypeptide may be absent from the polypeptide in a composition of the invention.
Polypeptides used with the invention are preferably staphylococcal polypeptides.
The term "polypeptide" refers to amino acid polymers of any length. The polymer may be linear or branched, it may comprise modified amino acids, and it may be interrupted by non-amino acids. The terms also encompass an amino acid polymer that has been modified naturally or by intervention; for example, disulphide bond formation, glycosylation, lipidation, acetylation, phosphorylation, or any other manipulation or modification, such as conjugation with a labelling component. Also included are, for example, polypeptides containing one or more analogs of an amino acid (including, for example, unnatural amino acids, etc.), as well as other modifications known in the art. Polypeptides can occur as single chains or associated chains.
The invention provides polypeptides comprising a sequence -P-Q- or -Q-P-, wherein: -P- is an amino acid sequence as defined above and -Q- is not a sequence as defined above i.e. the invention provides fusion proteins, provided that the polypeptides do not contain any free thiol group. Where the N-terminus codon of -P- is not ATG, but this codon is not present at the N-terminus of a polypeptide, it will be translated as the standard amino acid for that codon rather than as a Met. Where this codon is at the N-terminus of a polypeptide, however, it will be translated as Met. Examples of -Q- moieties include, but are not limited to, histidine tags {i.e. His„ where n = 3, 4, 5, 6, 7, 8, 9, 10 or more), maltose-binding protein, or glutathione-S-transferase (GST).
Although expression of the polypeptides of the invention may take place in a Staphylococcus, the invention will usually use a heterologous host for expression (recombinant expression). The heterologous host may be prokaryotic {e.g. a bacterium) or eukaryotic. It may be E.coli, but other suitable hosts include Bacillus subtilis, Vibrio cholerae, Salmonella typhi, Salmonella typhimurium, Neisseria lactamica, Neisseria cinerea, Mycobacteria {e.g. M.tuberculosis), yeasts, etc. Compared to the wild-type S. aureus genes encoding polypeptides of the invention, it is helpful to change codons to optimise expression efficiency in such hosts without affecting the encoded amino acids.
Nucleic acids
The invention provides nucleic acid encoding polypeptides and hybrid polypeptides of the invention. It also provides nucleic acid comprising a nucleotide sequence that encodes one or more polypeptides or hybrid polypeptides of the invention.
The invention provides a process for producing nucleic acid of the invention, wherein the nucleic acid is synthesised in part or in whole using chemical means. The invention provides vectors comprising nucleotide sequences of the invention (e.g. cloning or expression vectors) and host cells transformed with such vectors.
Methods of manipulating nucleic acids and expressing the encoded proteins are known in the art, and include those described in References 46 and 70. A nucleic acid sequence may be modified by replacing the codon for cysteine with a codon for another amino acid. The cysteine may be replaced with any other amino acid, including serine, alanine, glycine, valine, leucine, or isoleucine, or modified forms of an amino acid that does not have free thiol groups (i.e. cannot readily form disulphide bonds). Alternatively, the cysteine residue may simply be deleted from the sequence. Thus, a deletion must remove the codon for the cysteine from the nucleic acid sequence without introducing a frameshift. Techniques for making substitution and deletion mutations at predetermined sites in a nucleic acid having a known sequence are well known and include, but are not limited to, primer mutagenesis and other forms of site-directed mutagenesis.
The invention also provides nucleic acid comprising nucleotide sequences having sequence identity to such nucleotide sequences. Identity between sequences is preferably determined by the Smith Waterman homology search algorithm as described above. Such nucleic acids include those using alternative codons to encode the same amino acid.
Nucleic acid according to the invention can take various forms (e.g. single stranded, double stranded, vectors, primers, probes, labelled etc.). Nucleic acids of the invention may be circular or branched, but will generally be linear. Unless otherwise specified or required, any embodiment of the invention that utilizes a nucleic acid may utilize both the double-stranded form and each of two complementary single- stranded forms which make up the double stranded form. Nucleic acids of the invention are preferably provided in purified or substantially purified form i.e. substantially free from other nucleic acids (e.g. free from naturally- occurring nucleic acids), particularly from other staphylococcal or host cell nucleic acids, generally being at least about 50% pure (by weight), and usually at least about 90%> pure. Nucleic acids of the invention are preferably staphylococcal nucleic acids.
Nucleic acids of the invention may be prepared in many ways e.g. by chemical synthesis (e.g. phosphoramidite synthesis of DNA) in whole or in part, by digesting longer nucleic acids using nucleases (e.g. restriction enzymes), by joining shorter nucleic acids or nucleotides (e.g. using ligases or polymerases), from genomic or cDNA libraries, etc.
The term "nucleic acid" includes in general means a polymeric form of nucleotides of any length, which contain deoxyribonucleotides, ribonucleotides, and/or their analogs. It includes DNA, RNA, DNA/RNA hybrids. It also includes DNA or RNA analogs, such as those containing modified backbones (e.g. peptide nucleic acids (PNAs) or phosphorothioates) or modified bases. Thus the invention includes mRNA, tRNA, rRNA, ribozymes, DNA, cDNA, recombinant nucleic acids, branched nucleic acids, plasmids, vectors, probes, primers, etc. Where nucleic acid of the invention takes the form of RNA, it may or may not have a 5' cap.
Nucleic acids of the invention may be part of a vector i.e. part of a nucleic acid construct designed for transduction/transfection of one or more cell types. Vectors may be, for example, "cloning vectors" which are designed for isolation, propagation and replication of inserted nucleotides, "expression vectors" which are designed for expression of a nucleotide sequence in a host cell, "viral vectors" which is designed to result in the production of a recombinant virus or virus-like particle, or "shuttle vectors", which comprise the attributes of more than one type of vector. Preferred vectors are plasmids. A "host cell" includes an individual cell or cell culture which can be or has been a recipient of exogenous nucleic acid. Host cells include progeny of a single host cell, and the progeny may not necessarily be completely identical (in morphology or in total DNA complement) to the original parent cell due to natural, accidental, or deliberate mutation and/or change. Host cells include cells transfected or infected in vivo or in vitro with nucleic acid of the invention.
Where a nucleic acid is DNA, it will be appreciated that "U" in a RNA sequence will be replaced by "T" in the DNA. Similarly, where a nucleic acid is RNA, it will be appreciated that "T" in a DNA sequence will be replaced by "U" in the RNA.
The term "complement" or "complementary" when used in relation to nucleic acids refers to Watson- Crick base pairing. Thus the complement of C is G, the complement of G is C, the complement of A is T (or U), and the complement of T (or U) is A. It is also possible to use bases such as I (the purine inosine) e.g. to complement pyrimidines (C or T).
Strains and variants
An exemplary amino acid and nucleotide sequence for the antigens described herein can easily be found in public sequence databases from the NCTC 8325 and/or Newman S. aureus strain using their GI numbers, for example, but the invention is not limited to sequences from the NCTC 8325 and Newman strains. Genome sequences of several other strains of S. aureus are available, including those of MRSA strains N315 and Mu50 [13], MW2, N315, COL, MRSA252, MSSA476, RF122, USA300 (very virulent), JH1 and JH9. Standard search and alignment techniques can be used to identify in any of these (or other) further genome sequences the homolog of any particular sequence from the Newman or NCTC 8325 strain. Moreover, the available sequences from the Newman and NCTC 8325 strains can be used to design primers for amplification of homologous sequences from other strains. Thus the invention is not limited to these two strains, but rather encompasses such variants and homologs from other strains of S. aureus, as well as non-natural variants. In general, suitable variants of a particular SEQ ID NO include its allelic variants, its polymorphic forms, its homologs, its orthologs, its paralogs, its mutants, etc., provided they do not contain any free thiol group.
Thus, for instance, polypeptides used with the invention may, compared to the SEQ ID NO herein, include one or more {e.g. 1, 2, 3, 4, 5, 6, 7, 8, 9, etc.) amino acid substitutions, such as conservative substitutions {i.e. substitutions of one amino acid with another which has a related side chain), provided that the new amino acid residue does not contain a free thiol group. The polypeptides of the invention do not contain any cysteine residue. Genetically-encoded amino acids are generally divided into four families: (1) acidic i.e. aspartate, glutamate; (2) basic i.e. lysine, arginine, histidine; (3) non-polar i.e. alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan; and (4) uncharged polar i.e. glycine, asparagine, glutamine, cysteine, serine, threonine, tyrosine. Phenylalanine, tryptophan, and tyrosine are sometimes classified jointly as aromatic amino acids. In general, substitution of single amino acids within these families does not have a major effect on the biological activity. The polypeptide of the invention cannot be substituted with a cysteine. The polypeptides may also include one or more (e.g. 1, 2, 3, 4, 5, 6, 7, 8, 9, etc.) single amino acid deletions relative to the SEQ ID NO sequences. The polypeptides may also include one or more (e.g. 1 , 2, 3, 4, 5, 6, 7, 8, 9, etc.) insertions (e.g. each of 1 , 2, 3, 4 or 5 amino acids) relative to the SEQ ID NO sequences, provided that the inserted amino acid residue does not contain any free thiol group (e.g. the inserted amino acid is not a cysteine).
Similarly, a polypeptide used with the invention may comprise an amino acid sequence that:
■ is identical (i.e. 100% identical) to a sequence disclosed in the sequence listing;
■ shares sequence identity (e.g. 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5% or more) with a sequence disclosed in the sequence listing;
■ has 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 (or more) single amino acid alterations (deletions, insertions, substitutions), which may be at separate locations or may be contiguous, as compared to the sequences of (a) or (b); and
■ when aligned with a particular sequence from the sequence listing using a pairwise alignment algorithm, each moving window of x amino acids from N-terminus to C-terminus (such that for an alignment that extends to p amino acids, where p>x, there are p-x+1 such windows) has at least xy identical aligned amino acids, where: x is selected from 20, 25, 30, 35, 40, 45, 50, 60, 70,
80, 90, 100, 150, 200; y is selected from 0.50, 0.60, 0.70, 0.75, 0.80, 0.85, 0.90, 0.91, 0.92, 0.93, 0.94, 0.95, 0.96, 0.97, 0.98, 0.99; and if xy is not an integer then it is rounded up to the nearest integer. The preferred pairwise alignment algorithm is the Needleman-Wunsch global alignment algorithm [14], using default parameters (e.g. with Gap opening penalty = 10.0, and with Gap extension penalty = 0.5, using the EBLOSUM62 scoring matrix). This algorithm is conveniently implemented in the needle tool in the EMBOSS package [15];
provided that the polypeptide does not contain any free thiol group.
Where hybrid polypeptides are used, the individual antigens within the hybrid (i.e. individual -X- moieties) may be from one or more strains. Where n=2, for instance, X2 may be from the same strain as Xi or from a different strain. Where n=3, the strains might be (i)
Figure imgf000014_0001
Figure imgf000014_0002
Within group (c), deletions or substitutions may be at the N-terminus and/or C-terminus, or may be between the two termini. Thus a truncation is an example of a deletion. Truncations may involve deletion of up to 40 (or more) amino acids at the N-terminus and/or C-terminus. N-terminus truncation can remove leader peptides e.g. to facilitate recombinant expression in a heterologous host. C-terminus truncation can remove anchor sequences e.g. to facilitate recombinant expression in a heterologous host.
In general, when an antigen comprises a sequence that is not identical to a complete S. aureus sequence from the sequence listing (e.g. when it comprises a sequence listing with <100%> sequence identity thereto, or when it comprises a fragment thereof) it is preferred in each individual instance that the antigen can elicit an antibody which recognises the respective complete S. aureus sequence.
Combinations with saccharides
The immunogenic compositions of the invention may further comprise saccharide antigens (e.g. known saccharide antigens include the exopolysaccharide of S. aureus, which is a poly-N-acetylglucosamine (PNAG), and the capsular saccharides of S.aureus, which can be e.g. from type 5, type 8 or type 336). In some embodiments a composition does not include a S.aureus saccharide antigen.
Combinations with non-staphylococcal antigens
The immunogenic compositions of the invention may further comprise non-staphylococcal antigens, and in particular with antigens from bacteria associated with nosocomial infections. For example, the immunogenic composition may further comprise one or more antigen(s) selected from the group consisting of: Clostridium difficile; Pseudomonas aeruginosa; Candida albicans; and extraintestinal pathogenic Escherichia coli. Further suitable antigens for use in combination with staphylococcal antigens of the invention are listed on pages 33-46 of Reference 16.
Preferred compositions
A preferred composition of the invention comprises any two or more (e.g. 2, 3 or all 4) of the antigens selected from: (i) a EsxB polypeptide of the invention, e.g. having at least 90% (e.g. >91%, >92%, >93%, >94%, >95%, >96%, >97%, >98%) identity to SEQ ID NO: 16, wherein the EsxB antigen has no free thiol group, and can elicit antibodies (e.g. when administered to a human) which recognise a wild-type EsxB antigen (e.g. SEQ ID NO: 2); (ii) a Sta006 polypeptide of the invention, e.g. having at least 90% (e.g. >91%, >92%, >93%, >94%, >95%, >96%, >97%, >98%, >99%, >99.5%) identity to SEQ ID NO: 24, wherein the Sta006 antigen has no free thiol group, and can elicit antibodies (e.g. when administered to a human) which recognise a wild-type Sta006 antigen (e.g. SEQ ID NO: 10); (iii) a StaOl 1 polypeptide of the invention, e.g. having at least 90% (e.g. >91%, >92%, >93%, >94%, >95%, >96%, >97%, >98%, >99%, >99.5%) identity to SEQ ID NO: 28, wherein the StaOl 1 antigen has no free thiol group, and can elicit antibodies (e.g. when administered to a human) which recognise a wild-type StaOl l antigen (e.g. SEQ ID NO: 11); and (iv) a H35L mutant form of Hla e.g. comprising SEQ ID NO: 9, wherein H35L polypeptide can elicit antibodies which recognise a wild-type Hla (e.g. SEQ ID NO: 67).
Preferably, the composition comprises: (a) the EsxB polypeptide of (i) and the Sta006 polypeptide of (ii); (b) the EsxB polypeptide of (i) and the StaOl l polypeptide of (iii); (c) the Sta006 polypeptide of (ii) and the StaOl 1 polypeptide of (iii); (d) the EsxB polypeptide of (i) and the Hla-H35L polypeptide of (iv); (e) the Sta006 polypeptide of (ii) and the Hla-H35L polypeptide of (iv); or (f) the StaOl 1 polypeptide of (iii) and the Hla-H35L polypeptide of (iv).
Preferably, the composition comprises: (a) the EsxB polypeptide of (i), the Sta006 polypeptide of (ii) and the StaOl 1 polypeptide of (iii); (b) the EsxB polypeptide of (i), the Sta006 polypeptide of (ii) and the Hla- H35L polypeptide of (iv); (c) the Sta006 polypeptide of (ii) and the StaOl l polypeptide of (iii) and the Hla-H35L polypeptide of (iv); or (d) the EsxB polypeptide of (i) and the StaOl l polypeptide of (iii) and the Hla-H35L polypeptide of (iv).
Another preferred composition of the invention includes all four of the EsxB polypeptide of (i), the Sta006 polypeptide of (ii), the StaOl 1 polypeptide of (iii), and the Hla-H35L polypeptide of (iv).
The EsxB polypeptide of (i) can also comprise (a) an upstream amino acid sequence having at least 90%> (e.g. >91%, >92%, >93%, >94%, >95%, >96%, >97%, >98%) identity to SEQ ID NO: 15 and (b) a further upstream amino acid sequence having at least 90% (e.g. >91%, >92%, >93%, >94%, >95%, >96%, >97%, >98%) identity to SEQ ID NO: 1. Thus the polypeptide can be an EsxAB polypeptide as disclosed above, and it can elicit antibodies which recognise both SEQ ID NO: 1 and SEQ ID NO: 2.
The EsxAB hybrid polypeptide can comprise an amino acid sequence having 80% or more identity to SEQ ID NO: 59, wherein the EsxAB hybrid polypeptide can elicit antibodies which recognise SEQ ID NOs: 1 and 2.
A composition of the invention may comprise: (i) a single polypeptide including both an EsxA antigen and an EsxB antigen e.g. comprising SEQ ID NO: 14; (ii) a Sta006 antigen e.g. comprising SEQ ID NO: 12; and /or (iii) a StaOl 1 antigen e.g. comprising SEQ ID NO: 13; wherein at least one (e.g. 1, 2 or all 3) of (i), (ii) or (iii) comprises at least one point mutation that replaces, modifies or deletes the cysteine residue present in the wild-type form of the antigen (e.g. present in each of SEQ ID NOs: 12, 13 & 14). The cysteine residues at position 133 of SEQ ID NO: 14, at position 4 of SEQ ID NO: 12 and at position 3 of SEQ ID NO: 13 may independently be replaced, modified or deleted. Preferably, the replacement is with a serine or an alanine residue. Alternatively, the cysteine residue is deleted. Preferably, none of the polypeptides contains any cysteine residues.
Each of the polypeptides (i) to (iii) can elicit antibodies (e.g. when administered to a human) which recognise the respective wild-type cysteine-containing antigen. For example, (i) can elicit antibodies which recognise SEQ ID NO: 2 (EsxB), (ii) can elicit antibodies which recognise SEQ ID NO: 10 (Sta006), and (iii) can elicit antibodies which recognise SEQ ID NO: 11 (StaOl 1).
The composition may further comprise (iv) a H35L mutant form of Hla e.g. comprising SEQ ID NO: 9, which can elicit antibodies which recognise a wild-type Hla (e.g. SEQ ID NO: 67).
Thus, a useful composition of the invention comprises: (i) a Sta006 polypeptide having amino acid sequence SEQ ID NO: 26; (ii) a StaOl 1 polypeptide having amino acid sequence SEQ ID NO: 32; and/or (iii) a EsxAB hybrid polypeptide having amino acid sequence SEQ ID NO: 59. The composition can further comprise a Hla polypeptide having amino acid sequence SEQ ID NO: 9.
When two or more of the polypeptides are present in the composition, the polypeptides may be present at substantially equal masses i.e. the mass of each of them is within +5% of the mean mass of all the polypeptides. Thus when four polypeptides are present, they may be present at a mass ratio of a:b:c:d, where each of a-d is between 0.95 and 1.05.
In some embodiments the composition may include one or more further polypeptides; in other embodiments the only polypeptides in the composition are the polypeptides discussed above. If the composition does include one or more further polypeptides, it is preferred that these do not contain any free thiol groups (under reducing conditions). Preferably, the further polypeptides are staphylococcal polypeptides, e.g. the S. aureus polypeptides disclosed in Reference 5.
The composition of the invention is particularly useful when using TLR7 agonists of formula (K). These agonists are discussed in detail in Reference 17:
Figure imgf000017_0001
( )
wherein:
R1 is H, Ci-Cgalkyl, -C(R5)2OH, -L^5, -LlR6, -L2R5, -L2R6, -OL2R5, or -OL2R6;
L1 is -C(O)- or -0-;
L2 is Ci-C6alkylene, C2-C6alkenylene, arylene, heteroarylene or -((CR4R4)pO)q(CH2)p-, wherein the CpCealkylene and C2-C6alkenylene of L2 are optionally substituted with 1 to 4 fluoro groups; each L3 is independently selected from d-Cealkylene and -((CR4R4)pO)q(CH2)p-, wherein the Cp Cealkylene of L3 is optionally substituted with 1 to 4 fluoro groups;
L4 is arylene or heteroarylene;
R2 is H or Ci-Cgalkyl;
R3 is selected from CrC4alkyl, -L3R5, -L^5, -L3R7, -L3L4L3R7, -L3L4R5, -L3L4L3R5, -OL3R5, - OL3R7, -OL3L4R7, -OL3L4L3R7, -OR8, -OL3L4R5, -OL3L4L3R5 and -C(R5)2OH ;
each R4 is independently selected from H and fluoro;
R5 is -P(0)(OR9)2,
R6is -CF2P(0)(OR9)2 or -C(0)OR10;
R7 is -CF2P(0)(OR9)2 or -C(0)OR10;
R8 is H or CrC4alkyl;
each R9 is independently selected from H and Ci-Cealkyl;
R10 is H or CrC4alkyl;
each p is independently selected from 1, 2, 3, 4, 5 and 6, and
q is 1, 2, 3 or 4.
The compound of formula (K is preferably of formula (Κ'):
Figure imgf000017_0002
( ') wherein:
P1 is selected from H, Ci-C6alkyl optionally substituted with COOH and -Y-L-X- P(0)(ORx)(ORY);
P2 is selected from H, CrC6alkyl, CrC6alkoxy and -Y-L-X-P(0)(ORx)(ORY);
with the proviso that at least one of P1 and P2 is -Y-L-X-P(0)(ORx)(ORY);
RB is selected from H and Ci-C6alkyl;
Rx and RY are independently selected from H and CpCealkyl;
X is selected from a covalent bond, O and NH;
Y is selected from a covalent bond, O, C(O), S and NH;
L is selected from, a covalent bond Ci-C6alkylene, Ci-C6alkenylene, arylene, heteroarylene, Cr Cealkyleneoxy and -((CH2)pO)q(CH2)p- each optionally substituted with 1 to 4 substituents independently selected from halo, OH, CrC4alkyl, -OP(0)(OH)2 and -P(0)(OH)2;
each p is independently selected from 1, 2, 3, 4, 5 and 6; and
q is selected from 1, 2, 3 and 4.
In some embodiments of formula (Κ'): P1 is selected from CpCealkyl optionally substituted with COOH and -Y-L-X-P(0)(ORx)(ORY); P2 is selected from CrC6alkoxy and -Y-L-X-P(0)(ORx)(ORY); RB is Cr Cealkyl; X is a covalent bond; L is selected from CpCealkylene and -((CH2)pO)q(CH2)p- each optionally substituted with 1 to 4 substituents independently selected from halo, OH, Ci-C4alkyl, -OP(0)(OH)2 and -P(0)(OH)2; each p is independently selected from 1, 2 and 3; q is selected from 1 and 2.
A preferred compound of formula (K) for use with the invention is 3-(5-amino-2-(2-methyl-4-(2-(2-(2-phosphonoethoxy) ethoxy)ethoxy)phenethyl)benzo[fj [1 ,7] naphthyridin-8-yl)propanoic acid, or compound 'Κ :
Figure imgf000018_0001
This compound can be used as free base or in the form of a pharmaceutically acceptable salt e.g. an arginine salt.
Compounds of formula (K) can be mixed with an insoluble metal salt (preferably an aluminium salt, such as an aluminium hydroxide), and the compound is typically adsorbed to the metal salt. The antigen of the invention (and, optionally, further antigen(s) in a composition) can also be adsorbed to the metal salt. Thus a preferred composition comprises (i) an antigen as defined herein (e.g. Sta006, StaOl 1 or EsxB) (ii) a TLR7 agonist of formula (K), such as formula (Kl), and (iii) an insoluble metal salt, such as an aluminium hydroxide. The TLR7 agonist and the antigen are preferably adsorbed to the metal salt. Stabilizing additives
In some embodiments of the invention an immunogenic composition includes a stabilizing additive. Such additives include, but are not limited to, chelators of divalent metal cations (e.g. EDTA, ethylenediaminetetraacetic acid), sugars (e.g. disaccharides such as sucrose or trehalose), sugar alcohols (e.g. mannitol), free amino acids (e.g. arginine), buffer salts (e.g. phosphate, citrate), polyols (e.g. glycerol, mannitol), or protease inhibitors.
EDTA is a preferred additive. The final concentration of EDTA in the immunogenic composition of the invention can be about 1-50 mM, about 1-10 mM or about 1-5 mM, preferably about 2.5 mM.
A buffer is another useful additive, in order to control pH of a composition. This can be particularly important after reconstitution of lyophilized material. Compositions of the invention may include one or more buffer(s). Typical buffers include: a phosphate buffer; a Tris buffer; a borate buffer; a succinate buffer; a histidine buffer; or a citrate buffer. A phosphate buffer is preferable. Buffers will typically be included in the 5-20 mM range. Aqueous compositions of the invention preferably have a pH of between 5 and 8 e.g. between 5.5-6.5, or 5.9-6.1, or a pH of 6.
A saccharide or sugar alcohol (or mixture thereof e.g. a mannitol/sucrose mixture) is also useful, particularly when using lyophilization. Suitable materials include, but are not limited to, mannitol, lactose, sucrose, trehalose, dextrose, etc. The use of sucrose is particularly preferred. Such materials can be present at a concentration of about 1% by weight per volume, or about 3% to about 6% by weight per volume, or up to about 10% or about 12.5% by weight per volume, preferably about 5 % by weight per volume.
Lyophilization
One way of storing immunogenic compositions of the invention is in lyophilized form. This procedure can be used with or without the addition of a metal chelator (e.g. EDTA). The inventors have also shown that EDTA does not have a significant impact on the thermal characteristic of the vaccine and does not introduce any undesired plasticizing effect, thus meaning that EDTA-containing compositions can be lyophilized to further enhance storage stability.
Thus, generally, the invention also provides a lyophilizate which comprises a divalent metal cation chelator (e.g. EDTA) and at least one antigen (e.g. at least one polypeptide antigen).
The invention also provides a lyophilizate of an aqueous immunogenic composition of the invention. This is prepared by lyophilising an aqueous composition of the invention. It can then be reconstituted with aqueous material to provide an aqueous immunogenic composition of the invention. Materials present in the material which is lyophilized will remain in the lyophilizate and will thus also be present after reconstitution e.g. buffer salts, lyoprotectants (e.g. sucrose and/or mannitol), chelators, etc. If the material is reconstituted with a smaller volume of material than before lyophilization then these materials will be present in more concentrated form. The reconstituted lyophilizate preferably contains lyoprotectants (e.g. sucrose and/or mannitol) at a concentration of up to about 2.5% by weight per volume, preferably about 1%) to about 2% by weight per volume. The amount of EDTA which is present in a composition prior to lyophilization is ideally at least 0.75 mM, and preferably at least 2.5 mM. A maximum of 50 mM is envisaged. Liquid materials useful for reconstituting lyophilizates include, but are not limited to: salt solutions, such as physiological saline; buffers, such as PBS; water, such as wfi. They usefully have a pH between 4.5 and 7.5 e.g. between 6.8 and 7.2. The reconstituted lyophilizate preferably has a pH of between 5-6.5 e.g. between 5.8-6.2, or 5.9-6.1, or a pH of 6. A liquid material for reconstitution can include an adjuvant e.g. an aluminium salt adjuvant. Aqueous suspensions of adjuvants (optionally including buffers, such as a histidine buffer) are useful for simultaneously reconstituting and adsorbing lyophilized polypeptides. In other embodiments the liquid material is adjuvant-free. Typically the lyophilizate does not include an insoluble metal salt adjuvant.
The invention also provides a lyophilizate which comprises EDTA and at least one antigen.
Immunogenic compositions and medicaments
Immunogenic compositions of the invention may be useful as vaccines. Vaccines according to the invention may either be prophylactic (i.e. to prevent infection) or therapeutic (i.e. to treat infection), but will typically be prophylactic.
Compositions may thus be pharmaceutically acceptable. They will usually include components in addition to the antigens e.g. they typically include one or more pharmaceutical carrier(s) and/or excipient(s). A thorough discussion of such components is available in Reference 43.
Compositions will generally be administered to a mammal in aqueous form. Prior to administration, however, the composition may have been in a non-aqueous form. For instance, although some immunogenic compositions are manufactured in aqueous form, then filled and distributed and administered also in aqueous form, other immunogenic compositions are lyophilized during manufacture and are reconstituted into an aqueous form at the time of use. Thus a composition of the invention may be dried, such as a lyophilized formulation.
Where a composition of the invention includes more than one polypeptide, the mass of each different polypeptide can be the same or different. Ideally they are present at substantially equal masses i.e. the mass of each of them is within +5% of the mean mass of all the polypeptides. In embodiments where two antigens are present as a hybrid polypeptide, the hybrid is considered as a single polypeptide for this purpose. The factors that can influence the amount of the polypeptide to be included in a multivalent formulation include the amount of polypeptide sufficient to elicit an immune response and the amount that would cause aggregation (with itself or with other polypeptide) or influence the stability of the other polypeptide. Typical masses of a polypeptide in an immunogenic composition are between l-100μg.
The composition may include preservatives such as thiomersal or 2-phenoxyethanol. It is preferred, however, that the immunogenic compositions should be substantially free from (i.e. less than 5μg/ml) mercurial material e.g. thiomersal-free. Compositions containing no mercury are more preferred. Preservative-free compositions are particularly preferred.
To improve thermal stability, a composition may include a temperature protective agent. Further details of such agents are provided below. To control tonicity, it is preferred to include a physiological salt, such as a sodium salt. Sodium chloride (NaCl) is preferred, which may be present at between 1 and 20 mg/ml e.g. about 10+2 mg/ml NaCl. Other salts that may be present include potassium chloride, potassium dihydrogen phosphate, disodium phosphate dehydrate, magnesium chloride, calcium chloride, etc. Compositions will generally have an osmolality of between 200 mOsm/kg and 400 mOsm/kg, preferably between 240-360 mOsm/kg, and will more preferably fall within the range of 290-310 mOsm/kg.
Compositions may include one or more buffers. Typical buffers include: a phosphate buffer; a Tris buffer; a borate buffer; a succinate buffer; a histidine buffer (particularly with an aluminium hydroxide adjuvant); or a citrate buffer. Buffers will typically be included in the 5-20 mM range. The buffer is preferably 10 mM potassium phosphate.
The pH of the compositions are preferably between about 5 and about 8, and more preferably between about 5.5 and about 6.5, and most preferably at about 6.
The composition is preferably sterile. The composition is preferably non-pyrogenic e.g. containing <1 EU (endotoxin unit, a standard measure) per dose, and preferably <0.1 EU per dose. The composition is preferably gluten free.
The composition may include material for a single immunisation, or may include material for multiple immunisations (i.e. a 'multidose' kit). The inclusion of a preservative is preferred in multidose arrangements. As an alternative (or in addition) to including a preservative in multidose compositions, the compositions may be contained in a container having an aseptic adaptor for removal of material.
Human vaccines are typically administered in a dosage volume of about 0.5ml, although a half dose (i.e. about 0.25ml) may be administered to children.
Immunogenic compositions of the invention may also comprise one or more immunoregulatory agents. Preferably, one or more of the immunoregulatory agents include one or more adjuvants. The adjuvants may include a TH1 adjuvant and/or a TH2 adjuvant, further discussed below. Thus the immunogenic compositions may further comprise an adjuvant, such as an aluminium salt adjuvant (for example, one or more antigens may be adsorbed to aluminium salt). More generally, adjuvants which may be used in compositions of the invention include, but are not limited to, those already listed in Reference 5. These include mineral-containing adjuvants and oil-in-water emulsions.
Mineral-containing adjuvants
Mineral containing adjuvants include mineral salts such as aluminium salts and calcium salts (or mixtures thereof). Preferably, the composition contains an aluminium salt adjuvant. Aluminium salts include hydroxides, phosphates, etc., with the salts taking any suitable form (e.g. gel, crystalline, amorphous, etc.). Calcium salts include calcium phosphate (e.g. the "CAP" particles disclosed in Ref. 18). Adsorption to these salts is preferred (e.g. all antigens may be adsorbed). The mineral containing compositions may also be formulated as a particle of metal salt [19].
The adjuvants known as aluminium hydroxide and aluminium phosphate may be used. These names are conventional, but are used for convenience only, as neither is a precise description of the actual chemical compound which is present (e.g. see chapter 9 of Reference 20)). The invention can use any of the "hydroxide" or "phosphate" adjuvants that are in general use as adjuvants. The adjuvants known as "aluminium hydroxide" are typically aluminium oxyhydroxide salts, which are usually at least partially crystalline. The adjuvants known as "aluminium phosphate" are typically aluminium hydroxyphosphates, often also containing a small amount of sulphate (i.e. aluminium hydroxyphosphate sulphate). They may be obtained by precipitation, and the reaction conditions and concentrations during precipitation influence the degree of substitution of phosphate for hydroxyl in the salt.
A fibrous morphology (e.g. as seen in transmission electron micrographs) is typical for aluminium hydroxide adjuvants. The pi of aluminium hydroxide adjuvants is typically about 11 i.e. the adjuvant itself has a positive surface charge at physiological pH. Adsorptive capacities of between 1.8-2.6 mg protein per mg Al+++ at pH 7.4 have been reported for aluminium hydroxide adjuvants.
Aluminium phosphate adjuvants generally have a PO4/AI molar ratio between 0.3 and 1.2, preferably between 0.8 and 1.2, and more preferably 0.95+0.1. The aluminium phosphate will generally be amorphous, particularly for hydroxyphosphate salts. A typical adjuvant is amorphous aluminium hydroxyphosphate with PO4/AI molar ratio between 0.84 and 0.92, included at 0.6mg Al3+/ml. The aluminium phosphate will generally be particulate (e.g. plate-like morphology as seen in transmission electron micrographs). Typical diameters of the particles are in the range 0.1-10μιη (e.g. about 0.1-5μιη) after any antigen adsorption. Adsorptive capacities of between 0.7-1.5 mg protein per mg Al+++ at pH 7.4 have been reported for aluminium phosphate adjuvants.
The point of zero charge (PZC) of aluminium phosphate is inversely related to the degree of substitution of phosphate for hydroxyl, and this degree of substitution can vary depending on reaction conditions and concentration of reactants used for preparing the salt by precipitation. PZC is also altered by changing the concentration of free phosphate ions in solution (more phosphate = more acidic PZC) or by adding a buffer such as a histidine buffer (makes PZC more basic). Aluminium phosphates used according to the invention will generally have a PZC of between 4.0 and 7.0, more preferably between 5 and 6.5 e.g. about 5.7.
Suspensions of aluminium salts used to prepare compositions of the invention may contain a buffer (e.g. a phosphate or a histidine or a Tris buffer), but this is not always necessary. The suspensions are preferably sterile and pyrogen-free. A suspension may include free aqueous phosphate ions e.g. present at a concentration between 1.0 and 20 mM, preferably between 5 and 15 mM, and more preferably about 10 mM. The suspensions may also comprise sodium chloride.
The preferred aluminium salt adjuvant is an aluminium hydroxide adjuvant.
The invention can use a mixture of both an aluminium hydroxide and an aluminium phosphate. In this case there may be more aluminium phosphate than hydroxide e.g. a weight ratio of at least 2: 1 e.g. >5: 1, >6: l, >7: l, >8: l, >9:l, eic.
The concentration of Al+++ in a composition for administration to a patient is preferably less than lOmg/ml e.g. <5 mg/ml, <4 mg/ml, <3 mg/ml, <2 mg/ml, <1 mg/ml, etc. A preferred range is between 0.3 and lmg/ml. A maximum of 0.85mg/dose is preferred.
A mineral salt can usefully have a TLR agonist, such as a TLR7 agonist, adsorbed to it (e.g. see Ref. 21). The adsorbed TLR7 agonist is usefully a compound of formula (K) as described above. Oil & water emulsions
Oil emulsion compositions suitable for use as adjuvants in the invention include oil-in-water emulsions such as MF59 (Chapter 10 of Ref. 20; see also Ref. 22) and AS03. Complete Freund's adjuvant (CFA) and incomplete Freund's adjuvant (IF A) may also be used.
Various oil-in-water emulsion adjuvants are known, and they typically include at least one oil and at least one surfactant, with the oil(s) and surfactant(s) being biodegradable (metabolisable) and biocompatible. The oil droplets in the emulsion are generally less than 5μιη in diameter, and ideally have a sub-micron diameter, with these small sizes being achieved with a microfluidiser to provide stable emulsions. Droplets with a size less than 220nm are preferred as they can be subjected to filter sterilization.
The emulsion can comprise oils such as those from an animal (such as fish) or vegetable source. Sources for vegetable oils include nuts, seeds and grains. Peanut oil, soybean oil, coconut oil, and olive oil, the most commonly available, exemplify the nut oils. Jojoba oil can be used e.g. obtained from the jojoba bean. Seed oils include safflower oil, cottonseed oil, sunflower seed oil, sesame seed oil and the like. In the grain group, corn oil is the most readily available, but the oil of other cereal grains such as wheat, oats, rye, rice, teff, triticale and the like may also be used. 6-10 carbon fatty acid esters of glycerol and 1 ,2-propanediol, while not occurring naturally in seed oils, may be prepared by hydrolysis, separation and esterification of the appropriate materials starting from the nut and seed oils. Fats and oils from mammalian milk are metabolizable and may therefore be used in the practice of this invention. The procedures for separation, purification, saponification and other means necessary for obtaining pure oils from animal sources are well known in the art. Most fish contain metabolizable oils which may be readily recovered. For example, cod liver oil, shark liver oils, and whale oil such as spermaceti exemplify several of the fish oils which may be used herein. A number of branched chain oils are synthesized biochemically in 5-carbon isoprene units and are generally referred to as terpenoids. Shark liver oil contains a branched, unsaturated terpenoids known as squalene, 2,6,10,15, 19,23-hexamethyl-2,6,10, 14,18,22- tetracosahexaene, which is particularly preferred herein. Squalane, the saturated analog to squalene, is also a preferred oil. Fish oils, including squalene and squalane, are readily available from commercial sources or may be obtained by methods known in the art. Other preferred oils are the tocopherols (see below). Mixtures of oils can be used.
Surfactants can be classified by their 'HLB' (hydrophile/lipophile balance). Preferred surfactants of the invention have a HLB of at least 10, preferably at least 15, and more preferably at least 16. The invention can be used with surfactants including, but not limited to: the polyoxyethylene sorbitan esters surfactants (commonly referred to as the Tweens), especially polysorbate 20 and polysorbate 80; copolymers of ethylene oxide (EO), propylene oxide (PO), and/or butylene oxide (BO), sold under the DOWFAX™ tradename, such as linear EO/PO block copolymers; octoxynols, which can vary in the number of repeating ethoxy (oxy-l,2-ethanediyl) groups, with octoxynol-9 (Triton X-100, or t-octylphenoxypolyethoxyethanol) being of particular interest; (octylphenoxy)polyethoxyethanol (IGEPAL CA-630/NP-40); phospholipids such as phosphatidylcholine (lecithin); nonylphenol ethoxylates, such as the Tergitol™ NP series; polyoxyethylene fatty ethers derived from lauryl, cetyl, stearyl and oleyl alcohols (known as Brij surfactants), such as triethyleneglycol monolauryl ether (Brij 30); and sorbitan esters (commonly known as the SPANs), such as sorbitan trioleate (Span 85) and sorbitan monolaurate. Non-ionic surfactants are preferred. Preferred surfactants for including in the emulsion are Tween 80 (polyoxyethylene sorbitan monooleate), Span 85 (sorbitan trioleate), lecithin and Triton X-100.
Mixtures of surfactants can be used e.g. Tween 80/Span 85 mixtures. A combination of a polyoxyethylene sorbitan ester such as polyoxyethylene sorbitan monooleate (Tween 80) and an octoxynol such as t-octylphenoxypolyethoxyethanol (Triton X-100) is also suitable. Another useful combination comprises laureth 9 plus a polyoxyethylene sorbitan ester and/or an octoxynol.
Preferred amounts of surfactants (%> by weight) are: polyoxyethylene sorbitan esters (such as Tween 80) 0.01 to 1%, in particular about 0.1 %>; octyl- or nonylphenoxy polyoxyethanols (such as Triton X-100, or other detergents in the Triton series) 0.001 to 0.1 %>, in particular 0.005 to 0.02%; polyoxyethylene ethers (such as laureth 9) 0.1 to 20 %, preferably 0.1 to 10 % and in particular 0.1 to 1 % or about 0.5%.
Preferred emulsion adjuvants have an average droplets size of <1 μιη e.g. <750nm, <500nm, <400nm, <300nm, <250nm, <220nm, <200nm, or smaller. These droplet sizes can conveniently be achieved by techniques such as microfluidisation.
Specific oil- in- water emulsion adjuvants useful with the invention include, but are not limited to:
• A submicron emulsion of squalene, polysorbate 80, and sorbitan trioleate. These three components can be present at a volume ratio of 10: 1 : 1 or a weight ratio of 39:47:47. The composition of the emulsion by volume can be about 5%> squalene, about 0.5%> polysorbate 80 and about 0.5%> sorbitan trioleate. In weight terms, these ratios become 4.3%> squalene, 0.5%> polysorbate 80 and 0.48%) sorbitan trioleate. This adjuvant is known as 'MF59' [23-25], as described in more detail in
Chapter 10 of Ref. 26 and chapter 12 of Ref. 27. The MF59 emulsion advantageously includes citrate ions e.g. 10 mM sodium citrate buffer.
• An emulsion of squalene, a tocopherol, and polysorbate 80. The emulsion may include phosphate buffered saline. It may also include Span 85 (e.g. at 1%>) and/or lecithin. These emulsions may have from 2 to 10%> squalene, from 2 to 10%> tocopherol and from 0.3 to 3%> polysorbate 80, and the weight ratio of squalene:tocopherol is preferably <1 as this provides a more stable emulsion. Squalene and polysorbate 80 may be present volume ratio of about 5:2 or at a weight ratio of about 11 :5. Thus the three components (squalene, tocopherol, polysorbate 80) may be present at a weight ratio of 1068:1186:485 or around 55:61 :25. One such emulsion ('AS03') can be made by dissolving Tween 80 in PBS to give a 2%> solution, then mixing 90ml of this solution with a mixture of (5g of DL-a-tocopherol and 5ml squalene), then microfluidising the mixture. The resulting emulsion may have submicron oil droplets e.g. with an average diameter of between 100 and 250nm, preferably about 180nm. The emulsion may also include a 3-de-O-acylated monophosphoryl lipid A (3d-MPL). Another useful emulsion of this type may comprise, per human dose, 0.5-10 mg squalene, 0.5-11 mg tocopherol, and 0.1-4 mg polysorbate 80 [28] e.g. in the ratios discussed above.
• An emulsion of squalene, a tocopherol, and a Triton detergent (e.g. Triton X-100). The emulsion may also include a 3d-MPL (see below). The emulsion may contain a phosphate buffer. An emulsion comprising a polysorbate (e.g. polysorbate 80), a Triton detergent (e.g. Triton X-100) and a tocopherol (e.g. an a-tocopherol succinate). The emulsion may include these three components at a mass ratio of about 75: 1 1 : 10 (e.g. 750μg/ml polysorbate 80, 1 10μg/ml Triton X- 100 and 100μg/ml a-tocopherol succinate), and these concentrations should include any contribution of these components from antigens. The emulsion may also include squalene. The emulsion may also include a 3d-MPL (see below). The aqueous phase may contain a phosphate buffer.
An emulsion of squalane, polysorbate 80 and poloxamer 401 ("Pluronic™ L121"). The emulsion can be formulated in phosphate buffered saline, pH 7.4. This emulsion is a useful delivery vehicle for muramyl dipeptides, and has been used with threonyl-MDP in the "SAF-1" adjuvant [29] (0.05- 1% Thr-MDP, 5% squalane, 2.5% Pluronic L121 and 0.2% polysorbate 80). It can also be used without the Thr-MDP, as in the "AF" adjuvant [30] (5% squalane, 1.25% Pluronic L121 and 0.2% polysorbate 80). Microfluidisation is preferred.
An emulsion comprising squalene, an aqueous solvent, a polyoxyethylene alkyl ether hydrophilic nonionic surfactant (e.g. polyoxyethylene (12) cetostearyl ether) and a hydrophobic nonionic surfactant (e.g. a sorbitan ester or mannide ester, such as sorbitan monoleate or 'Span 80'). The emulsion is preferably thermoreversible and/or has at least 90%> of the oil droplets (by volume) with a size less than 200 nm [31 ]. The emulsion may also include one or more of: alditol; a cryoprotective agent (e.g. a sugar, such as dodecylmaltoside and/or sucrose); and/or an alkylpolyglycoside. The emulsion may include a TLR4 agonist [32]. Such emulsions may be lyophilized.
An emulsion of squalene, poloxamer 105 and Abil-Care [33]. The final concentration (weight) of these components in adjuvanted vaccines are 5% squalene, 4% poloxamer 105 (pluronic polyol) and 2% Abil-Care 85 (Bis-PEG/PPG-16/16 PEG/PPG- 16/16 dimethicone; caprylic/capric triglyceride).
An emulsion having from 0.5-50% of an oil, 0.1 -10%) of a phospholipid, and 0.05-5%) of a non-ionic surfactant. As described in Reference 34, preferred phospholipid components are phosphatidylcholine, phosphatidylethanolamine, phosphatidylserine, phosphatidylinositol, phosphatidylglycerol, phosphatidic acid, sphingomyelin and cardiolipin. Submicron droplet sizes are advantageous.
A submicron oil-in-water emulsion of a non-metabolisable oil (such as light mineral oil) and at least one surfactant (such as lecithin, Tween 80 or Span 80). Additives may be included, such as QuilA saponin, cholesterol, a saponin- lipophile conjugate (such as GPI-0100, described in Reference 35, produced by addition of aliphatic amine to desacylsaponin via the carboxyl group of glucuronic acid), dimethyidioctadecylammonium bromide and/or N,N-dioctadecyl-N,N-bis (2- hydroxyethyl)propanediamine.
An emulsion in which a saponin (e.g. QuilA or QS21) and a sterol (e.g. a cholesterol) are associated as helical micelles [36]. • An emulsion comprising a mineral oil, a non-ionic lipophilic ethoxylated fatty alcohol, and a non-ionic hydrophilic surfactant (e.g. an ethoxylated fatty alcohol and/or polyoxyethylene- polyoxypropylene block copolymer) [37].
• An emulsion comprising a mineral oil, a non-ionic hydrophilic ethoxylated fatty alcohol, and a non-ionic lipophilic surfactant (e.g. an ethoxylated fatty alcohol and/or polyoxyethylene- polyoxypropylene block copolymer) [37].
In some embodiments an emulsion may be mixed with antigen extemporaneously, at the time of delivery, and thus the adjuvant and antigen may be kept separately in a packaged or distributed composition, ready for final formulation at the time of use. In other embodiments an emulsion is mixed with antigen during manufacture, and thus the composition is packaged in a liquid adjuvanted form,. The antigen will generally be in an aqueous form, such that the composition is finally prepared by mixing two liquids. The volume ratio of the two liquids for mixing can vary (e.g. between 5: 1 and 1 :5) but is generally about 1 : 1. Where concentrations of components are given in the above descriptions of specific emulsions, these concentrations are typically for an undiluted composition, and the concentration after mixing with an antigen solution will thus decrease.
Where a composition includes a tocopherol, any of the α, β, γ, δ, ε or ξ tocopherols can be used, but a-tocopherols are preferred. The tocopherol can take several forms e.g. different salts and/or isomers. Salts include organic salts, such as succinate, acetate, nicotinate, etc. D-a-tocopherol and DL-a-tocopherol can both be used. Tocopherols are advantageously included in compositions for use in elderly patients (e.g. aged 60 years or older) because vitamin E has been reported to have a positive effect on the immune response in this patient group [38]. They also have antioxidant properties that may help to stabilize the emulsions [39]. A preferred a-tocopherol is DL-a-tocopherol, and the preferred salt of this tocopherol is the succinate.
The use of an aluminium hydroxide and/or aluminium phosphate adjuvant is particularly preferred, and antigens are generally adsorbed to these salts.
Compositions of the invention may elicit both a cell mediated immune response as well as a humoral immune response. This immune response will preferably induce long lasting (e.g. neutralising) antibodies and a cell mediated immunity that can quickly respond upon exposure to S. aureus.
The immune response may be one or both of a TH1 immune response and a TH2 response. Preferably, immune response provides for one or both of an enhanced TH1 response and an enhanced TH2 response.
The enhanced immune response may be one or both of a systemic and a mucosal immune response. Preferably, the immune response provides for one or both of an enhanced systemic and an enhanced mucosal immune response. Preferably the mucosal immune response is a TH2 immune response. Preferably, the mucosal immune response includes an increase in the production of IgA.
S. aureus infections can affect various areas of the body and so the compositions of the invention may be prepared in various forms. For example, the compositions may be prepared as injectables, either as liquid solutions or suspensions. Solid forms suitable for solution in, or suspension in, liquid vehicles prior to injection can also be prepared (e.g. a lyophilized composition or a spray-freeze dried composition). The composition may be prepared for topical administration e.g. as an ointment, cream or powder. The composition may be prepared for oral administration e.g. as a tablet or capsule, as a spray, or as a syrup (optionally flavoured). The composition may be prepared for pulmonary administration e.g. as an inhaler, using a fine powder or a spray. The composition may be prepared as a suppository or pessary. The composition may be prepared for nasal, aural or ocular administration e.g. as drops. The composition may be in kit form, designed such that a combined composition is reconstituted just prior to administration to a patient. Such kits may comprise one or more antigens in liquid form and one or more lyophilized antigens.
Where a composition is to be prepared extemporaneously prior to use (e.g. where a component is presented in lyophilized form) and is presented as a kit, the kit may comprise two vials, or it may comprise one ready- filled syringe and one vial, with the contents of the syringe being used to reactivate the contents of the vial prior to injection.
Immunogenic compositions used as vaccines comprise an immunologically effective amount of antigen(s), as well as any other components, as needed. By 'immunologically effective amount', it is meant that the administration of that amount to an individual, either in a single dose or as part of a series, is effective for treatment or prevention. This amount varies depending upon the health and physical condition of the individual to be treated, age, the taxonomic group of individual to be treated (e.g. non- human primate, primate, etc.), the capacity of the individual's immune system to synthesise antibodies, the degree of protection desired, the formulation of the vaccine, the treating doctor's assessment of the medical situation, and other relevant factors. It is expected that the amount will fall in a relatively broad range that can be determined through routine trials. Where more than one antigen is included in a composition then two antigens may be present at the same dose as each other or at different doses.
As mentioned above, a composition may include a temperature protective agent, and this component may be particularly useful in adjuvanted compositions (particularly those containing a mineral adjuvant, such as an aluminium salt). As described in Reference 40, a liquid temperature protective agent may be added to an aqueous vaccine composition to lower its freezing point e.g. to reduce the freezing point to below 0°C. Thus the composition can be stored below 0°C, but above its freezing point, to inhibit thermal breakdown. The temperature protective agent also permits freezing of the composition while protecting mineral salt adjuvants against agglomeration or sedimentation after freezing and thawing, and may also protect the composition at elevated temperatures e.g. above 40°C. A starting aqueous vaccine and the liquid temperature protective agent may be mixed such that the liquid temperature protective agent forms from 1 -80% by volume of the final mixture. Suitable temperature protective agents should be safe for human administration, readily miscible/soluble in water, and should not damage other components (e.g. antigen and adjuvant) in the composition. Examples include glycerin, propylene glycol, and/or polyethylene glycol (PEG). Suitable PEGs may have an average molecular weight ranging from 200- 20,000 Da. In a preferred embodiment, the polyethylene glycol can have an average molecular weight of about 300 Da ('PEG-300').
Methods of treatment, and administration of the vaccine
The invention also provides a method for raising an immune response in a mammal comprising the step of administering a composition of the invention to the mammal. The immune response is preferably protective and preferably involves antibodies and/or cell-mediated immunity. The method may raise a booster response.
At least some of the antibodies raised in response to polypeptides which are administered in accordance with the invention should be protective.
The invention also provides the use of variant forms of: a EsxB antigen, a Sta006 antigen and/or a StaOl 1 antigen, as described above, provided that the variant does not contain any free thiol group, in the manufacture of a medicament for raising an immune response in a mammal. The use may also involve a Hla antigen and a EsxA antigen. It may also involve the use of an adjuvant.
By raising an immune response in the mammal by these uses and methods, the mammal can be protected against S. aureus infection, including a nosocomial infection. More particularly, the mammal may be protected against a skin infection, pneumonia, meningitis, osteomyelitis endocarditis, toxic shock syndrome, and/or septicaemia.
The invention also provides a kit comprising a first component and a second component wherein neither the first component nor the second component is a composition of the invention as described above, but wherein the first component and the second component can be combined to provide a composition of the invention as described above. The kit may further include a third component comprising one or more of the following: instructions, syringe or other delivery device, adjuvant, or pharmaceutically acceptable formulating solution.
The invention also provides a delivery device pre-filled with an immunogenic composition of the invention.
The mammal is preferably a human. Where the vaccine is for prophylactic use, the human is preferably a child {e.g. a toddler or infant) or a teenager; where the vaccine is for therapeutic use, the human is preferably a teenager or an adult. A vaccine intended for children may also be administered to adults e.g. to assess safety, dosage, immunogenicity, etc. Other mammals which can usefully be immunised according to the invention are cows, dogs, horses, and pigs.
One way of checking efficacy of therapeutic treatment involves monitoring S. aureus infection after administration of the compositions of the invention. One way of checking efficacy of prophylactic treatment involves monitoring immune responses, systemically (such as monitoring the level of IgGl and IgG2a production) and/or mucosally (such as monitoring the level of IgA production), against the antigens in the compositions of the invention after administration of the composition. Typically, antigen- specific serum antibody responses are determined post-immunisation but pre-challenge whereas antigen- specific mucosal antibody responses are determined post-immunisation and post-challenge.
Another way of assessing the immunogenicity of the compositions of the present invention is to express the proteins recombinantly for screening patient sera or mucosal secretions by immunoblot and/or microarrays. A positive reaction between the protein and the patient sample indicates that the patient has mounted an immune response to the protein in question. This method may also be used to identify immunodominant antigens and/or epitopes within antigens. The efficacy of immunogenic compositions can also be determined in vivo by challenging animal models of S. aureus infection, e.g., guinea pigs or mice, with the immunogenic compositions. In particular, there are three useful animal models for the study of S. aureus infectious disease, namely: (i) the murine abscess model [41], (ii) the murine lethal infection model [41] and (iii) the murine pneumonia model [42]. The abscess model looks at abscesses in mouse kidneys after intravenous challenge. The lethal infection model looks at the number of mice which survive after being infected by a normally- lethal dose of S. aureus by the intravenous or intraperitoneal route. The pneumonia model also looks at the survival rate, but uses intranasal infection. A useful immunogenic composition may be effective in one or more of these models. For instance, for some clinical situations it may be desirable to protect against pneumonia, without needing to prevent hematic spread or to promote opsonisation; in other situations the main desire may be to prevent hematic spread. Different antigens, and different antigen combinations, may contribute to different aspects of an effective immunogenic composition.
Compositions of the invention will generally be administered directly to a patient. Direct delivery may be accomplished by parenteral injection {e.g. subcutaneously, intraperitoneally, intravenously, intramuscularly, or to the interstitial space of a tissue), or mucosally, such as by rectal, oral {e.g. tablet, spray), vaginal, topical, transdermal or transcutaneous, intranasal, ocular, aural, pulmonary or other mucosal administration.
The invention may be used to elicit systemic and/or mucosal immunity, preferably to elicit an enhanced systemic and/or mucosal immunity.
Preferably the enhanced systemic and/or mucosal immunity is reflected in an enhanced TH1 and/or TH2 immune response. Preferably, the enhanced immune response includes an increase in the production of IgGl and/or IgG2a and/or IgA.
Dosage can be by a single dose schedule or a multiple dose schedule. Multiple doses may be used in a primary immunisation schedule and/or in a booster immunisation schedule. In a multiple dose schedule the various doses may be given by the same or different routes e.g. a parenteral prime and mucosal boost, a mucosal prime and parenteral boost, etc. Multiple doses will typically be administered at least 1 week apart {e.g. about 2 weeks, about 3 weeks, about 4 weeks, about 6 weeks, about 8 weeks, about 10 weeks, about 12 weeks, about 16 weeks, etc.).
Vaccines prepared according to the invention may be used to treat both children and adults. Thus a human patient may be less than 1 year old, 1-5 years old, 5-15 years old, 15-55 years old, or at least 55 years old. Preferred patients for receiving the vaccines are the elderly {e.g. >50 years old, >60 years old, and preferably >65 years), the young {e.g. <5 years old), hospitalised patients, healthcare workers, armed service and military personnel, pregnant women, the chronically ill, or immunodeficient patients. The vaccines are not suitable solely for these groups, however, and may be used more generally in a population.
Vaccines produced by the invention may be administered to patients at substantially the same time as {e.g. during the same medical consultation or visit to a healthcare professional or vaccination centre) other vaccines e.g. at substantially the same time as an influenza vaccine, a measles vaccine, a mumps vaccine, a rubella vaccine, a MMR vaccine, a varicella vaccine, a MMRV vaccine, a diphtheria vaccine, a tetanus vaccine, a pertussis vaccine, a DTP vaccine, a conjugated H.influenzae type b vaccine, an inactivated poliovirus vaccine, a hepatitis B virus vaccine, a meningococcal conjugate vaccine (such as a tetravalent A-C-W135-Y vaccine), a respiratory syncytial virus vaccine, etc. Further non-staphylococcal vaccines suitable for co-administration may include one or more antigens listed on pages 33-46 of Reference 16. General
The practice of the present invention will employ, unless otherwise indicated, conventional methods of chemistry, biochemistry, molecular biology, immunology and pharmacology, within the skill of the art. Such techniques are explained fully in the literature. See, e.g., References 43-50, etc.
"Gl" numbering is used above. A Gl number, or "Genlnfo Identifier", is a series of digits assigned consecutively to each sequence record processed by NCBI when sequences are added to its databases. The Gl number bears no resemblance to the accession number of the sequence record. When a sequence is updated {e.g. for correction, or to add more annotation or information) then it receives a new Gl number. Thus the sequence associated with a given Gl number is never changed.
Where the invention concerns an "epitope", this epitope may be a B-cell epitope and/or a T-cell epitope. Such epitopes can be identified empirically (e.g. using PEPSCAN [51,52] or similar methods), or they can be predicted (e.g. using the Jameson-Wolf antigenic index [53], matrix-based approaches [54], MAPITOPE [55], TEPITOPE [56,57], neural networks [58], OptiMer & EpiMer [59, 60], ADEPT [61], Tsites [62], hydrophilicity [63], antigenic index [64] or the methods disclosed in References 65-69, etc.). Epitopes are the parts of an antigen that are recognised by and bind to the antigen binding sites of antibodies or T-cell receptors, and they may also be referred to as "antigenic determinants".
Where an antigen "domain" is omitted, this may involve omission of a signal peptide, of a cytoplasmic domain, of a transmembrane domain, of an extracellular domain, etc.
The term "comprising" encompasses "including" as well as "consisting" e.g. a composition "comprising" X may consist exclusively of X or may include something additional e.g. X + Y.
The term "about" in relation to a numerical value x is optional and means, for example, x+10%.
References to a percentage sequence identity between two amino acid sequences means that, when aligned, that percentage of amino acids are the same in comparing the two sequences. This alignment and the percent homology or sequence identity can be determined using software programs known in the art, for example those described in section 7.7.18 of Ref. 70. A preferred alignment is determined by the Smith- Waterman homology search algorithm using an affine gap search with a gap open penalty of 12 and a gap extension penalty of 2, BLOSUM matrix of 62. The Smith- Waterman homology search algorithm is disclosed in Ref. 71. The percentage sequence identity between two sequences of different lengths is preferably calculated over the length of the longer sequence.
Phosphorous-containing adjuvants used with the invention may exist in a number of protonated and deprotonated forms depending on the pH of the surrounding environment, for example the pH of the solvent in which they are dissolved. Therefore, although a particular form may be illustrated, it is intended that these illustrations are merely representative and not limiting to a specific protonated or deprotonated form. For example, in the case of a phosphate group, this has been illustrated as - OP(0)(OH)2 but the definition includes the protonated forms [OP(0)(OH2)(OH)]+ and -[OP(0)(OH)2]2+ that may exist in acidic conditions and the deprotonated forms -[OP(0)(OH)(0)]~ and [OP(0)(0)2]2" that may exist in basic conditions.
Compounds can exist as pharmaceutically acceptable salts. Thus, compounds (e.g. adjuvants) may be used in the form of their pharmaceutically acceptable salts i.e. physiologically or toxicologically tolerable salt (which includes, when appropriate, pharmaceutically acceptable base addition salts and pharmaceutically acceptable acid addition salts).
The word "substantially" does not exclude "completely" e.g. a composition which is "substantially free" from Y may be completely free from Y. Where necessary, the word "substantially" may be omitted from the definition of the invention.
BRIEF DESCRIPTION OF DRAWINGS
Figure 1 shows the anti-EsxAB antibody titres in CD1 mice which have been immunized with various compositions. "Combo Cys(+) Lyo form": mice immunized with tetravalent vaccine containing EsxAB- Cys(+), Sta006 Cys(+), StaOl l Cys(+), HlaH35L and aluminium hydroxide adjuvant. "Combo Cys(-)": mice immunized with tetravalent vaccine containing EsxAB Cys(-), Sta006 Cys(-), StaOl l Cys(-), HlaH35L and aluminium hydroxide adjuvant. "Alum 2mg/ml+NaCl": mice received equal amounts of PBS and aluminium hydroxide adjuvant.
Figure 2 shows the anti-Sta006 antibody titres in CD1 mice which have been immunized with various compositions. The mice groups are as explained in Figure 1 above.
Figure 3 shows the anti-StaOl l antibody titres in CD1 mice which have been immunized with various compositions. The mice groups are as explained in Figure 1 above.
Figure 4 shows the anti-HlaH35L antibody titres in CD1 mice which have been immunized with various compositions. The mice groups are as explained in Figure 1 above.
Figure 5 shows the normalised melting curves of the Sta006 Cys(+) and Cys(-) antigens.
Figure 6 shows the normalised melting curves of the StaOl 1 Cys(+) and Cys(-) antigens.
Figure 7 shows SDS-PAGE of vaccines with cysteine-containing antigens (A) and cysteine- deficient antigens (B). MW: EsxAB monomer (22.8 kDa), StaOl l monomer (27 kDa), Sta006 monomer (32 kDa), HlaH35L (33 kDa), EsxAB dimer (45.6 kDa), StaOl l dimer (54 kDa), Sta006 dimer (64 kDa), Sta006- EsxAB dimer (54.8 kDa), StaOl 1-EsxAB dimer (49.8 kDa) and Sta006-Sta011 dimer (49.8 kDa).
Figure 8 shows RP-HPLC profiles of vaccines with cysteine-containing antigens (A) and cysteine- deficient antigens (B). The HPLC profiles a t=0 (solid lines), 3 days (dot-dash) and 7 days (dashes) are shown.
MODES FOR CARRYING OUT THE INVENTION
Immunogenicity studies in mice
Immunogenicity of cysteine-containing (Cys(+)) S. aureus antigens was compared with the corresponding cysteine- deficient variants (Cys(-)). Five week old CD1 mice were immunized intraperitoneally with a prime-booster injection with the purified recombinant proteins adsorbed to aluminium hydroxide adjuvant (alum, 2 mg/ml) in 14-day interval. The mice are split into three groups: (1) "Combo Cys(+) Lyo form": mice immunized with tetravalent vaccine containing EsxAB Cys(+), Sta006 Cys(+), StaOl l Cys(+), HlaH35L and aluminium hydroxide adjuvant; (2) "Combo Cys(-)": mice immunized with tetravalent vaccine containing EsxAB Cys(-), Sta006 Cys(-), StaOl l Cys(-), HlaH35L and aluminium hyrdroxide adjuvant; and (3) "Alum 2mg/ml+NaCl": control mice received equal amounts of PBS and aluminium hydroxide adjuvant. Animals were bled immediately prior to the first immunization and 23 days thereafter, and sera were examined for IgG antibodies directed against the purified proteins using the Luminex technology. The assay read-out is a measure of fluorescence intensity expressed as arbitrary Relative Luminex Units (RLU/mL).
The antigens were recombinant proteins purified from E.coli. The SEQ ID NOs of the antigens in the Combo Cys(+) and Combo Cys(-) are listed in Table 1.
Table 1 : SEQ ID NOs of the antigens used in the experiments.
Figure imgf000032_0001
Figures 1 -4 report antibody titres of mice following immunization. The antibody titres for each antigen do not differ significantly between the Combo Cys(+)/Alum and Combo Cys (-)/Alum mice groups, as confirmed by the Mann- Whitney test.
In a further study, monovalent vaccines containing Cys(-) and Cys(+) antigens were compared. The vaccines were adjuvanted with aluminium hydroxide. Each vaccine contains 30 μg of antigen and aluminium hydroxide at 2 mg/ml.
Sixteen CD1 mice (five week old) were immunized subcutaneously three times (at t=0, 14 and 28 days). Animals were bled immediately prior to the first immunization, and 13, 27 and 42 days following the first immunization. The sera were examined for IgG antibodies directed against the purified proteins using the Luminex technology. The assay read-out is a measure of fluorescence intensity expressed as arbitrary Relative Luminex Units (RLU/mL).
It was found that antibodies were specifically elicited by monovalent vaccines containing the corresponding Cys(-) and Cys(+) antigens. There are no significant differences between the monovalent Cys(-) and the Cys(+) vaccines.
Thermal denaturation assay
Thermal stability of the Cys(+) antigen was compared the corresponding Cys(-) antigen by Differential Scanning Fluorimetry (DSF). Samples containing antigen (10 μΜ in PBS) were heated under controlled conditions with a ramp rate of 1 0C/min in Strategen Mx3000p Real Time PCR instrument. The dye SyproOrange 5x was used, and the changes in fluorescence were monitored. Assays were performed over a temperature range of 10-100 °C. Figures 5 and 6 report the melting curves for the antigens tested. Melting temperatures (Tm) were determined by fitting the first derivative of each experimental curve. The Tm values are summarised in Table 2.
Data obtained by DSF were confirm and extended using Differential Scanning Calorimetry (DSC), a technique allowing more accurate Tm determination. Samples containing antigen (0.5-1 mg/mL) were heated in a Micorcal CapDSC instrument with a ramp rate of 90 °C/hour. The experimental data were adjusted for molar concentration after subtraction of a blank containing the matching buffer and automatic baseline subtraction using the dedicated analysis software AutoCapDSC. The melting profiles for the two samples are very well superimposable and the Tm values are reported in Table 2.
Table 2: Melting temperatures of Cys(+) and Cys(-) antigens.
Figure imgf000033_0001
The results show that the thermal stability profiles of the Cys(-) antigens are comparable to the corresponding Cys(+) antigens. Therefore, modifying the antigen by deleting or replacing the cysteine residue does not have a significant impact on the thermal stability of the antigen.
Purification process
The purification steps for each antigen are explained below.
Sta006
1. Lysis and clarification - cell lysis and clarification; adding a flocculating agent (PEI) that reduces DNA, endotoxins and proteic impurities.
2. SPFF chromatography - removal of HCP and other impurities.
3. Oxidative dimerization reaction - oxidation step.
4. cHT chromatography - removal of HCP and other residual impurities and separation of monomer from dimer.
5. Final lOkDa diafiltration - diafiltration in final buffer.
For purifying Cys(-) Sta006, the oxidative dimerization reaction step was no longer necessary as the antigen can be purified as a monomer. The cHT chromatography step was also simplified because it was no longer necessary to separate the monomer from the dimer.
StaOll
1. Lysis and clarification - cell lysis and clarification adding a flocculating agent (PEI) that reduces DNA, endotoxins and proteic impurities. 2. CaptoQ chromatography - removal of HCP and other impurities and dimerization of Cys(+) antigen.
3. cHT chromatography - removal of HCP and other impurities and separation of monomer from dimer.
4. Final 1 OkDa diafiltration - diafiltration in final buffer.
For purifying StaOl l Cys(-), the CaptoQ chromatography step was simplified as the antigen can be purified as a monomer. The cHT chromatography step was also simplified because it was no longer necessary to separate the monomer from the dimer.
EsxAB
Steps for purifying Cys(+) EsxAB:
1. Lysis and clarification - cell lysis and clarification; adding a flocculating agent (PEI) that reduces DNA, endotoxins and proteic impurities.
2. QHP chromatography - removal of HCP, and residual DNA and endotoxins.
3. Phenyl chromatography - removal of HCP contaminants.
4. Final 30kDa diafiltration - diafiltration in final buffer.
For purifying Cys-EsxAB, a SPFF chromatography step is added between steps 3 and 4 above to improve the purity/introduction of a pH gradient elution for fractions collection.
Purity and yield of the antigens obtained from the process explained above were determined, and the results are shown in Table 3. Purity is determined using detector PDA 214nm. Yield is calculated by: total proteins (mBCA content (mg/ml)) x purity (RPC (%) 214nm).
Table 3: Purity and yield of the Cys(-) and Cys(+) antigens.
Antigen Cys? RP purity (%) Yield (g/L ferm)
Sta006 Cys(-) 90.1 0.091
Biomass of fermentation recovered was about 54% (theoretical yield without slurry from centrifugation loss was: 1.176 g/L ferm)
Cys(+) 95.8 0.012
StaOl l Cys(-) 90.1 0.091
Biomass of fermentation recovered was about 79% (theoretical yield without slurry from centrifugation loss was: 0.110 g/L ferm)
Cys(+) 95.8 0.012
EsxAB Cys(-) 88.8 0.224
Biomass of fermentation recovered was about 79%) (theoretical yield without slurry from centrifugation loss was: 0.110 g/L ferm) Cys(+) 80.8 0.216
The purified Cys(-) antigens had comparable purity and yield to the corresponding Cys(+) antigens. The analytical panel conformed to in-house specification limits. Removal of cysteines allowed higher flexibility in the purification process. The purification process can be further optimised in order to improve purity and yield. The three antigens were stable in freezing/thawing cycles and had good stability at 2-8 °C storage temperature.
Compatibility of adjuvants with tetravalent vaccines
The tested vaccines contained EsxAB (Cys(+)), HlaH35L, Sta006 (Cys(+)) and StaOl 1 (Cys(+)) antigens. The adjuvants tested were: Alum, Alum/TLR7 (i.e. formula Kl discussed above) and MF59. The following observations were made:
• Alum - Good adsorption (>80%) for all except HlaH35L, issues with recovery for all upon desorption, detection of homo/heterodimers
• Alum/TLR7 - Same behaviour as for the Alum vaccines. Alum/TLR7 stably adsorbed on Alum in the full liquid formulation of proteins at all doses tested (1 - 50 μg)
· MF59 - Same electrophoretic profile of an aqueous mixture of standards and MF59 vaccine supernatant (detection of homo/heterodimers)
Therefore, the tested adjuvants are suitable for use with the tetravalent vaccine containing EsxAB Cys(+), HlaH35L, Sta006 Cys(+) and StaOl l Cys(+) antigens.
Stability of antigens in a tetravalent vaccines
The stability of antigens in a tetravalent vaccine containing Cys(+) antigens (EsxAB, Hla-H35L, Sta006 and StaOl 1) was compared to a vaccine containing the corresponding Cys(-) antigens.
The samples were analysed using SDS-PAGE (Nu PAGE 4-12%) in MOPS (lx) under non-reducing conditions. The SDS-PAGE of the Cys(+) vaccine is shown in Figure 7A, and of the Cys(-) vaccine is shown in Figure 7B.
The samples was also analysed using HPLC. The HPLC profiles of the Cys(+) vaccine is shown in Figure 8A, and of the Cys(-) vaccine is shown in Figure 8B. The HPLC profiles at t=0, 3 days and 7 days are shown.
It was also found that Cys(-) antigens provided a superior stability for the tetravalent combination with respect to the Cys(+) antigens. The Cys(+) antigens provide a complex analysis due to the presence of homo/heterodimers species. In contrast, the Cys(-) proteins provide no additional peaks observed in Alum containing vaccines. Thus, modifying the antigens from Cys(+) to Cys(-) allows a better analytical resolution or definition of each antigen in the vaccine.
Stability evaluation of tetravalent vaccines
The stability of antigens in vaccines containing Cys(-) antigens (EsxAB, Sta006, StaOl l and Hla-H35L) in the presence and absence of adjuvant (aluminum hydroxide) was investigated. The antigens were present at a concentration of 72 μg/mL. The samples were exposed to temperatures: 2-8°C, 15°C, 25°C and 37°C for 0 to 4 weeks. The highest temperature tested (37°C) was below the lowest Tm of the antigens (StaOl l, Tm=40°C). Hence, protein instability driven by the protein unfolding was not an influencing factor in this experiment.
The samples were analysed using RP-HPLC, and the pH and osmolality were also analysed (3 determinations on 3 different vials at each temperature and timepoint). The following two conditions were used for desorption: (1) 300 mM KH2P04 pH 6.8 with overnight incubation at 25°C (to desorb StaOl l, Sta006 and EsxA-B); and (2) 300 mM KH2P04 pH 6.8 / Tween80 0.05% with o/n incubation at 25°C (to desorb HlaH35L). The same conditions were applied for sample treatment at all time points (assumption: no influence of vaccine aging).
It was observed that all antigens were completely adsorbed onto Alum with adsorption > 96%. The osmolality and pH remained constant over time and within acceptable range. No additional peaks (e.g. degradation products) were seen in the HPLC profiles of the desorbed samples at any condition tested (except at T = 37°C for StaOl l and EsxAB). A higher degree of degradation was observed (i.e. for HlaH35L at 37°C) in vaccines without Alum compared to in the presence of Alum.
It was also found that total antigens recovery from Alum upon desorption (0.5 M phosphate, pH 9, overnight, room temperature) was acceptable for all Cys(-) antigens except HlaH35L. The recovery from Alum remains constant up to 4 weeks at all temperatures except 37°C (20 to 30%> loss for Sta006, StaOl 1 and HlaH35L, same behaviour found in vaccines without Alum).
EsxAB: even though the recovery is consistently high, a change in shape of the peak was observed at 25 and 37°C.
It was found that high reproducibility of analysis was observed for all samples.
The vaccines also provided high purity, as shown in Table 4.
Table 4: Purity of the antigens in vaccines.
Figure imgf000036_0001
It will be understood that the invention is described above by way of example only and modifications may be made whilst remaining within the scope and spirit of the invention.
REFERENCES
[1] Harro et al. (2010) Clin Vaccine Immunol 17: 1868-74.
[2] Kuklin et al. (2006) Infect Immun. 74(4):2215-23.
[3] Sheridan (2009) Nature Biotechnology 27:499-501. [4] Merck and Intercell AG Announce Termination of Phase II/III Clinical Trial of Investigational
Staphylococcus aureus Vaccine, V710 - Merck Research and Development News - 8 June 2011
[5] WO2010/119343.
[6] US provisional application 61/580191.
[7] Sebulsky & Heinrichs (2001) J Bacteriol 183:4994-5000.
[8] Sebulsky et al. (2003) J Biol Chem 278:49890-900.
[9] Rable & Wardenburg (2009) Infect Immun 77:2712-8.
[10] WO2007/145689.
[11] WO2009/029831.
[12] Protective Groups in organic synthesis, Third Edition, Theodora W Greene, Peter G M Wuts,
(1999) John Wiley, Chapter 6 Protection for the Thiol Group.
[13] Kuroda ei «/. (2001) Lancet 357: 1225-1240.
[14] Needleman & Wunsch (1970) J. Mol. Biol. 48, 443-453.
[15] Rice et al. (2000) Trends Genet 16:276-277.
[16] WO2008/019162.
[17] WO2011/027222.
[18] US patent 6355271.
[19] WO00/23105.
[20] Vaccine Design... (1995) eds. Powell & Newman. ISBN: 030644867X. Plenum.
[21] WO2011/027222.
[22] WO90/14837.
[23] WO90/14837.
[24] Podda & Del Giudice (2003) Expert Rev Vaccines 2: 197-203.
[25] Podda (2001) Vaccine 19: 2673-2680.
[26] Vaccine Design: The Subunit and Adjuvant Approach (eds. Powell & Newman) Plenum Press 1995 (ISBN 0-306-44867-X).
[27] Vaccine Adjuvants: Preparation Methods and Research Protocols (Volume 42 of Methods in Molecular Medicine series). ISBN: 1-59259-083-7. Ed. O'Hagan.
[28] WO2008/043774.
[29] Allison & Byars (1992) Res Immunol 143:519-25.
[30] Hariharan et al. (1995) Cancer Res 55:3486-9.
[31] US-2007/014805.
[32] US-2007/0191314.
[33] Suli et al. (2004) Vaccine 22(25-26):3464-9.
[34] WO95/11700.
[35] US patent 6,080,725.
[36] WO2005/097181.
[37] WO2006/113373.
[38] Han et al. (2005) Impact of Vitamin E on Immune Function and Infectious Diseases in the Aged at Nutrition, Immune functions and Health EuroConference, Paris, 9-10 June 2005.
[39] US- 6630161.
[40] WO2006/110603.
[41] Stranger- Jones et al. (2006) PNAS USA 103: 16942-7.
[42] Wardenburg et al. (2007) Infect Immun 75: 1040-4.
[43] Gennaro (2000) Remington: The Science and Practice of Pharmacy. 20th edition, ISBN: 0683306472.
[44] Methods In Enzymology (S. Colowick and N. Kaplan, eds., Academic Press, Inc.)
[45] Handbook of Experimental Immunology, Vols. I-IV (D.M. Weir and C.C. Blackwell, eds, 1986, Blackwell Scientific Publications)
[46] Sambrook et al. (2001) Molecular Cloning: A Laboratory Manual, 3rd edition (Cold Spring Harbor Laboratory Press). [47] Handbook of Surface and Colloidal Chemistry (Birdi, K.S. ed., CRC Press, 1997)
[48] Ausubel et al. (eds) (2002) Short protocols in molecular biology, 5th edition (Current
Protocols).
[49] Molecular Biology Techniques: An Intensive Laboratory Course, (Ream et al, eds., 1998, Academic Press)
[50] PCR (Introduction to Biotechniques Series), 2nd ed. (Newton & Graham eds., 1997, Springer Verlag)
[51] Geysen et al. (1984) PNAS USA 81 :3998-4002.
[52] Carter (1994) Methods Mol Biol 36:207-23.
[53] Jameson, BA et al. 1988, CABIOS 4(1): 181-186.
[54] Raddrizzani & Hammer (2000) Brief Bioinform 1(2): 179-89.
[55] Bublil et al. (2007) Proteins 68(l):294-304.
[56] De Lalla et al. (1999) J. Immunol. 163: 1725-29.
[57] Kwok et al. (2001) Trends Immunol 22:583-88.
[58] Brusic et al. (1998) Bioinformatics 14(2): 121-30
[59] Meister et al. (1995) Vaccine 13(6):581-91.
[60] Roberts et al. (1996) AIDS Res Hum Retroviruses 12(7):593-610.
[61] Maksyutov & Zagrebelnaya (1993) Comput Appl Biosci 9(3):291-7.
[62] Feller & de la Cruz (1991) Nature 349(6311):720-1.
[63] Hopp (1993) Peptide Research 6:183-190.
[64] Welling et al. (1985) FEBS Lett. 188:215-218.
[65] Davenport et al. (1995) Immunogenetics 42:392-297.
[66] Tsurui & Takahashi (2007) J Pharmacol Sci. 105(4):299-316.
[67] Tong et al. (2007) Brief Bioinform. 8(2):96-108.
[68] Schirle et al. (2001) J Immunol Methods. 257(1-2): 1-16.
[69] Chen et al. (2007) Amino Acids 33(3):423-8.
[70] Current Protocols in Molecular Biology (F.M. Ausubel et al., eds., 1987) Supplement 30
[71] Smith & Waterman (1981) Adv. Appl. Math. 2: 482-489.

Claims

I . An immunogenic composition comprising: (i) a Sta006 antigen comprising an amino acid sequence having at least 90% identity to SEQ ID NO: 24, wherein the polypeptide has no free thiol group and can elicit antibodies which recognise SEQ ID NO: 10; (ii) a StaOl l antigen comprising an amino acid sequence having at least 90% identity to SEQ ID NO: 28, wherein the polypeptide has no free thiol group and can elicit antibodies which recognise SEQ ID NO: 11; and/or (iii) a EsxB antigen comprising an amino acid sequence having at least 90% identity to SEQ ID NO: 16; wherein the polypeptide has no free thiol group and can elicit antibodies which recognise SEQ ID NO: 2.
2. The immunogenic composition of claim 1, wherein the EsxB antigen is combined as a hybrid polypeptide with EsxA antigen, and the hybrid polypeptide comprises an amino acid sequence having 80%) or more identity to SEQ ID NO: 59, wherein the EsxAB hybrid polypeptide can elicit antibodies which recognise SEQ ID NO: 1 and 2.
3. The immunogenic composition of claim 2, wherein the composition comprises: (i) a Sta006 polypeptide having amino acid sequence SEQ ID NO: 26; (ii) a StaOl 1 polypeptide having amino acid sequence SEQ ID NO: 32; and/or (iii) a EsxAB hybrid polypeptide having amino acid sequence SEQ ID NO: 59.
4. The immunogenic composition of any of the preceding claim, further comprising: (iv) a Hla polypeptide comprising an amino acid sequence having at least 90%> identity to SEQ ID NO: 9, and can elicit antibodies which recognise SEQ ID NO: 67.
5. The immunogenic composition of any preceding claim, further comprising one or more conjugates of (i) a S.aureus exopolysaccharide and (ii) a carrier protein.
6. The immunogenic composition of any preceding claim, further comprising one or more conjugates of (i) a S.aureus capsular polysaccharide and (ii) a carrier protein.
7. The immunogenic composition according to any preceding claim, further comprising an adjuvant {e.g. an aluminium hydroxide adjuvant) and/or a saccharide {e.g. sucrose).
8. The immunogenic composition according to any preceding claim, further comprising a stabilizing additive.
9. The immunogenic composition of any preceding claim, in lyophilized form.
10. The immunogenic composition of any preceding claim, in aqueous form.
I I . A method for preparing the composition of claim 10, by reconstituting the composition of claim 9 with aqueous material.
12. A pharmaceutical composition comprising the composition of any preceding claim.
13. A method for raising an immune response in a mammal comprising the step of administering to the mammal an effective amount of the composition of any preceding claim.
PCT/EP2013/067855 2012-08-31 2013-08-29 Stabilised proteins for immunising against staphylococcus aureus WO2014033192A1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
US14/420,229 US20150202277A1 (en) 2012-08-31 2013-08-29 Stabilised proteins for immunising against staphylococcus aureus
EP13758801.8A EP2890387A1 (en) 2012-08-31 2013-08-29 Stabilised proteins for immunising against staphylococcus aureus
JP2015529013A JP2015528457A (en) 2012-08-31 2013-08-29 Stabilized protein for immunization against STAPHYLOCOCUSAUREUS
CN201380042842.7A CN104736165A (en) 2012-08-31 2013-08-29 Stabilised proteins for immunising against Staphylococcus aureus

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261695782P 2012-08-31 2012-08-31
US61/695,782 2012-08-31

Publications (1)

Publication Number Publication Date
WO2014033192A1 true WO2014033192A1 (en) 2014-03-06

Family

ID=49117832

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2013/067855 WO2014033192A1 (en) 2012-08-31 2013-08-29 Stabilised proteins for immunising against staphylococcus aureus

Country Status (5)

Country Link
US (1) US20150202277A1 (en)
EP (1) EP2890387A1 (en)
JP (1) JP2015528457A (en)
CN (1) CN104736165A (en)
WO (1) WO2014033192A1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015140108A1 (en) * 2014-03-17 2015-09-24 Gaxosmithkline Biologicals Sa Immunising against staphylococcal bone and joint infections
EP3639850A1 (en) 2014-03-26 2020-04-22 GlaxoSmithKline Biologicals S.A. Mutant staphylococcal antigens

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014525429A (en) * 2011-09-01 2014-09-29 ノバルティス アーゲー Staphylococcus aureus antigen adjuvanted formulation
JP2015532594A (en) * 2012-08-31 2015-11-12 ノバルティス アーゲー Stabilized protein for immunization against STAPHYLOCOCUSAUREUS
GB201802339D0 (en) * 2018-02-13 2018-03-28 Glaxosmithkline Biologicals Sa Immunogenic composition

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007044382A2 (en) * 2005-10-07 2007-04-19 Health Protection Agency Proteins with improved solubility and methods for producing and using same
WO2010119343A2 (en) * 2009-04-14 2010-10-21 Novartis Ag Compositions for immunising against staphylococcus aureus
WO2013030378A1 (en) * 2011-09-01 2013-03-07 Novartis Ag Adjuvanted formulations of staphylococcus aureus antigens

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2340848A3 (en) * 2004-10-21 2011-09-14 Wyeth LLC Immunogenic compositions of Staphylococcus epidermidis polypeptide and polynucleotide antigens
JO3257B1 (en) * 2009-09-02 2018-09-16 Novartis Ag Compounds and compositions as tlr activity modulators

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007044382A2 (en) * 2005-10-07 2007-04-19 Health Protection Agency Proteins with improved solubility and methods for producing and using same
WO2010119343A2 (en) * 2009-04-14 2010-10-21 Novartis Ag Compositions for immunising against staphylococcus aureus
WO2013030378A1 (en) * 2011-09-01 2013-03-07 Novartis Ag Adjuvanted formulations of staphylococcus aureus antigens

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015140108A1 (en) * 2014-03-17 2015-09-24 Gaxosmithkline Biologicals Sa Immunising against staphylococcal bone and joint infections
BE1022359B1 (en) * 2014-03-17 2016-03-25 Glaxosmithkline Biologicals Sa IMMUNIZATION AGAINST STAPHYLOCOCCAL INFECTIONS OF BONES AND JOINTS
EP3639850A1 (en) 2014-03-26 2020-04-22 GlaxoSmithKline Biologicals S.A. Mutant staphylococcal antigens

Also Published As

Publication number Publication date
CN104736165A (en) 2015-06-24
JP2015528457A (en) 2015-09-28
US20150202277A1 (en) 2015-07-23
EP2890387A1 (en) 2015-07-08

Similar Documents

Publication Publication Date Title
EP2890394B1 (en) Stabilised proteins for immunising against staphylococcus aureus
US20150044251A1 (en) Stable compositions for immunising against staphylococcus aureus
EP3122378B1 (en) Mutant staphylococcal antigens
US20150202277A1 (en) Stabilised proteins for immunising against staphylococcus aureus
AU2018203852A1 (en) Pseudomanas Antigens and Antigen Combinations
US20150203543A1 (en) Stabilised proteins for immunising against staphylococcus aureus
US20150191513A1 (en) Stabilised proteins for immunising against staphylococcus aureus
WO2014067912A1 (en) Staphylococcus aureus sdre cnab domain and its use for vaccination

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13758801

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 14420229

Country of ref document: US

REEP Request for entry into the european phase

Ref document number: 2013758801

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2015529013

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE